



00 223263 A

Express Mail No. IB 906 102 428
Date Mailed: 4 April 1994
Docket No. 871P3

5

mpl Ligand

FIELD OF THE INVENTION

This invention relates to the isolation and purification or chemical synthesis of proteins that influence survival, proliferation, differentiation or maturation of hematopoietic cells, including platelet progenitor cells. This invention further relates to the cloning and expression of nucleic acids encoding a protein ligand capable of binding to and activating *mpl*, a member of the cytokine receptor superfamily. This invention further relates to the use of these proteins alone or in combination with other cytokines to treat immune or hematopoietic disorders including thrombocytopenia.

BACKGROUND OF THE INVENTION

20 **I. The Hematopoietic System**
The mammalian hematopoietic system produces a large number of mature highly specialized blood cells. These mature cells include: erythrocytes specialized to transport oxygen and carbon dioxide, T and B lymphocytes responsible for cell- and 25 antibody-mediated immune responses, platelets or thrombocytes specialized to form blood clots, and granulocytes and macrophages specialized as scavengers and as accessory cells to combat infection. Granulocytes are further subdivided into; neutrophils, eosinophils, basophils and mast cells, specialized cell types having discrete functions. Remarkably, these specialized mature blood cells are all derived 30 from a single common primitive cell type, referred to as the pluripotential (totipotent) stem cells, found primarily in bone marrow (Dexter *et al.*, *Ann. Rev. Cell Biol.*, 3:423-441 [1987]).

35 Large numbers of mature blood cells are produced continuously throughout life, the vast majority of which are destined to remain functionally active for only a few hours to weeks (Cronkite *et al.*, *Blood Cells*, 2:263-284 [1976]). Thus, continuous renewal of mature blood cells, the primitive stem cells themselves, as well as any

intermediate or lineage-committed progenitor cell lines is necessary to maintain the normal steady state blood cell needs of the mammal.

At the heart of the hematopoietic system is the pluripotent stem cell(s). These are relatively few in number and undergo self-renewal by proliferation to produce 5 daughter stem cells or are transformed, in a series of differentiation steps, into increasingly mature lineage-restricted progenitor cells.

For example, certain multipotent progenitor cells, referred to as CFC-Mix, derived from stem cells undergo proliferation (self-renewal) and development to produce colonies containing all the different myeloid cells: erythrocytes, neutrophils, 10 megakaryocytes (predecessors of platelets), macrophages, basophils, eosinophils, and mast cells. Other progenitor cells of the lymphoid lineage undergo proliferation and development into T-cells and B-cells.

Additionally, between the CFC-Mix progenitor cells and myeloid cells lie another rank of progenitor cells of intermediate commitment to their progeny. These 15 lineage-restricted progenitor cells are classified on the basis of the progeny they produce. Thus, the known immediate predecessors of the myeloid cells are: erythroid colony-forming units (CFU-E) for erythrocytes, granulocyte/macrophage colony-forming cells (GM-CFC) for neutrophils and macrophages, megakaryocyte colony-forming cells (Meg-CFC) for megakaryocytes, eosinophil colony-forming cells (Eos- 20 CFC) for eosinophils, and basophil colony-forming cells (Bas-CFC) for mast cells. Other intermediate predecessor cells between the pluripotent stem cells and mature blood cells are known (see below) or will likely be discovered having varying degrees of lineage-restriction and self-renewal capacity.

The underlying principal of the normal hematopoietic cell system appears to be 25 decreased capacity of self-renewal as multipotency is lost and lineage-restriction and maturity is acquired. Thus, at one end of the hematopoietic cell spectrum lies the pluripotent stem cell possessing the capacity for self-renewal and differentiation into various lineage-specific committed progenitor cells. This capacity is the basis of bone marrow transplant therapy where stem cells reconstitute the entire hematopoietic cell 30 system. At the other end of the spectrum lie the highly lineage-restricted progenitors and their progeny which have lost the ability of self-renewal but have acquired mature functional activity.

The proliferation and development of stem cells and lineage-restricted progenitor cells is carefully controlled by a variety of hematopoietic growth factors or 35 cytokines. The role of these growth factors *in vivo* is complex and incompletely understood. Some growth factors, such as interleukin-3 (IL-3), are capable of

stimulating both multipotent stem cells as well as committed progenitor cells of several lineages, including for example, megakaryocytes. Other factors such as granulocyte/macrophage colony-stimulating factor (GM-CSF) was initially thought to be restricted in its action to GM-CFC's. Later, however, it was discovered GM-CSF 5 also influenced the proliferation and development of *interalia* megakaryocytes. Thus, IL-3 and GM-CSF were found to have overlapping biological activities, although with differing potency. More recently, both interleukin-6 (IL-6) and interleukin-11 (IL-11), while having no apparent influence on meg-colony formation alone, act synergistically with IL-3 to stimulate maturation of megakaryocytes (Yonemura *et al.*, *Exp. Hematol.*, 10 **20**:1011-1016 [1992]).

Thus, hematopoietic growth factors may influence growth and differentiation of one or more lineages, may overlap with other growth factors in affecting a single progenitor cell line, or may act synergistically with other factors.

It also appears that hematopoietic growth factors can exhibit their effect at 15 different stages of cell development from the totipotent stem cell through various committed lineage-restricted progenitors to the mature blood cell. For example, erythropoietin (EPO) appears to promote proliferation only of mature erythroid progenitor cells. IL-3 appears to exert its effect earlier influencing primitive stem cells and intermediate lineage-restricted progenitor cells. Other growth factors such as 20 stem cell factor (SCF) may influence even more primitive cell development.

It will be appreciated from the foregoing that novel hematopoietic growth factors that affect survival, proliferation, differentiation or maturation of any of the blood cells or 25 predecessors thereof would be useful, especially to assist in the re-establishment of a diminished hematopoietic system caused by disease or after radiation- or chemo- therapy.

II. Megakaryocytopoiesis

Regulation of megakaryocytopoiesis and platelet production has been reviewed by: Mazur, E. M., *Exp. Hematol.* **15**:248 [1987] and Hoffman, R., *Blood*, **74**:1196-1212 30 [1989]. Briefly, bone marrow pluripotent stem cells differentiate into megakaryocytic, erythrocytic, and myelocytic cell lines. It is believed there is a hierarchy of committed megakaryocytic progenitor cells between stem cells and megakaryocytes. At least three classes of megakaryocytic progenitor cells have been identified, namely; burst forming unit megakaryocytes (BFU-MK), colony-forming unit megakaryocytes (CFU- 35 MK), and light density megakaryocyte progenitor cells (LD-CFU-MK). Megakaryocytic maturation itself is a continuum of development that has been separated into stages

based on standard morphologic criteria. The earliest recognizable member of the megakaryocyte (MK) family are the megakaryoblasts. These cells are initially 20 to 30 μm in diameter having basophilic cytoplasm and a slightly irregular nucleus with loose, somewhat reticular chromatin and several nucleoli. Later, megakaryoblasts 5 may contain up to 32 nuclei, but the cytoplasm remains sparse and immature. As maturation proceeds, the nucleus becomes more lobulate and pyknotic, the cytoplasm increases in quantity and becomes more acidophilic and granular. The most mature cells of this family may give the appearance of releasing platelets at their periphery. Normally, less than 10% of megakaryocytes are in the blast stage and more than 50% 10 are mature. Arbitrary morphologic classifications commonly applied to the megakaryocyte series are megakaryoblast for the earliest form; promegakaryocyte or basophilic megakaryocyte for the intermediate form; and mature (acidophilic, granular, or platelet-producing) megakaryocyte for the late forms. The mature megakaryocyte extends filaments of cytoplasm into sinusoidal spaces where they detach and fragment 15 into individual platelets (Williams *et al.*, *Hematology*, 1972).

Megakaryocytopoiesis is believed to involve several regulatory factors (Williams *et al.*, *Br. J. Haematol.*, **52**:173 [1982] and Williams *et al.*, *J. Cell Physiol.*, **110**:101 [1982]). The early level of megakaryocytopoiesis is postulated as being mitotic, concerned with cell proliferation and colony initiation from CFU-MK but is not affected 20 by platelet count (Burstein *et al.*, *J. Cell Physiol.*, **109**:333 [1981] and Kimura *et al.*, *Exp. Hematol.*, **13**:1048 [1985]). The later stage of maturation is non-mitotic, involved with nuclear polyploidization and cytoplasmic maturation and is probably regulated in a feedback mechanism by peripheral platelet number (Odell *et al.*, *Blood*, **48**:765 [1976] and Ebbe *et al.*, *Blood*, **32**:787 [1968]). The existence of a distinct and specific 25 megakaryocyte colony-stimulating factor (MK-CSF) has been disputed (Mazur, E., *Exp. Hematol.*, **15**:340-350 [1987]). However most authors believe that a process so vital to survival as platelet production would be regulated by cytokine(s) exclusively responsible for this process. The hypothesis that megakaryocyte/platelet specific cytokine(s) exist has provided the basis for more than 30 years of search but to date no 30 such cytokine has been purified, sequenced and established by assay as a unique MK-CSF.

Although it has been reported that MK-CSF's have been partly purified from experimentally produced thrombocytopenia (Hill *et al.*, *Exp. Hematol.*, **14**:752 [1986]) and human embryonic kidney conditioned medium [CM] (McDonald *et al.*, *J. Lab. Clin. Med.*, **85**:59 [1975]) and in man from a plastic anemia and idiopathic thrombocytopenic purpura urinary extracts (Kawakita *et al.*, *Blood*, **6**:556 [1983]) and

plasma (Hoffman *et al.*, *J. Clin. Invest.*, **75**:1174 [1985]), their physiological function is as yet unknown in most cases.

The conditioned medium of pokeweed mitogen-activated spleen cells (PWM-SpCM) and the murine myelomonocyte cell line WEHI-3 (WEHI-3CM) have been used as megakaryocyte potentiators. PWM-SpCM contains factors enhancing CFU-MK growth (Metcalf *et al.*, *Proc. Natl. Acad. Sci., USA*, **72**:1744-1748 [1975]; Quesenberry *et al.*, *Blood*, **65**:214 [1985]; and Iscove, N.N., in *Hematopoietic Cell Differentiation, ICN-UCLA Symposia on Molecular and Cellular Biology*, Vol. 10, Golde *et al.*, eds. [New York, Academy Press] pp 37-52 [1978]), one of which is interleukin-3 (IL-3), a multilineage colony stimulating factor (multi-CSF [Burstein, S.A., *Blood Cells*, **11**:469 [1986]). The other factors in this medium have not yet been identified and isolated. WEHI-3 is a murine myelomonocytic cell line secreting relatively large amounts of IL-3 and smaller amounts of GM-CSF. IL-3 has been found to potentiate the growth of a wide range of hematopoietic cells (Ihle *et al.*, *J. Immunol.*, **13**:282 [1983]). IL-3 has also been found to synergize with many of the known hematopoietic hormones or growth factors (Bartelmez *et al.*, *J. Cell Physiol.*, **122**:362-369 [1985] and Warren *et al.*, *Cell*, **46**:667-674 [1988]), including both erythropoietin (EPO) and interleukin-1 (IL-1), in the induction of very early multipotential precursors and the formation of very large mixed hematopoietic colonies.

Other sources of megakaryocyte potentiators have been found in the conditioned media of murine lung, bone, macrophage cell lines, peritoneal exudate cells and human embryonic kidney cells. Despite certain conflicting data (Mazur, E., *Exp. Hematol.*, **15**:340- 350 [1987]), there is some evidence (Geissler *et al.*, *Br. J. Haematol.*, **60**:233-238 [1985]) that activated T lymphocytes rather than monocytes play an enhancing role in megakaryocytopoiesis. These findings suggest that activated T-lymphocyte secretions such as interleukins may be regulatory factors in MK development (Geissler *et al.*, *Exp. Hematol.*, **15**:845-853 [1987]). A number of studies on megakaryocytopoiesis with purified erythropoietin EPO (Vainchenker *et al.*, *Blood*, **54**:940 [1979]; McLeod *et al.*, *Nature*, **261**:492-4 [1976]; and Williams *et al.*, *Exp. Hematol.*, **12**:734 [1984]) indicate that this hormone has an enhancing effect on MK colony formation. This has also been demonstrated in both serum-free and serum-containing cultures and in the absence of accessory cells (Williams *et al.*, *Exp. Hematol.*, **12**:734 [1984]). EPO was postulated to be involved more in the single and two-cell stage aspects of megakaryocytopoiesis as opposed to the effect of PWM-SpCM which was involved in the four-cell stage of megakaryocyte development. The

interaction of all these factors on both early and late phases of megakaryocyte development remains to be elucidated.

Data produced from several laboratories suggests that the only multi-lineage factors that individually have MK-colony stimulating activity are GM-CSF and IL-3 and, 5 to a lesser extent, the B-cell stimulating factor IL-6 (Ikebuchi *et al.*, *Proc. Natl. Acad. Sci. USA*, **84**:9035 [1987]). More recently, several authors have reported that IL-11 and leukemia inhibitory factor (LIF) act synergistically with IL-3 to increase megakaryocyte size and ploidy (Yonemura *et al.*, *British Journal of Hematology*, **84**:16-23 [1993]; Burstein *et al.*, *J. Cell. Physiol.*, **153**:305-312 [1992]; Metcalf *et al.*, **10 Blood**, **76**:50-56 [1990]; Metcalf *et al.*, *Blood*, **77**:2150-2153 [1991]; Bruno *et al.*, *Exp. Hematol.*, **19**:378-381 [1991]; and Yonemura *et al.*, *Exp. Hematol.*, **20**:1011-1016 [1992]).

Other documents of interest include: Eppstein *et al.*, U.S. Patent No. 4,962,091; Chong, U.S. Patent No. 4,879,111; Fernandes *et al.*, U.S. Patent No. 4,604,377; 15 Wissler *et al.*, U.S. Patent No. 4,512,971; Gottlieb, U.S. Patent No. 4,468,379; Bennett *et al.*, U.S. Patent No. 5,215,895; Kogan *et al.*, U.S. Patent No. 5,250,732; Kimura *et al.*, *Eur. J. Immunol.*, **20**(9):1927-1931 [1990]; Secor *et al.*, *J. of Immunol.*, **144**(4):1484-1489 [1990]; Warren *et al.*, *J. of Immunol.*, **140**(1):94-99 [1988]; Warren *et al.*, *Exp. Hematol.*, **17**(11):1095-1099 [1989]; Bruno *et al.*, *Exp. Hematol.*, **20** **17**(10):1038-1043 [1989]; Tanikawa *et al.*, *Exp. Hematol.*, **17**(8):883-888 [1989]; Koike *et al.*, *Blood*, **75**(12):2286-2291 [1990]; Lotem, *Blood*, **75**(5):1545-1551 [1989]; Rennick *et al.*, *Blood*, **73**(7):1828-1835 [1989]; and Clutterbuck *et al.*, *Blood*, **73**(6):1504-1512 [1989].

25 III. Thrombocytopenia

Platelets are critical elements of the blood clotting mechanism. Depletion of the circulating level of platelets, called thrombocytopenia, occurs in various clinical conditions and disorders. Thrombocytopenia is commonly defined as a platelet count below 150×10^9 per liter. The major causes of thrombocytopenia can be broadly 30 divided into three categories on the basis of platelet life span, namely; (1) impaired production of platelets by the bone marrow, (2) platelet sequestration in the spleen (splenomegaly), or (3) increased destruction of platelets in the peripheral circulation (e.g., autoimmune thrombocytopenia or chemo- and radiation-therapy). Additionally, in patients receiving large volumes of rapidly administered platelet-poor blood 35 products, thrombocytopenia may develop due to dilution.

The clinical bleeding manifestations of thrombocytopenia depend on the severity of thrombocytopenia, its cause, and possible associated coagulation defects. In general, patients with platelet counts between 20 and 100×10^9 per liter are at risk of excessive post traumatic bleeding, while those with platelet counts below 20×10^9 per liter may bleed spontaneously. These latter patients are candidates for platelet transfusion with attendant immune and viral risk. For any given degree of thrombocytopenia, bleeding tends to be more severe when the cause is decreased production rather than increased destruction of platelets; in the latter situation, accelerated platelet turnover results in the circulation of younger, larger and hemostatically more effective platelets. Thrombocytopenia may result from a variety of disorders briefly described below. A more detailed description may be found in Schafner, A. I., "Thrombocytopenia and Disorders of Platelet Function," *Internal Medicine*, 3rd Ed., John J. Hutton et al., Eds., Little Brown and Co., Boston/Toronto/London [1990].

15 (a) Thrombocytopenia due to impaired platelet production

Causes of congenital thrombocytopenia include constitutional aplastic anemia (Fanconi syndrome) and congenital amegakaryocytic thrombocytopenia, which may be associated with skeletal malformations. Acquired disorders of platelet production are caused by either hypoplasia of megakaryocytes or ineffective thrombopoiesis. Megakaryocytic hypoplasia can result from a variety of conditions, including marrow aplasia (including idiopathic forms or myelosuppression by chemotherapeutic agents or radiation therapy), myelofibrosis, leukemia, and invasion of the bone marrow by metastatic tumor or granulomas. In some situations, toxins, infectious agents, or drugs may interfere with thrombopoiesis relatively selectively; examples include transient thrombocytopenias caused by alcohol and certain viral infections and mild thrombocytopenia associated with the administration of thiazide diuretics. Finally, ineffective thrombopoiesis secondary to megaloblastic processes (folate or B₁₂ deficiency) can also cause thrombocytopenia, usually with coexisting anemia and leukopenia.

30 Current treatment of thrombocytopenias due to decreased platelet production depends on identification and reversal of the underlying cause of the bone marrow failure. Platelet transfusions are usually reserved for patients with serious bleeding complications, or for coverage during surgical procedures, since isoimmunization may lead to refractoriness to further platelet transfusions. Mucosal bleeding resulting from 35 severe thrombocytopenia may be ameliorated by the oral or intravenous administration of the antifibrinolytic agents. Thrombotic complications may develop,

however, if antifibrinolytic agents are used in patients with disseminated intravascular coagulation (DIC).

(b) Thrombocytopenia due to splenic sequestration

Splenomegaly due to any cause may be associated with mild to moderate 5 thrombocytopenia. This is a largely passive process (hypersplenism) of splenic platelet sequestration, in contrast to the active destruction of platelets by the spleen in cases of immunomediated thrombocytopenia discussed below. Although the most common cause of hypersplenism is congestive splenomegaly from portal hypertension due to alcoholic cirrhosis, other forms of congestive, infiltrative, or lymphoproliferative 10 splenomegaly are also associated with thrombocytopenia. Platelet counts generally do not fall below 50×10^9 per liter as a result of hypersplenism alone.

(c) Thrombocytopenia due to nonimmune-mediated platelet destruction

Thrombocytopenia can result from the accelerated destruction of platelets by various nonimmunologic processes. Disorders of this type include disseminated 15 intravascular coagulation, prosthetic intravascular devices, extra corporeal circulation of the blood, and thrombotic microangiopathies such as thrombotic thrombocytic purpura. In all of these situations, circulating platelets that are exposed to either artificial surfaces or abnormal vascular intima either are consumed at these sites or are damaged and then prematurely cleared by the reticuloendothelial system. 20 Disease states or disorders in which disseminated intravascular coagulation (DIC) may arise are set forth in greater detail in Braunwald *et al.* (eds), *Harrison's Principles of Internal Medicine*, 11th Ed., p.1478, McGraw Hill [1987]. Intravascular prosthetic devices, including cardiac valves and intra-aortic balloons can cause a mild to moderate destructive thrombocytopenia and transient thrombocytopenia in patients 25 undergoing cardiopulmonary bypass or hemodialysis may result from consumption or damage of platelets in the extra corporeal circuit.

(d) Drug-induced immune thrombocytopenia

More than 100 drugs have been implicated in immunologically mediated 30 thrombocytopenia. However, only quinidine, quinine, gold, sulfonamides, cephalothin, and heparin have been well characterized. Drug-induced thrombocytopenia is frequently very severe and typically occurs precipitously within days while patients are taking the sensitizing medication.

(e) Immune (autoimmune) thrombocytopenic purpura (ITP)

ITP in adults is a chronic disease characterized by autoimmune platelet 35 destruction. The autoantibody is usually IgG although other immunoglobulins have also been reported. Although the autoantibody of ITP has been found to be

associated with platelet membrane GPII_bIII_a, the platelet antigen specificity has not been identified in most cases. Extravascular destruction of sensitized platelets occurs in the reticuloendothelial system of the spleen and liver. Although over one-half of all cases of ITP are idiopathic, many patients have underlying rheumatic or autoimmune diseases (e.g., systemic lupus erythematosus) or lymphoproliferative disorders (e.g., chronic lymphocytic leukemia).

5 (f) HIV-Induced ITP

ITP is an increasingly common complication of HIV infection (Morris *et al.*, *Ann. Intern. Med.*, **96**:714-717 [1982]), and can occur at any stage of the disease progression, both in patients diagnosed with the Acquired Immune Deficiency Syndrome (AIDS), those with AIDS-related complex, and those with HIV infection but without AIDS symptoms. HIV infection is a transmissible disease ultimately characterized by a profound deficiency of cellular immune function as well as the occurrence of opportunistic infection and malignancy. The primary immunologic 15 abnormality resulting from infection by HIV is the progressive depletion and functional impairment of T lymphocytes expressing the CD4 cell surface glycoprotein (Lane *et al.*, *Ann. Rev. Immunol.*, **3**:477 [1985]). The loss of CD4 helper/inducer T cell function probably underlies the profound defects in cellular and humoral immunity leading to the opportunistic infections and malignancies characteristic of AIDS (H. Lane *supra*).

20 Although the mechanism of HIV-associated ITP is unknown, it is believed to be different from the mechanism of ITP not associated with HIV infection. (Walsh *et al.*, *N. Eng. J. Med.*, **311**:635-639 [1984]; and Ratner, L., *Am. J. Med.*, **86**:194-198 [1989]).

IV. Therapy

25 The therapeutic approach to the treatment of patients with HIV-induced ITP is dictated by the severity and urgency of the clinical situation. The treatment is similar for HIV-associated and non-HIV-related ITP, and although a number of different therapeutic approaches have been used, the therapy remains controversial.

30 Platelet counts in patients diagnosed with ITP have been successfully increased by glucocorticoid (e.g., prednisolone) therapy, however in most patients, the response is incomplete, or relapse occurs when the glucocorticoid dose is reduced or its administration is discontinued. Based upon studies with patients having HIV-associated ITP, some investigators have suggested that glucocorticoid therapy may result in predisposition to AIDS. Glucocorticoids are usually administered if platelet 35 count falls below 20 X 10⁹/liter or when spontaneous bleeding occurs.

For patients refractory to glucocorticoids, the compound 4-(2-chlorophenyl)-9-methyl-2-[3-(4-morpholinyl)-3-propanon-1-yl]6H-thieno[3,2,f][1,2,4]triazolo[4,3,a,][1,4]diazepin (WEB 2086) has been successfully used to treat a severe case of non HIV-associated ITP. A patient having platelet counts of 37,000-58,000/ μ l was treated with 5 WEB 2086 and after 1-2 weeks treatment platelet counts increased to 140,000-190,000/ μ l. (EP 361,077 and Lohman *et al.*, *Lancet*, 1147 [1988]).

Although the optimal treatment for acquired amegakaryocytic thrombocytopenia purpura (AATP) is uncertain, antithymocyte globulin (ATG), a horse antiserum to human thymus tissue, has been shown to produce prolonged complete remission 10 (Trimble *et al.*, *Am. J. Hematol.*, 37:126-127 [1991]). A recent report however, indicates that the hematopoietic effects of ATG are attributable to thimerosal, where presumably the protein acts as a mercury carrier (Panella *et al.*, *Cancer Research*, 50:4429-4435 [1990]).

Good results have been reported with splenectomy. Splenectomy removes the 15 major site of platelet destruction and a major source of autoantibody production in many patients. This procedure results in prolonged treatment-free remissions in a large number of patients. However, since surgical procedures are generally to be avoided in immune compromised patients, splenectomy is recommended only in 20 severe cases of HIV-associated ITP, in patients who fail to respond to 2 to 3 weeks of glucocorticoid treatment, or do not achieve sustained response after discontinuation of glucocorticoid administration. Based upon current scientific knowledge, it is unclear whether splenectomy predisposes patients to AIDS.

In addition to prednisolone therapy and splenectomy, certain cytotoxic agents, e.g., vincristine, and azidothimidine (AZT, zidovudine) also show promise in treating 25 HIV-induced ITP; however, the results are preliminary.

It will be appreciated from the foregoing that one way to treat thrombocytopenia would be to obtain an agent capable of accelerating the differentiation and maturation of megakaryocytes or precursors thereof into the platelet-producing form. Considerable efforts have been expended on identifying such an agent, commonly 30 referred to as "thrombopoietin" (TPO). Other names for TPO commonly found in the literature include; thrombocytopoiesis stimulating factor (TSF), megakaryocyte colony-stimulating factor (MK-CSF), megakaryocyte-stimulating factor and megakaryocyte 35 potentiator. TPO activity was observed as early as 1959 (Rak *et al.*, *Med. Exp.*, 1:125) and attempts to characterize and purify this agent have continued to the present day. While reports of partial purification of TPO-active polypeptides exist (see, for example, Tayrien *et al.*, *J. Biol. Chem.*, 262:3262 [1987] and Hoffman *et al.*, *J. Clin. Invest.*

75:1174 [1985]), others have postulated that TPO is not a discrete entity in its own right but rather is simply the polyfunctional manifestation of a known hormone (IL-3, Sparrow *et al.*, *Prog. Clin. Biol. Res.*, **215**:123 [1986]). Regardless of its form or origin, a molecule possessing thrombopoietic activity would be of significant therapeutic 5 value. Although no protein has been unambiguously identified as TPO, considerable interest surrounds the recent discovery that *mpl*, a putative cytokine receptor, may transduce a thrombopoietic signal.

V. *Mpl* is a cytokine receptor

10 It is believed that the proliferation and maturation of hematopoietic cells is tightly regulated by factors that positively or negatively modulate pluripotential stem cell proliferation and multilineage differentiation. These effects are mediated through the high-affinity binding of extracellular protein factors to specific cell surface receptors. These cell surface receptors share considerable homology and are generally 15 classified as members of the cytokine receptor superfamily. Members of the superfamily include receptors for: IL-2 (beta and gamma chains) (Hatakeyama *et al.*, *Science*, **244**:551-556 [1989]; Takeshita *et al.*, *Science*, **257**:379-382 [1991]), IL-3 (Itoh *et al.*, *Science*, **247**:324-328 [1990]; Gorman *et al.*, *Proc. Natl. Acad. Sci. USA*, **87**:5459-5463 [1990]; Kitamura *et al.*, *Cell*, **66**:1165-1174 [1991a]; Kitamura *et al.*, *Proc. Natl. Acad. Sci. USA*, **88**:5082-5086 [1991b]), IL-4 (Mosley *et al.*, *Cell*, **59**:335-348 [1989], IL-5 (Takaki *et al.*, *EMBO J.*, **9**:4367-4374 [1990]; Tavernier *et al.*, *Cell*, **66**:1175-1184 [1991]), IL-6 (Yamasaki *et al.*, *Science*, **241**:825-828 [1988]; Hibi *et al.*, *Cell*, **63**:1149-1157 [1990]), IL-7 (Goodwin *et al.*, *Cell*, **60**:941-951 [1990]), IL-9 (Renault *et al.*, *Proc. Natl. Acad. Sci. USA*, **89**:5690-5694 [1992]), granulocyte-25 macrophage colony-stimulating factor (GM-CSF) (Gearing *et al.*, *EMBO J.*, **8**:3667-3676 [1991]; Hayashida *et al.*, *Proc. Natl. Acad. Sci. USA*, **244**:9655-9659 [1990]), granulocyte colony-stimulating factor (G-CSF) (Fukunaga *et al.*, *Cell*, **61**:341-350 [1990a]; Fukunaga *et al.*, *Proc. Natl. Acad. Sci. USA*, **87**:8702-8706 [1990b]; Larsen *et al.*, *J. Exp. Med.*, **172**:1559-1570 [1990]), EPO (D'Andrea *et al.*, *Cell*, **57**:277-285 [1989]; Jones *et al.*, *Blood*, **76**:31-35 [1990]), Leukemia inhibitory factor (LIF) (Gearing *et al.*, *EMBO J.*, **10**:2839-2848 [1991]), oncostatin M (OSM) (Rose *et al.*, *Proc. Natl. Acad. Sci. USA*, **88**:8641-8645 [1991]) and also receptors for prolactin (Boutin *et al.*, *Proc. Natl. Acad. Sci. USA*, **88**:7744-7748 [1988]; Edery *et al.*, *Proc. Natl. Acad. Sci. USA*, **86**:2112-2116 [1989]), growth hormone (GH) (Leung *et al.*, *Nature*, **330**:537-35 543 [1987]) and ciliary neurotrophic factor (CNTF) (Davis *et al.*, *Science*, **253**:59-63 [1991].

Members of the cytokine receptor superfamily may be grouped into three functional categories (for review see Nicola *et al.*, *Cell*, **67**:1-4 [1991]). The first class comprises single chain receptors, such as erythropoietin receptor (EPO-R) or granulocyte colony stimulating factor receptor (G-CSF-R), which bind ligand with high affinity via the extracellular domain and also generate an intracellular signal. A second class of receptors, so called α -subunits, includes interleukin-6 receptor (IL6-R), granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R), interleukin-3 receptor (IL3-R α) and other members of the cytokine receptor superfamily. These α -subunits bind ligand with low affinity but cannot transduce an intracellular signal. A high affinity receptor capable of signaling is generated by a heterodimer between an α -subunit and a member of a third class of cytokine receptors, termed β -subunits, *e.g.*, β_c , the common β -subunit for the three α -subunits IL3-R α and GM-CSF-R. *IL6-R α*

Evidence that *mpl* is a member of the cytokine receptor superfamily comes from sequence homology (Gearing, D.P., *EMBO J.*, **8**:3667-3676 [1989]; Bazan, J. F., *Proc. Natl. Acad. Sci. USA*, **87**:~~6834-6838~~¹⁹⁸⁹ [1990]; Davis S., *et al.*, *Science*, **253**:59-63 [1991] and Vigon *et al.*, *Proc. Natl. Acad. Sci. USA*, **89**:5640-5644 [1992]) and its ability to transduce proliferative signals.

Deduced protein sequence from molecular cloning of murine *c-mpl* reveals this protein is homologous to other cytokine receptors. The extracellular domain contains 465 amino acid residues and is composed of two subdomains each with four highly conserved cysteines and a particular motif in the N-terminal subdomain and in the C-terminal subdomain. The ligand-binding extracellular domains are predicted to have similar double β -barrel fold structural geometries. This duplicated extracellular domain is highly homologous to the signal transducing chain common to IL-3, IL-5 and GM-CSF receptors as well as the low-affinity binding domain of LIF (Vigon *et al.*, *Oncogene*, **8**:2607-2615 [1993]). Thus *mpl* may belong to the low affinity ligand binding class of cytokine receptors.

The extracellular domain is followed by a 22 residue transmembrane domain and a 121 residue cytoplasmic domain rich in serine and proline. The cytoplasmic domain contains no consensus protein kinase or phosphatase motif associated with signal transduction.

A comparison of murine *mpl* and mature human *mpl* P, reveals these two proteins show 81% sequence identity. More specifically, the N-terminus and C-terminus extracellular subdomains share 75% and 80% sequence identity respectively. The most conserved *mpl* region is the cytoplasmic domain showing 91%

amino acid identity, with a sequence of 37 residues near the transmembrane domain being identical in both species. Accordingly, *mpl* is reported to be one of the most conserved members of the cytokine receptor superfamily (Vigon *supra*).

Evidence that *mpl* is a functional receptor capable of transducing a proliferative signal comes from construction of chimeric receptors containing an extracellular domain from a cytokine receptor having high affinity for a known cytokine with the *mpl* cytoplasmic domain. Since no known ligand for *mpl* has been reported, it was necessary to construct the chimeric high affinity ligand binding extracellular domain from a class one cytokine receptor such as IL-4R or G-CSFR. Vigon *et al.*, *supra* fused the extracellular domain of G-CSFR with both the transmembrane and cytoplasmic domain of c-*mpl*. An IL-3 dependent cell line, BAF/B03 was transfected with the G-CSFR/*mpl* chimera along with a full length G-CSFR control. Cells transfected with the chimera grew equally well in the presence of cytokine IL-3 or G-CSF. Similarly, cells transfected with G-CSFR also grew well in either IL-3 or G-CSF. All cells died in the absence of growth factors. A similar experiment was conducted by Skoda *et al.*, *EMBO J.*, 12(7):2645-2653 [1993] in which both the extracellular and transmembrane domains of human IL-4 receptor (hIL-4-R) were fused to the murine *mpl* cytoplasmic domain, and transfected into a murine IL-3 dependent Ba/F3 cell line. Ba/F3 cells transfected with wildtype hIL-4-R proliferated normally in the presence of either of the species specific IL-4 or IL-3. Ba/F3 cells transfected with hIL-4R/*mpl* proliferated normally in the presence of hIL-4 (in the presence or absence of IL-3) demonstrating that in Ba/F3 cells the *mpl* cytoplasmic domain contains all the elements necessary to transduce a proliferative signal.

These chimeric experiments demonstrate the proliferation signaling capability of the *mpl* extracellular domain but are silent regarding whether the *mpl* extracellular domain can bind a ligand. These results are consistent with at least two possibilities, namely, *mpl* is a single chain (class one) receptor like EPO-R or G-CSFR or it is a signal transducing β -subunit (class three) requiring an α -subunit like IL-3 (Skoda *et al.* *supra*).

VI. *Mpl* ligand stimulates megakaryocytopoiesis

As described above, it has been suggested that serum contains a unique factor, sometimes referred to as thrombopoietin, that acts synergistically with various other cytokines to promote growth and maturation of megakaryocytes. No such natural factor has ever been isolated from serum or any other source even though considerable effort has been expended by numerous groups. Even though it is not

known whether *mpl* is capable of directly binding a megakaryocyte stimulating factor, recent experiments demonstrate that *mpl* is involved in proliferative signal transduction from a factor or factors found in the serum of patients with aplastic bone marrow (Methia *et al.*, *Blood*, 82(5):1395-1401 [1993]).

5 Evidence that a unique serum colony-forming factor distinct from IL-1 α , IL-3, IL-4, IL-6, IL-11, SCF, EPO, G-CSF, and GM-CSF transduces a proliferative signal through *mpl* comes from examination of the distribution of c-*mpl* expression in primitive and committed hematopoietic cell lines and from *mpl* antisense studies in one of these cell lines.

10 Using reverse transcriptase (RT)-PCR in immuno-purified human hematopoietic cells, Methia *et al.*, *supra* demonstrated that strong *mpl* mRNA messages were only found in CD34 $^{+}$ purified cells, megakaryocytes and platelets. CD34 $^{+}$ cells purified from bone marrow (BM) represents about 1% of all BM cells and are enriched in primitive and committed progenitors of all lineages (e.g., erythroid, 15 granulomacrophage, and megakaryocytic).

15 *Mpl* antisense oligodeoxynucleotides were shown to suppress megakaryocytic colony formation from the pluripotent CD34 $^{+}$ cells cultured in serum from patients with aplastic marrow (a rich source of megakaryocyte colony-stimulating activity [MK-CSA]). These same antisense oligodeoxynucleotides had no effect on erythroid or 20 granulomacrophage colony formation.

25 Whether *mpl* directly binds a ligand and whether the serum factor shown to cause megakaryocytopoiesis acts through *mpl* is still unknown. It has been suggested, however, that if *mpl* does directly bind a ligand, its amino acid sequence is likely to be highly conserved and have species cross-reactivity owing to the considerable sequence identity between human and murine *mpl* extracellular domains (Vigon *et al.*, *supra* [1993]).

30 In view of the foregoing, it will be appreciated there is a current and continuing need in the art to isolate and identify molecules capable of stimulating proliferation, differentiation and maturation of hematopoietic cells, especially megakaryocytes or their predecessors for therapeutic use in the treatment of thrombocytopenia. It is believed such a molecule is a *mpl* ligand and thus there exists a further need to isolate 35 such ligand(s) to evaluate their role(s) in cell growth and differentiation.

Accordingly, it is an object of this invention to obtain a pharmaceutically pure molecule capable of stimulating proliferation, differentiation and/or maturation of megakaryocytes into the mature platelet-producing form.

It is another object to provide the molecule in a form for therapeutic use in the treatment of a hematopoietic disorder, especially thrombocytopenia.

It is a further object of the present invention to isolate, purify and specifically identify protein ligands capable of binding *in vivo* a cytokine superfamily receptor 5 known as *mpl* and to transduce a proliferative signal.

It is still another object to provide nucleic acid molecules encoding such protein ligands and to use these nucleic acid molecules to produce *mpl* binding ligands in recombinant cell culture for diagnostic and therapeutic use.

It is yet another object to provide derivatives and modified forms of the protein 10 ligands including amino acid sequence variants, variant glycoprotein forms and covalent derivatives thereof.

It is an additional object to provide fusion polypeptide forms combining a *mpl* ligand and a heterologous protein and covalent derivatives thereof.

It is still an additional object to provide variant polypeptide forms combining a 15 *mpl* ligand with amino acid additions and substitutions from the EPO sequence to produce a protein capable of regulating proliferation and growth of both platelets and red blood cell progenitors.

It is yet an additional object to prepare immunogens for raising antibodies 20 against *mpl* ligands or fusion forms thereof, as well as to obtain antibodies capable of binding such ligands.

These and other objects of the invention will be apparent to the ordinary artisan upon consideration of the specification as a whole.

SUMMARY OF THE INVENTION

25 The objects of the invention are achieved by providing an isolated mammalian megakaryocytopoietic proliferation and maturation promoting protein capable of stimulating proliferation, maturation and/or differentiation of megakaryocytes into the mature platelet-producing form. This substantially homogeneous protein, denominated 30 the "mpl ligand" (ML), may be purified from a natural source by a method comprising; (1) contacting a source plasma containing the *mpl* ligand molecules to be purified with an immobilized receptor polypeptide, specifically *mpl* or a *mpl* fusion polypeptide immobilized on a support, under conditions whereby the *mpl* ligand molecules to be purified are selectively adsorbed onto the immobilized receptor polypeptide, (2) 35 washing the immobilized receptor polypeptide and its support to remove non-adsorbed material, and (3) eluting the molecules to be purified from the immobilized

receptor polypeptide to which they are adsorbed with an elution buffer. Preferably the natural source is mammalian plasma or urine containing the *mpl* ligand. Optionally the mammal is aplastic and the immobilized receptor is a *mpl*-IgG fusion. Also preferably the immobilized support is washed with PBS/PBS in 2M NaCl and the elution buffer is 0.1M glycine-HCl, pH 2.25. The most ~~preferred~~ ^{referred} megakaryocytopoietic proliferation and maturation promoting protein is an isolated substantially homogeneous *mpl* ligand polypeptide made by recombinant means.

The "*mpl* ligand" polypeptide of this invention preferably has at least 80% sequence identity with the amino acid sequence of the highly purified substantially homogeneous human *mpl* ligand polypeptide. Optionally, the *mpl* ligand of this invention is mature human *mpl* ligand, having the mature amino acid sequence provided in **Fig. 8** (SEQ ID NO: 1), or a posttranscriptionally modified form thereof or a protein having about 80% sequence identity with mature human *mpl* ligand. Optionally the *mpl* ligand polypeptide or fragment thereof may be fused to a heterologous polypeptide (chimera). A preferred heterologous polypeptide is a cytokine or fragment thereof, especially kit-ligand, IL-1, IL-3, IL-6, IL-11, EPO, GM-CSF and LIF.

Another aspect of this invention provides a composition comprising an isolated *mpl* ligand that is biologically active and is preferably capable of stimulating the incorporation of labeled nucleotides (e.g., 3 H-thymidine) into the DNA of IL-3 dependent Ba/F3 cells transfected with human *mpl*. Optionally, the biologically active *mpl* ligand is preferably capable of stimulating the incorporation of 35 S into circulating platelets in a mouse platelet rebound assay.

In another embodiment, this invention provides an isolated antibody capable of binding to the *mpl* ligand. The isolated antibody capable of binding to the *mpl* ligand may optionally be fused to a second polypeptide and the antibody or fusion thereof may be used to isolate and purify *mpl* ligand from a source as described above for immobilized *mpl*. In a further aspect of this embodiment, the invention provides a method for detecting the *mpl* ligand *in vitro* or *in vivo* comprising contacting the antibody with a sample, especially a serum sample, suspected of containing the ligand and detecting if binding has occurred.

In still further embodiments, the invention provides an isolated nucleic acid molecule, encoding the *mpl* ligand or fragments thereof, which nucleic acid molecule may optionally be labeled with a detectable moiety, and a nucleic acid molecule having a sequence that is complementary to, or hybridizes under moderate to highly stringent conditions with, a nucleic acid molecule having a sequence encoding a *mpl*

ligand. Preferred nucleic acid molecules are those encoding human, porcine, and murine *mpl* ligand, and include RNA and DNA, both genomic and cDNA. In a further aspect of this embodiment, the nucleic acid molecule is DNA encoding the *mpl* ligand and further comprises a replicable vector in which the DNA is operably linked to 5 control sequences recognized by a host transformed with the vector. Optionally the DNA is cDNA having the sequence provided in **Fig. 8**, 5'-3' (SEQ ID NO: 2) 3'-5' or a fragment thereof. This aspect further includes host cells transformed with the vector and a method of using the DNA to effect production of *mpl* ligand, preferably comprising expressing the cDNA encoding the *mpl* ligand in a culture of the 10 transformed host cells and recovering the *mpl* ligand from the host cells or the host cell culture. The *mpl* ligand prepared in this manner is preferably human *mpl* ligand.

The invention further includes a method for treating a mammal having a hematopoietic disorder, especially thrombocytopenia, comprising administering a therapeutically effective amount of a *mpl* ligand to the mammal. Optionally the *mpl* 15 ligand is administered in combination with a cytokine, especially a colony stimulating factor or interleukin. Preferred colony stimulating factors or interleukins include; kit-ligand, LIF, G-CSF, GM-CSF, M-CSF, EPO, IL-1, IL-3, IL-6, and IL-11.

BRIEF DESCRIPTION OF THE FIGURES

Fig. 1 shows the effect of pronase, DTT and heat on the ability of APP to stimulate Ba/F3-*mpl* cell proliferation. For pronase digestion of APP, pronase (Boehringer Mannheim) or bovine serum albumin was coupled to Affi-gel10 (Biorad) and incubated individually with APP for 18hrs. at 37°C. Subsequently, the resins were removed by centrifugation and supernatants assayed. APP was also heated to 80°C for 4 min. or made 100µM DTT followed by dialysis against PBS.

Fig. 2 shows the elution of *mpl* ligand activity from Phenyl-Toyopearl, Blue-Sepharose and Ultralink-*mpl* columns. Fractions 4-8 from the *mpl* affinity column were the peak activity fractions eluted from the column.

Fig. 3 shows the SDS-PAGE of eluted Ultralink-*mpl* fractions. To 200µl of each fraction 2-8, 1 ml of acetone containing 1mM HCl at -20°C was added. After 3hrs. at -20°C samples were centrifuged and resultant pellets were washed 2x with acetone at -20°C. The acetone pellets were subsequently dissolved in 30 µl of SDS-solubilization buffer, made 100µM DTT and heated at 90°C for 5 min. The samples were then resolved on a 4-20% SDS-polyacrylamide gel and proteins were visualized by silver staining.

Fig. 4 shows elution of *mpl* ligand activity from SDS-PAGE. Fraction 6 from the *mpl*-affinity column was resolved on a 4-20% SDS-polyacrylamide gel under non-reducing conditions. Following electrophoresis the gel was sliced into 12 equal regions and electroeluted as described in the examples. The electroeluted samples were dialyzed into PBS and assayed at a 1/20 dilution. The Mr standards used to calibrate the gel were Novex Mark 12 standards.

Fig. 5 shows the effect of *mpl* ligand depleted APP on human megakaryocytopoiesis. *mpl* ligand depleted APP was made by passing 1 ml over a 1 ml *mpl*-affinity column (700 µg *mpl*-IgG/ml NHS-superose, Pharmacia). Human peripheral stem cell cultures were made 10% APP or 10% *mpl* ligand depleted APP and cultured for 12 days. Megakaryocytopoiesis was quantitated as described in the examples.

Fig. 6. shows the effect of *mpl*-IgG on the stimulation of human megakaryocytopoiesis by APP. Human peripheral stem cell cultures were made 10% with APP and cultured

for 12 days. At day 0, 2 and 4, *mpl*-IgG (0.5 μ g) or ANP-R-IgG (0.5 μ g) was added. After 12 days megakaryocytopoiesis was quantitated as described in the examples. The average of duplicate samples is graphed with the actual duplicate data in parenthesis.

5 **Fig. 7.** shows both strands of a 390 bp fragment of human genomic DNA encoding the *mpl* ligand. The deduced amino acid sequence of "exon 3" (SEQ ID NO: 3), the coding sequence (SEQ ID NO: 4), and its compliment (SEQ ID NO: 5) are shown.

10 **Fig. 8.** shows the nucleotide sequence: coding (SEQ ID NO: 2) and deduced amino acid sequence (SEQ ID NO: 1) of human *mpl* ligand cDNA. Nucleotides are numbered at the beginning of each line. The 5' and 3' untranslated regions are indicated in lower case letters. Amino acid residues are numbered above the sequence starting at Ser 1 of the mature *mpl* ligand (ML) protein sequence. The
B ^{boundaries}_{boundaries} of presumed exon 3 are indicated by the arrows and the potential N-
15 glycosylation sites are boxed. Cysteine residues are indicated by a dot above the sequence. The underlined sequence correspond to the N-terminal sequence determined from *mpl* ligand purified from porcine plasma.

A 20 **Fig. 9.** shows deduced amino acid sequence of human *mpl* ligand (h-ML) (SEQ ID NO: 9) and human erythropoietin (h-epo) (SEQ ID NO: 6). The predicted amino acid sequence for the human *mpl* ligand is aligned with the human erythropoietin sequence. Identical amino acids are boxed and gaps introduced for optimal alignment are indicated by dashes. Potential N-glycosylation sites are underlined with a plain line for the h-ML and with a broken line for h-epo. The two cysteines important for
25 erythropoietin activity are indicated by a large dot.

A 28 **Fig. 10.** shows the nucleotide sequence: coding (SEQ ID NO: 7) and deduced A amino acid sequence (SEQ ID NO: 8) of murine *mpl* ligand cDNA. Nucleotides are numbered at the beginning of each line. Amino acid residues are numbered above 30 the sequence starting at Ser 1 of the mature *mpl* ligand (ML) protein sequence. The potential N-glycosylation sites are underlined. Cysteine residues are indicated by a dot above the sequence.

A 35 **Fig. 11.** shows deduced amino acid sequence of mature human *mpl* ligand (hML) (SEQ ID NO: 1) and murine *mpl* ligand (mML) (SEQ ID NO: 2). The predicted amino acid sequence for the human *mpl* ligand is aligned with the murine *mpl* ligand

sequence. Identical amino acids are boxed and gaps introduced for optimal alignment are indicated by dashes.

5 **Fig. 12.** shows the effect of human *mpl* ligand on Ba/F3-*mpl* cell proliferation (A), *in vitro* human megakaryocytopoiesis quantitated using a radiolabeled murine IgG monoclonal antibody specific to the megakaryocyte glycoprotein GPIIbIIIa (B), and murine thrombopoiesis measured in a platelet rebound assay(C).

293 cells were transfected by the CaPO₄ method (Gorman, C in *DNA Cloning : A New Approach* 2:143-190 [1985]) with pRK5 vector alone, pRK5-hML or with pRK5-10 ML153 overnight (pRK5-ML153 was generated by introducing a stop codon after residue 153 of hML by PCR). Media was then conditioned for 36h and assayed for stimulation of cell proliferation of Ba/F3-*mpl* as described in **Example I** (A) or *in vitro* human megakaryocytopoiesis (B). Megakaryocytopoiesis was quantitated using a ¹²⁵I radiolabeled murine IgG monoclonal antibody (HP1-1D) to the megakaryocyte 15 specific glycoprotein GPIIbIIIa as described (Grant, B. et al. *Blood* 69:1334-1339 [1987]). The effect of partially purified recombinant ML (rML) on *in vivo* platelet production (C) was determined using the rebound thrombocytosis assay described by McDonald, T.P. *Proc. Soc. Exp. Biol. Med.* 144:1006-10012 (1973). Partially purified rML was prepared from 200ml of conditioned media containing the recombinant ML. 20 The media was passed through a 2ml Blue-Sepharose column ^{equilibrated} in PBS and the column was washed with PBS and eluted with PBS containing 2M each of urea and NaCl. The active fraction was dialyzed into PBS and made 1mg/ml with endotoxin free BSA. The sample contained less than one unit of endotoxin /ml. Mice were injected with either 64,000, 32,000 or 16,000 units of rML or excipient alone. 25 Each group consisted of six mice. The mean and standard deviation of each group is shown. p values were determined by a 2 tailed T-test comparing medians.

DETAILED DESCRIPTION OF THE INVENTION

30 I. Definitions

In general, the following words or phrases have the indicated definition when used in the description, examples, and claims.

35 "Cytokine" is a generic term for proteins released by one cell population which act on another cell as intercellular mediators. Examples of such cytokines are lymphokines, monokines, and traditional polypeptide hormones. Included among the cytokines are growth hormone, insulin-like growth factors, human growth hormone, N-

methionyl human growth hormone, bovine growth hormone, parathyroid hormone, thyroxine, insulin, proinsulin, relaxin, prorelaxin, glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and leutinizing hormone (LH), hematopoietic growth factor, hepatic growth factor, fibroblast growth factor, prolactin, placental lactogen, tumor necrosis factor- α (TNF- α) and - β (TNF- β) mullerian-inhibiting substance, mouse gonadotropin-associated peptide, inhibin, activin, vascular endothelial growth factor, integrin, nerve growth factors such as NGF- β , platelet-growth factor, transforming growth factors (TGFs) such as TGF- α and TGF- β , insulin-like growth factor-I and -II, erythropoietin (EPO), osteoinductive factors, 10 interferons such as interferon- α , - β , and - γ , colony stimulating factors (CSFs) such as macrophage-CSF (M-CSF), granulocyte-macrophage-CSF (GM-CSF), and granulocyte-CSF (G-CSF), interleukins (IL's) such as IL-1, IL-1 α , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12 and other polypeptide factors including LIF, SCF, and kit-ligand. As used herein the foregoing terms are meant to include proteins from 15 natural sources or from recombinant cell culture. Similarly, the terms are intended to include biologically active equivalents; e.g., differing in amino acid sequence by one or more amino acids or in type or extent of glycosylation.

A "mpl ligand", "mpl ligand polypeptide" or "ML" comprises any polypeptide that possesses the property of binding to *mpl*, a member of the cytokine receptor 20 superfamily, and having a biological property of the *mpl* ligand as defined below. An exemplary and preferred biological property is the ability to stimulate the incorporation of labeled nucleotides (e.g., 3 H-thymidine) into the DNA of IL-3 dependent Ba/F3 cells transfected with human *mpl* P. Another exemplary and preferred biological property is the ability to stimulate the incorporation of 35 S into circulating platelets in a mouse 25 platelet rebound assay. This definition encompasses the polypeptide isolated from a *mpl* ligand source such as aplastic porcine plasma described herein or from another source, such as another animal species, including humans or prepared by recombinant or synthetic methods and includes variant forms including functional derivatives, fragments, alleles, isoforms and analogues thereof.

A "mpl ligand fragment" is a portion of a naturally occurring mature full length 30 *mpl* ligand sequence having one or more amino acid residues or carbohydrate units deleted. The deleted amino acid residue(s) may occur anywhere in the peptide including at either the N-terminal or C-terminal end or internally. The fragment will share at least one biological property in common with *mpl* ligand. *Mpl* ligand 35 fragments typically will have a consecutive sequence of at least 10, 15, 20, 25, 30, or 40 amino acid residues that are identical to the sequences of the *mpl* ligand isolated

from a mammal including the ligand isolated from aplastic porcine plasma or the human or murine ligand.

"*Mpl* ligand variants" or "*mpl* ligand sequence variants" as defined herein means a biologically active *mpl* ligand as defined below having less than 100% sequence identity with the *mpl* ligand isolated from recombinant cell culture or aplastic porcine plasma or the human ligand having the deduced sequence described in **Fig. 8**. Ordinarily, a biologically active *mpl* ligand variant will have an amino acid sequence having at least about 70% amino acid sequence identity with the *mpl* ligand isolated from aplastic porcine plasma or the mature murine or human ligand or fragments thereof (see **Fig. 8**), preferably at least about 75%, more preferably at least about 80%, still more preferably at least about 85%, even more preferably at least about 90%, and most preferably at least about 95%.

A "chimeric *mpl* ligand" is a polypeptide comprising full length *mpl* ligand or one or more fragments thereof fused or bonded to a second protein or one or more fragments thereof. The chimera will share at least one biological property in common with *mpl* ligand. The second protein will typically be a cytokine.

"Isolated *mpl* ligand", "highly purified *mpl* ligand" and "substantially homogeneous *mpl* ligand" are used interchangeably and mean a *mpl* ligand that has been purified from a *mpl* ligand source or has been prepared by recombinant or synthetic methods and is sufficiently free of other peptides or proteins (1) to obtain at least 15 and preferably 20 amino acid residues of the N-terminal or of an internal amino acid sequence by using a spinning cup sequenator or the best commercially available amino acid sequenator marketed or as modified by published methods as of the filing date of this application, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain. Homogeneity here means less than about 5% contamination with other source proteins.

"Biological property" when used in conjunction with either the "*mpl* ligand" or "Isolated *mpl* ligand" means having thrombopoietic activity or having an *in vivo* effector or antigenic function or activity that is directly or indirectly caused or performed by a *mpl* ligand (whether in its native or denatured conformation) or a fragment thereof. Effector functions include *mpl* binding and any carrier binding activity, agonism or antagonism of *mpl*, especially transduction of a proliferative signal including replication, DNA regulatory function, modulation of the biological activity of other cytokines, receptor (especially cytokine) activation, deactivation, up- or down regulation, cell growth or differentiation and the like. An antigenic function means

possession of an epitope or antigenic site that is capable of cross-reacting with antibodies raised against the native *mpl* ligand. The principal antigenic function of a *mpl* ligand polypeptide is that it binds with an affinity of at least about 10⁶ l/mole to an antibody raised against the *mpl* ligand isolated from aplastic porcine plasma.

5 Ordinarily, the polypeptide binds with an affinity of at least about 10⁷ l/mole. Most preferably, the antigenically active *mpl* ligand polypeptide is a polypeptide that binds to an antibody raised against the *mpl* ligand having one of the above described effector functions. The antibodies used to define "biologically activity" are rabbit polyclonal antibodies raised by formulating the *mpl* ligand isolated from recombinant

10 cell culture or aplastic porcine plasma in Freund's complete adjuvant, subcutaneously injecting the formulation, and boosting the immune response by intraperitoneal injection of the formulation until the titer of *mpl* ligand antibody plateaus.

"Biologically active" when used in conjunction with either the "*mpl* ligand" or "Isolated *mpl* ligand" means a *mpl* ligand or polypeptide that exhibits thrombopoietic

15 activity or shares an effector function of the *mpl* ligand isolated from aplastic porcine plasma or expressed in recombinant cell culture described herein. A principal known effector function of the *mpl* ligand or polypeptide herein is binding to *mpl* and stimulating the incorporation of labeled nucleotides (³H-thymidine) into the DNA of IL-3 dependent Ba/F3 cells transfected with human *mpl* P. Another known effector

20 function of the *mpl* ligand or polypeptide herein is the ability to stimulate the incorporation of ³⁵S into circulating platelets in a mouse platelet rebound assay. Yet another known effector function of *mpl* ligand is the ability to stimulate *in vitro* human megakaryocytopoiesis that may be quantitated by using a radio labeled monoclonal antibody specific to the megakaryocyte glycoprotein GPII_bIII_a.

25 "Percent amino acid sequence identity" with respect to the *mpl* ligand sequence is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the residues in the *mpl* ligand sequence isolated from aplastic porcine plasma or the murine or human ligand having the deduced amino acid sequence described in **Fig. 8**, after aligning the sequences and introducing gaps, if

30 necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. None of N-terminal, C-terminal, or internal extensions, deletions, or insertions into the *mpl* ligand sequence shall be construed as affecting sequence identity or homology. Thus exemplary biologically active *mpl* ligand polypeptides considered to have identical sequences

35 include; prepro-*mpl* ligand, pro-*mpl* ligand, and mature *mpl* ligand.

"*Mpl* ligand microsequencing" may be accomplished by any appropriate standard procedure provided the procedure is sensitive enough. In one such method, highly purified polypeptide obtained from SDS gels or from a final HPLC step are sequenced directly by automated Edman (phenyl isothiocyanate) degradation using a 5 model 470A Applied Biosystems gas phase sequencer equipped with a 120A phenylthiohydantion (PTH) amino acid analyzer. Additionally, *mpl* ligand fragments prepared by chemical (e.g., CNBr, hydroxylamine, 2-nitro-5-thiocyanobenzoate) or enzymatic (e.g., trypsin, clostripain, staphylococcal protease) digestion followed by fragment purification (e.g., HPLC) may be similarly sequenced. PTH amino acids are 10 analyzed using the ChromPerfect data system (Justice Innovations, Palo Alto, CA). Sequence interpretation is performed on a VAX 11/785 Digital Equipment Co. computer as described by Henzel *et al.*, *J. Chromatography*, **404**:41-52 [1987]. Optionally, aliquots of HPLC fractions may be electrophoresed on 5-20% SDS-PAGE, 15 electrotransferred to a PVDF membrane (ProBlott, AIB, Foster City, CA) and stained with Coomassie Brilliant Blue (Matsurdiara, P., *J. Biol. Chem.*, **262**:10035-10038 [1987]. A specific protein identified by the stain is excised from the blot and N-terminal sequencing is carried out with the gas phase sequenator described above. For 20 internal protein sequences, HPLC fractions are dried under vacuum (SpeedVac), resuspended in appropriate buffers, and digested with cyanogen bromide, the Lys-specific enzyme Lys-C (Wako Chemicals, Richmond, VA), or Asp-N (Boehringer Mannheim, Indianapolis, IN). After digestion, the resultant peptides are sequenced as a mixture or after HPLC resolution on a C4 column developed with a propanol gradient in 0.1% TFA prior to gas phase sequencing.

"Thrombocytopenia" is defined as a platelet count below 150 X 10⁹ per liter of 25 blood.

"Thrombopoietic activity" is defined as biological activity that consists of accelerating the proliferation, differentiation and/or maturation of megakaryocytes or megakaryocyte precursors into the platelet producing form of these cells. This activity may be measured in various assays including an *in vivo* mouse platelet rebound 30 synthesis assay, induction of platelet cell surface antigen assay as measured by an anti-platelet immunoassay (anti-GPII_bIII_a) for a human leukemia megakaryoblastic cell line (CMK), and induction of polyploidization in a megakaryoblastic cell line (DAMI).

"Thrombopoietin" (TPO) is defined as a compound having thrombopoietic activity or being capable of increasing serum platelet counts in a mammal. TPO is 35 preferably capable of increasing endogenous platelet counts by at least 10%, more

preferably by 50%, and most preferably capable of elevating platelet counts in a human to greater than 150×10^9 per liter of blood.

"Isolated *mpl* ligand nucleic acid" is RNA or DNA containing greater than 16 and preferably 20 or more sequential nucleotide bases that encode biologically active *mpl* ligand or a fragment thereof, is complementary to the RNA or DNA, or hybridizes to the RNA or DNA and remains stably bound under moderate to stringent conditions. This RNA or DNA is free from at least one contaminating source nucleic acid with which it is normally associated in the natural source and preferably substantially free of any other mammalian RNA or DNA. The phrase "free from at least one contaminating source nucleic acid with which it is normally associated" includes the case where the nucleic acid is present in the source or natural cell but is in a different chromosomal location or is otherwise flanked by nucleic acid sequences not normally found in the source cell. An example of isolated *mpl* ligand nucleic acid is RNA or DNA that encodes a biologically active *mpl* ligand sharing at least 75% sequence identity, more preferably at least 80%, still more preferably at least 85%, even more preferably 90%, and most preferably 95% sequence identity with the porcine *mpl* ligand.

"Control sequences" when referring to expression means DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, a ribosome binding site, and possibly, other as yet poorly understood sequences. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

"Operably linked" when referring to nucleic acids means that the nucleic acids are placed in a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accord with conventional practice.

"Exogenous" when referring to an element means a nucleic acid sequence that is foreign to the cell, or homologous to the cell but in a position within the host cell nucleic acid in which the element is ordinarily not found.

"Cell," "cell line," and "cell culture" are used interchangeably herein and such 5 designations include all progeny of a cell or cell line. Thus, for example, terms like "transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny that have the same function or biological 10 activity as screened for in the originally transformed cell are included. Where distinct designations are intended, it will be clear from the context.

"Plasmids" are autonomously replicating circular DNA molecules possessing independent origins of replication and are designated herein by a lower case "p" preceded and/or followed by capital letters and/or numbers. The starting plasmids 15 herein are either commercially available, publicly available on an unrestricted basis, or can be constructed from such available plasmids in accordance with published procedures. In addition, other equivalent plasmids are known in the art and will be apparent to the ordinary artisan.

"Restriction enzyme digestion" when referring to DNA means catalytic cleavage 20 of internal phosphodiester bonds of DNA with an enzyme that acts only at certain locations or sites in the DNA sequence. Such enzymes are called "restriction endonucleases". Each restriction endonuclease recognizes a specific DNA sequence called a "restriction site" that exhibits two-fold symmetry. The various restriction enzymes used herein are commercially available and their reaction conditions, 25 cofactors, and other requirements as established by the enzyme suppliers are used. Restriction enzymes commonly are designated by abbreviations composed of a capital letter followed by other letters representing the microorganism from which each restriction enzyme originally was obtained and then a number designating the particular enzyme. In general, about 1 μ g of plasmid or DNA fragment is used with 30 about 1-2 units of enzyme in about 20 μ l of buffer solution. Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer. Incubation of about 1 hour at 37°C is ordinarily used, but may vary in accordance with 35 the supplier's instructions. After incubation, protein or polypeptide is removed by extraction with phenol and chloroform, and the digested nucleic acid is recovered from the aqueous fraction by precipitation with ethanol. Digestion with a restriction enzyme may be followed with bacterial alkaline phosphatase hydrolysis of the terminal 5'

phosphates to prevent the two restriction-cleaved ends of a DNA fragment from "circularizing" or forming a closed loop that would impede insertion of another DNA fragment at the restriction site. Unless otherwise stated, digestion of plasmids is not followed by 5' terminal dephosphorylation. Procedures and reagents for 5 dephosphorylation are conventional as described in sections 1.56-1.61 of Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual* [New York: Cold Spring Harbor Laboratory Press, 1989].

"Recovery" or "isolation" of a given fragment of DNA from a restriction digest means separation of the digest on polyacrylamide or agarose gel by electrophoresis, 10 identification of the fragment of interest by comparison of its mobility versus that of marker DNA fragments of known molecular weight, removal of the gel section containing the desired fragment, and separation of the gel from DNA. This procedure is known generally. For example, see Lawn *et al.*, *Nucleic Acids Res.*, 9:6103-6114 [1981], and Goeddel *et al.*, *Nucleic Acids Res.*, 8:4057 [1980].

15 "Southern analysis" or "Southern blotting" is a method by which the presence of DNA sequences in a restriction endonuclease digest of DNA or DNA-containing composition is confirmed by hybridization to a known, labeled oligonucleotide or DNA fragment. Southern analysis typically involves electrophoretic separation of DNA digests on agarose gels, denaturation of the DNA after electrophoretic separation, and 20 transfer of the DNA to nitrocellulose, nylon, or another suitable membrane support for analysis with a radiolabeled, biotinylated, or enzyme-labeled probe as described in sections 9.37-9.52 of Sambrook *et al.*, *supra*.

"Northern analysis" or "Northern blotting" is a method used to identify RNA sequences that hybridize to a known probe such as an oligonucleotide, DNA fragment, 25 cDNA or fragment thereof, or RNA fragment. The probe is labeled with a radioisotope such as ³²P, or by biotinylation, or with an enzyme. The RNA to be analyzed is usually electrophoretically separated on an agarose or polyacrylamide gel, transferred to nitrocellulose, nylon, or other suitable membrane, and hybridized with the probe, using standard techniques well known in the art such as those described in sections 7.39- 30 7.52 of Sambrook *et al.*, *supra*.

"Ligation" is the process of forming phosphodiester bonds between two nucleic acid fragments. For ligation of the two fragments, the ends of the fragments must be compatible with each other. In some cases, the ends will be directly compatible after endonuclease digestion. However, it may be necessary first to convert the staggered 35 ends commonly produced after endonuclease digestion to blunt ends to make them compatible for ligation. For blunting the ends, the DNA is treated in a suitable buffer

for at least 15 minutes at 15°C with about 10 units of the Klenow fragment of DNA polymerase I or T4 DNA polymerase in the presence of the four deoxyribonucleotide triphosphates. The DNA is then purified by phenol-chloroform extraction and ethanol precipitation. The DNA fragments that are to be ligated together are put in solution in
5 about equimolar amounts. The solution will also contain ATP, ligase buffer, and a ligase such as T4 DNA ligase at about 10 units per 0.5 µg of DNA. If the DNA is to be ligated into a vector, the vector is first linearized by digestion with the appropriate restriction endonuclease(s). The linearized fragment is then treated with bacterial
10 alkaline phosphatase or calf intestinal phosphatase to prevent self-ligation during the ligation step.

"Preparation" of DNA from cells means isolating the plasmid DNA from a culture of the host cells. Commonly used methods for DNA preparation are the large- and small-scale plasmid preparations described in sections 1.25-1.33 of Sambrook *et al.*, *supra*. After preparation of the DNA, it can be purified by methods well known in the
15 art such as that described in section 1.40 of Sambrook *et al.*, *supra*.

"Oligonucleotides" are short-length, single- or double-stranded polydeoxynucleotides that are chemically synthesized by known methods (such as phosphotriester, phosphite, or phosphoramidite chemistry, using solid-phase techniques such as described in EP 266,032 published 4 May 1988, or via
20 deoxynucleoside H-phosphonate intermediates as described by Froehler *et al.*, *Nucl. Acids Res.*, **14**:5399-5407 [1986]. Further methods include the polymerase chain reaction defined below and other autoprimer methods and oligonucleotide syntheses on solid supports. All of these methods are described in Engels *et al.*, *Agnew. Chem. Int. Ed. Engl.*, **28**:716-734 [1989]). These methods are used if the entire nucleic acid
25 sequence of the gene is known, or the sequence of the nucleic acid complementary to the coding strand is available. Alternatively, if the target amino acid sequence is known, one may infer potential nucleic acid sequences using known and preferred coding residues for each amino acid residue. The oligonucleotides are then purified on polyacrylamide gels.

"Polymerase chain reaction" or "PCR" refers to a procedure or technique in which minute amounts of a specific piece of nucleic acid, RNA and/or DNA, are amplified as described in U.S. Patent No. 4,683,195 issued 28 July 1987. Generally, sequence information from the ends of the region of interest or beyond needs to be available, such that oligonucleotide primers can be designed; these primers will be
35 identical or similar in sequence to opposite strands of the template to be amplified. The 5' terminal nucleotides of the two primers may coincide with the ends of the amplified

material. PCR can be used to amplify specific RNA sequences, specific DNA sequences from total genomic DNA, and cDNA transcribed from total cellular RNA, bacteriophage or plasmid sequences, etc. See generally Mullis *et al.*, *Cold Spring Harbor Symp. Quant. Biol.*, 51:263 [1987]; Erlich, ed., *PCR Technology*, (Stockton Press, NY, 1989). As used herein, PCR is considered to be one, but not the only, example of a nucleic acid polymerase reaction method for amplifying a nucleic acid test sample comprising the use of a known nucleic acid as a primer and a nucleic acid polymerase to amplify or generate a specific piece of nucleic acid.

"Stringent conditions" are those that (1) employ low ionic strength and high temperature for washing, for example, 0.015 M NaCl/0.0015 M sodium citrate/0.1% NaDODSO₄ (SDS) at 50°C, or (2) employ during hybridization a denaturing agent such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium citrate at 42°C. Another example is use of 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC and 0.1% SDS.

"Moderately stringent conditions" are described in Sambrook *et al.*, *supra*, and include the use of a washing solution and hybridization conditions (e.g., temperature, ionic strength, and %SDS) less stringent than described above. An example of moderately stringent conditions are conditions such as overnight incubation at 37°C in a solution comprising: 20% formamide, 5 X SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 X Denhardt's solution, 10% dextran sulfate, and 20 µl/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1 X SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength etc. as necessary to accommodate factors such as probe length and the like.

"Antibodies" (Abs) and "immunoglobulins" (Igs) are glycoproteins having the same structural characteristics. While antibodies exhibit binding specificity to a specific antigen, immunoglobulins include both antibodies and other antibody-like molecules which lack antigen specificity. Polypeptides of the latter kind are, for example, produced at low levels by the lymph system and at increased levels by myelomas.

"Native antibodies and immunoglobulins" are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and

two identical heavy (H) chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies between the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a 5 variable domain (V_H) followed by a number of constant domains. Each light chain has a variable domain at one end (V_L) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the 10 light and heavy chain variable domains (Clothia *et al.*, *J. Mol. Biol.*, **186**:651-663 [1985]; Novotny and Haber, *Proc. Natl. Acad. Sci. USA*, **82**:4592-4596 [1985]).

The term "variable" refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability 15 is not evenly distributed through the variable domains of antibodies. It is concentrated in three segments called complementarity determining regions (CDRs) or hypervariable regions both in the light chain and the heavy chain variable domains. The more highly conserved portions of variable domains are called the framework (FR). The variable domains of native heavy and light chains each comprise four FR 20 regions, largely adopting a β -sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the β -sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen binding site of 25 antibodies (see Kabat *et al.*, *Sequences of Proteins of Immunological Interest*, National Institute of Health, Bethesda, MD [1987]). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector 30 functions, such as participation of the antibody in antibody-dependent cellular toxicity.

Papain digestion of antibodies produces two identical antigen binding fragments, called "Fab" fragments, each with a single antigen binding site, and a 35 residual "Fc" fragment, whose name reflects its ability to crystallize readily. Pepsin treatment yields an $F(ab')_2$ fragment that has two antigen combining sites and is still capable of cross-linking antigen.

"Fv" is the minimum antibody fragment which contains a complete antigen recognition and binding site. This region consists of a dimer of one heavy and one 30 light chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen binding site

on the surface of the V_H - V_L dimer. Collectively, the six CDRs confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

5 The Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant 10 domains bear a free thiol group. $F(ab')_2$ antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other, chemical couplings of antibody fragments are also known.

15 The "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda (λ), based on the amino acid sequences of their constant domains.

20 Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG-1, IgG-2, IgG-3, and IgG-4; IgA-1 and IgA-2. The heavy chain constant domains that correspond to the different classes 25 of immunoglobulins are called α , delta, epsilon, γ , and μ , respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.

30 The term "antibody" is used in the broadest sense and specifically covers single monoclonal antibodies (including agonist and antagonist antibodies), antibody compositions with polyepitopic specificity, as well as antibody fragments (e.g., Fab, $F(ab')_2$, and Fv), so long as they exhibit the desired biological activity.

35 The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized

by the hybridoma culture, uncontaminated by other immunoglobulins. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the 5 monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler & Milstein, *Nature*, **256**:495 [1975], or may be made by recombinant DNA methods [see, e.g., U.S. Patent No. 4,816,567 (Cabilly *et al.*)].

The monoclonal antibodies herein specifically include "chimeric" antibodies 10 (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as 15 well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567 (Cabilly *et al.*; Morrison *et al.*, *Proc. Natl. Acad. Sci. USA*, **81**:6851-6855 [1984])).

"Humanized" forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', 20 F(ab')₂ or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit 25 having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibody may comprise residues which are found --neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and optimize antibody performance. In 30 general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an 35 immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For

further details see: Jones *et al.*, *Nature*, **321**:522-525 [1986]; Reichmann *et al.*, *Nature*, **332**:323-329 [1988]; and Presta, *Curr. Op. Struct. Biol.*, **2**:593-596 [1992].

"Non-immunogenic in a human" means that upon contacting the polypeptide in a pharmaceutically acceptable carrier and in a therapeutically effective amount with 5 the appropriate tissue of a human, no state of sensitivity or resistance to the polypeptide is demonstratable upon the second administration of the polypeptide after an appropriate latent period (e.g., 8 to 14 days).

II. Preferred Embodiments of the Invention

Preferred polypeptides of this invention are substantially homogeneous polypeptide(s), referred to as *mpl* ligand(s), that possess the property of binding to *mpl*, a member of the receptor cytokine superfamily, and having the biological property of stimulating the incorporation of labeled nucleotides (^3H -thymidine) into the DNA of IL-3 dependent Ba/F3 cells transfected with human *mpl* P. More preferred *mpl* ligand(s) are isolated mammalian protein(s) having hematopoietic, especially megakaryocytopoietic or thrombocytopoietic activity - namely, being capable of stimulating proliferation, maturation and/or differentiation of immature megakaryocytes or their predecessors into the mature platelet-producing form. Most preferred polypeptides of this invention are human *mpl* ligand(s) including fragments thereof 15 having hematopoietic, megakaryocytopoietic or thrombopoietic activity. Optionally 20 these human *mpl* ligand(s) lack glycosylation.

Optional preferred polypeptides of this invention are biologically active *mpl* ligand variant(s) that have an amino acid sequence having at least 70% amino acid sequence identity with the human *mpl* ligand (see **Fig. 8**) the murine *mpl* ligand (see 25 **Fig. 10**) or the *mpl* ligand isolated from aplastic porcine plasma, preferably at least 75%, more preferably at least 80%, still more preferably at least 85%, even more preferably at least 90%, and most preferably at least 95%.

The *mpl* ligand isolated from aplastic porcine plasma has the following characteristics:

- 30 (1) The partially purified ligand isolated from aplastic porcine plasma elutes from a gel filtration column run in either PBS, PBS containing 0.1% SDS or PBS containing 4M MgCl_2 with Mr of 60,000-70,000;
- (2) The ligand's activity is destroyed by pronase;
- (3) The ligand is stable to low pH (2.5), SDS to 0.1%, and 2M urea;
- 35 (4) The ligand is a glycoprotein, based on its binding to a variety of lectin columns;

(5) The highly purified ligand elutes from non-reduced SDS-PAGE with a Mr of 25,000-35,000. Smaller amounts of activity also elute with Mr of ~18,000 and 60,000;

5 (6) The highly purified ligand resolves on reduced SDS-PAGE as a doublet with Mr of 28,000 and 31,000;

C (7) The amino-terminal sequence of the 18,000, 28,000 and 31,000 bands is the same - SPAPPACDPRLLNKLLRDDHVLHGR (SEQ ID NO: ³⁰8); and

(8) The ligand binds and elutes from the following affinity columns

10 Blue-Sepharose,

CM Blue-Sepharose,

MONO-Q,

MONO-S,

Lentil lectin-Sepharose,

WGA-Sepharose,

15 Con A-Sepharose,

Ether 650m Toyopearl,

Butyl 650 m Toyopearl,

Phenyl 650m Toyopearl, and

Phenyl-Sepharose.

20 More preferred *mpl* ligand polypeptides are those encoded by human genomic or cDNA having an amino acid sequence described in **Fig. 8** (SEQ ID NO: 1).

Other preferred naturally occurring biologically active *mpl* ligand polypeptides of this invention include prepro-*mpl* ligand, pro-*mpl* ligand, mature *mpl* ligand, *mpl* ligand fragments and glycosylation variants thereof.

25 Still other preferred polypeptides of this invention include *mpl* ligand sequence variants and chimeras. Ordinarily, preferred *mpl* ligand sequence variants and chimeras are biologically active *mpl* ligand variants that have an amino acid sequence having at least 70% amino acid sequence identity with the human *mpl* ligand or the *mpl* ligand isolated from aplastic porcine plasma, preferably at least 75%, more 30 preferably at least 80%, still more preferably at least 85%, even more preferably at least 90%, and most preferably at least 95%. An exemplary preferred *mpl* ligand variant is a C-terminal domain hML variant in which one or more of the basic or dibasic amino acid residue(s) (e.g., R or K) is substituted with a non-basic amino acid residue(s) (e.g., hydrophobic, neutral, acidic, aromatic, gly, Pro and the like). An 35 exemplary preferred chimera is a fusion between *mpl* ligand or fragment (defined below) thereof and another cytokine or fragment thereof.

Another exemplary preferred human *mpl* ligand is a "ML-EPO domain chimera" that consists of the N-terminus 153 to about 157 hML residues substituted with one or more, but not all, of the human EPO residues approximately aligned as shown in **Fig. 9**. In this embodiment, the hML chimera would be about 153-166 residues in length in which individual or blocks of residues from the human EPO sequence are added or substituted into the hML sequence at positions corresponding to the alignment shown in **Fig. 9**. Exemplary block sequence inserts into the N-terminus portion of hML would include one or more of the N-glycosylation sites at positions (EPO) 24-27, 38-40, and 83-85; one or more of the four predicted amphipathic α -helical bundles at positions (EPO) 9-22, 59-76, 90-107, and 132-152; and other highly conserved regions including the N-terminus and C-terminus regions and residue positions (EPO) 44-52 (see e.g., Wen *et al.*, *Blood*, **82**:1507-1516 [1993] and Boissel *et al.*, *J. Biol. Chem.*, **268**(21):15983-15993 [1993]). It is contemplated this "ML-EPO domain chimera" will have mixed thrombopoietic-erythropoietic (TEPO) biological activity.

Other preferred polypeptides of this invention include *mpl* ligand fragments having a consecutive sequence of at least 10, 15, 20, 25, 30, or 40 amino acid residues that are identical to the sequences of the *mpl* ligand isolated from aplastic porcine plasma or the human *mpl* ligand described herein. A preferred *mpl* ligand fragment is human ML[1-X] where X is 153, 164, 191, 205, 207, 217, 229, or 245 (see **Fig. 8** for the sequence of residues 1-X). Other preferred *mpl* ligand fragments include those produced as a result of chemical or enzymatic hydrolysis or digestion of the purified ligand.

Another preferred aspect of the invention is a method for purifying *mpl* ligand molecules comprises contacting a *mpl* ligand source containing the *mpl* ligand molecules to be purified with an immobilized receptor polypeptide, specifically *mpl* or a *mpl* fusion polypeptide, under conditions whereby the *mpl* ligand molecules to be purified are selectively adsorbed onto the immobilized receptor polypeptide, washing the immobilized support to remove non-adsorbed material, and eluting the molecules to be purified from the immobilized receptor polypeptide to which they are adsorbed with an elution buffer. The source containing the *mpl* ligand may be plasma where the immobilized receptor is preferably a *mpl*-IgG fusion.

Alternatively, the source containing the *mpl* ligand is recombinant cell culture where the concentration of *mpl* ligand in either the culture medium or in cell lysates is generally higher than in plasma or other natural sources. In this case the above described *mpl*-IgG immunoaffinity method, while still useful, is usually not necessary and more traditional protein purification methods known in the art may be applied.

B Briefly, the preferred purification method to provide substantially homogeneous *mpl* ligand comprises: removing particulate debris, either host cells or lysed fragments by, for example, centrifugation or ultrafiltration; optionally, *protein* may be concentrated with a commercially available protein concentration filter; followed by separating the 5 ligand from other impurities by one or more steps selected from; immunoaffinity, ion-exchange (e.g., DEAE or *matrices* containing carboxymethyl or sulfopropyl groups), Blue-Sepharose, CM Blue-Sepharose, MONO-Q, MONO-S, lentil lectin-Sepharose, WGA-Sepharose, Con A-Sepharose, Ether Toypearl, Butyl Toypearl, Phenyl Toypearl, protein A Sepharose, SDS-PAGE, reverse phase HPLC (e.g., silica gel with appended 10 aliphatic groups) or Sephadex molecular *size* or size exclusion chromatography, and ethanol or ammonium sulfate precipitation. A protease inhibitor such as methylsulfonylfluoride (PMSF) may be included in any of the foregoing steps to inhibit proteolysis.

In another preferred embodiment, this invention provides an isolated antibody 15 capable of binding to the *mpl* ligand. A preferred *mpl* ligand isolated antibody is monoclonal (Kohler and Milstein, *Nature*, 256:495-497 [1975]; Campbell, *Laboratory Techniques in Biochemistry and Molecular Biology*, Burdon *et al.*, Eds, Volume 13, Elsevier Science *Publishers*, Amsterdam [1985]; and Huse *et al.*, *Science*, 246:1275-20 1281 [1989]). Preferred *mpl* ligand isolated antibody is one that binds to *mpl* ligand with an affinity of at least about 10⁶ l/mole. More preferably the antibody binds with an affinity of at least about 10⁷ l/mole. Most preferably, the antibody is raised against the *mpl* ligand having one of the above described effector functions. The isolated antibody capable of binding to the *mpl* ligand may optionally be fused to a second polypeptide and the antibody or fusion thereof may be used to isolate and purify *mpl* 25 ligand from a source as described above for immobilized *mpl* polypeptide. In a further preferred aspect of this embodiment, the invention provides a method for detecting the *mpl* ligand *in vitro* or *in vivo* comprising contacting the antibody with a sample, especially a serum sample, suspected of containing the ligand and detecting if binding 30 has occurred.

In still further preferred embodiments, the invention provides an isolated nucleic 35 acid molecule encoding the *mpl* ligand or fragments thereof, which nucleic acid molecule may be labeled or unlabeled with a detectable moiety, and a nucleic acid molecule having a sequence that is complementary to, or hybridizes under stringent or moderately stringent conditions with, a nucleic acid molecule having a sequence encoding a *mpl* ligand. A preferred *mpl* ligand nucleic acid is RNA or DNA that encodes a biologically active *mpl* ligand sharing at least 75% sequence identity, more

preferably at least 80%, still more preferably at least 85%, even more preferably 90%, and most preferably 95% sequence identity with the human *mpl* ligand. More preferred isolated nucleic acid molecules are DNA sequences encoding biologically active *mpl* ligand, selected from: (a) DNA based on the coding region of a mammalian *mpl* ligand gene (e.g., DNA comprising the nucleotide sequence provided in **Fig. 8**, or fragments thereof); (b) DNA capable of hybridizing to a DNA of (a) under at least moderately stringent conditions; and (c) DNA that is degenerate to a DNA defined in (a) or (b) which results from degeneracy of the genetic code. It is contemplated that the novel *mpl* ligands described herein may be members of a family of ligands or cytokines having suitable sequence identity that their DNA may hybridize with the DNA of **Fig. 8** (or fragments thereof) under low to moderate stringency conditions. Thus a further aspect of this invention includes DNA that hybridizes under low to moderate stringency conditions with DNA encoding the *mpl* ligand polypeptides.

In a further preferred embodiment of this invention, the nucleic acid molecule is cDNA encoding the *mpl* ligand and further comprises a replicable vector in which the cDNA is operably linked to control sequences recognized by a host transformed with the vector. This aspect further includes host cells transformed with the vector and a method of using the cDNA to effect production of *mpl* ligand, comprising expressing the cDNA encoding the *mpl* ligand in a culture of the transformed host cells and recovering the *mpl* ligand from the host cell culture. The *mpl* ligand prepared in this manner is preferably substantially homogeneous human *mpl* ligand.

The invention further includes a preferred method for treating a mammal having an immunological or hematopoietic disorder, especially thrombocytopenia comprising administering a therapeutically effective amount of a *mpl* ligand to the mammal. Optionally, the *mpl* ligand is administered in combination with a cytokine, especially a colony stimulating factor or interleukin. Preferred colony stimulating factors or interleukins include; kit-ligand, LIF, G-CSF, GM-CSF, M-CSF, EPO, IL-1, IL-2, IL-3, IL-5, IL-6, IL-7, IL-8, IL-9 or IL-11.

30 III. Methods of Making

Platelet production has long been thought to be controlled by lineage specific humoral factors. It has been postulated that two distinct cytokine activities, referred to as megakaryocyte colony-stimulating factor (meg-CSF) and thrombopoietin, regulate megakaryocytopoiesis and thrombopoiesis (Williams *et al.*, *J. Cell Physiol.*, **110**:101-104 [1982]; Williams *et al.*, *Blood Cells*, **15**:123-133 [1989]; and Gordon *et al.*, *Blood*, **80**:302-307 [1992]). Meg-CSF stimulates the proliferation of progenitor

megakaryocytes while thrombopoietin primarily affects maturation of more differentiated cells and ultimately platelet release. Since the 1960's the induction and appearance of meg-CSF and thrombopoietin activities in the plasma, serum and urine of animals and humans following thrombocytopenic episodes has been well documented (Odell *et al.*, *Proc. Soc. Exp. Biol. Med.*, **108**:428-431 [1961]; Nakeff *et al.*, *Acta Haematol.*, **54**:340-344 [1975]; Specter, *Proc. Soc. Exp. Biol.*, **108**:146-149 [1961]; Schreiner *et al.*, *J.Clin.Invest.*, **49**:1709-1713 [1970]; Ebbe, *Blood*, **44**:605-608 [1974]; Hoffman *et al.*, *N. Engl. J. Med.*, **305**:533 [1981]; Straneva *et al.*, *Exp. Hematol.*, **17**:1122-1127 [1988]; Mazur *et al.*, *Exp. Hematol.*, **13**:1164 [1985]; Mazur *et al.*, *J.Clin. Invest.*, **68**:733-741 [1981]; Sheiner *et al.*, *Blood*, **56**:183-188 [1980]; Hill *et al.*, *Exp. Hematol.*, **20**:354-360 [1992]; and Hegyi *et al.*, *Int. J. Cell Cloning*, **8**:236-244 [1990]). These activities are reported to be lineage specific and distinct from known cytokines (Hill R.J. *et al.*, *Blood* **80**:346 (1992); Erickson-Miller C.L. *et al.*, *Brit. J. Haematol.* **84**:197-203 (1993); Straneva J.E. *et al.*, *Exp. Hematol.* **20**:4750(1992); and Tsukada J. *et al.*, *Blood* **81**:866-867 (1993)). Heretofore, attempts to purify meg-CSF or thrombopoietin from thrombocytopenic plasma or urine have been unsuccessful.

Consistent with the above observations describing thrombocytopenic plasma, we have found that aplastic porcine plasma (APP) obtained from irradiated pigs stimulates human megakaryocytopoiesis *in vitro*. Here we report that this stimulatory activity is abrogated by the soluble extracellular domain of c-*mpl*, confirming APP as a potential source of the putative *mpl* ligand (ML). The ML was purified from APP and amino acid sequence information used to isolate a human ML cDNA. The ML has sequence homology to erythropoietin and has both meg-CSF and thrombopoietin-like activities.

25

1. Purification and Identification of *mpl* Ligand from Plasma

Aplastic plasma from a variety of species has been reported to contain activities that stimulate hematopoiesis *in vitro*, however no hematopoietic stimulatory factor has previously been reported isolated from plasma. One source of aplastic plasma is that obtained from irradiated pigs. This aplastic porcine plasma (APP) stimulates human hematopoiesis *in vitro*. To determine if APP contained the *mpl* ligand, its effect on ³H-thymidine incorporation into Ba/F3 cells transfected with human *mpl* P (Ba/F3-*mpl*) was measured. APP stimulated ³H-thymidine incorporation into Ba/F3-*mpl* cells but not Ba/F3 control cells (*i.e.*, not transfected with human *mpl* P). Additionally, no such activity was observed in normal porcine plasma. These results indicated that APP contained a factor or factors that transduces a proliferative signal through the *mpl*

β receptor and therefore may be the natural ligand for this receptor. This was further supported by the finding that treatment of APP with soluble *mpl*-IgG blocked the stimulatory effects of APP on Ba/F3-*mpl* cells.

5 The activity in APP appeared to be a protein since pronase, DTT, or heat destroy the activity in APP (Fig. 1). The activity was also non-dialyzable. The activity was, however, stable to low pH (pH 2.5 for 2 hrs.) and was shown to bind and elute from several lectin-affinity columns, indicating that it was a glycoprotein. To further elucidate the structure and identity of this activity it was affinity purified from APP.

Briefly, 5 liters of APP was purified according to the protocol in **Example I**. ML 10 was purified using hydrophobic interaction chromatography (HIC), immobilized dye chromatography, and *mpl*-affinity chromatography. The recovery of activity from each step is shown in **Fig. 2** and the fold purification is provided in **Table 1**. The overall recovery of activity through the *mpl*-affinity column was approximately 10%. The peak activity fraction (F6) from the *mpl*-affinity column has an estimated specific activity of 15 9.8×10^6 units/mg. The overall purification from 5L of APP was approximately 4×10^6 fold (0.8 units/mg to 3.3×10^6 units/mg) with a 83×10^6 fold reduction in protein (250 gms to 3μg). We estimated the specific activity of the ligand eluted from the *mpl*-affinity column to be ~ 3×10^6 units/mg.

20

Table 1
Purification of *mpl* Ligand

Sample	Volume mls	Protein mg/ml	Units/ml	Units	Specific Acitivity Units/mg	Yield %	Fold Purification
APP	5000	50	40	200,000	0.8	-	1
Phenyl	4700	0.8	40	200,000	50	94	62
Blue-Sep.	640	0.93	400	256,000	430	128	538
<i>mpl</i> (μl) (Fxns 5-7)	12	5×10^{-4}	1666	20,000	3,300,000	10	4,100,000

25 Protein was determined by the Bradford assay. Protein concentration of *mpl*-eluted fractions 5-7 are estimates based on staining intensity of a silver stained SDS-gel. One unit is defined as that causing 50% maximal stimulation of Ba/F3-*mpl* cell proliferation.

Analysis of eluted fractions from the *mpl* affinity column by SDS-PAGE (4-20%, Novex gel) run under reducing conditions, reveal the presence of several proteins (Fig. 3). Proteins that silver stain with the strongest intensity resolve with apparent Mr of 66,000, 55,000, 30,000, 28,000 and 14,000. To determine which of these proteins stimulate proliferation of Ba/F3-*mpl* cell cultures, these proteins were eluted from the gel as described in **Example II**.

The results of this experiment show that most of the activity elutes from a gel slice that includes proteins with Mr 28,000-32,000, with lesser activity eluting in the 18,000-20,000 region of the gel (Fig. 4). The only proteins visible in these regions had Mr of 30,000, 28,000 and 18,000. To identify and obtain protein sequence for the proteins resolving in this region of the gel (i.e. bands at 30, 28 and 18 kDa), these three proteins were electroblotted to PVDF and sequenced as described in **Example III**. Protein sequences obtained were as follows:

15 1) 30 kDa

1 5 10 15 20 25 11
 A (S) P A P P A(C)D P R L L N K L L R D D (H/S) V L H (G) R L (SEQ ID NO: 9)

2) 28 kDa

1 5 10 15 20 25 12
 20 A (S) P A P P A X D P R L L N K L L R D D (H) V L (H) G R (SEQ ID NO: 10)

3) 18 kDa

1 5 10 13
 A X P A P P A X D P R L X (N) (K) (SEQ ID NO: 11)

25 Computer-assisted analysis revealed these sequences to be novel. Because all three sequences were the same, it is believed the 30 kDa, 28 kDa and 18 kDa proteins are related and may be different forms of the same novel protein. ^{furthermore} ^{furthermore} this protein(s) was a likely candidate as the natural *mpl* ligand because the activity resolved on SDS-PAGE in the same region (28,000-32,000) of a 4-20% gel. In 30 addition, the partially purified ligand migrated with a Mr of 17,000-30,000 when subjected to gel filtration chromatography using a Superose 12 (Pharmacia) column. It is believed the different Mr forms of the ligand are a result of proteolysis or glycosylation differences or other post or pre-translational modifications.

As described earlier, antisense human *mpl* RNA abrogated 35 megakaryocytopoiesis in human bone marrow cultures enriched with CD 34+ progenitor cells without affecting the differentiation of other hematopoietic cell lineages

(Methia *et al.*, *supra*). This result suggested that the *mpl* receptor plays a role in the differentiation and proliferation of megakaryocytes *in vitro*. To further elucidate the role of the *mpl* ligand in megakaryocytopoiesis, the effects of APP and *mpl* ligand depleted APP on *in vitro* human megakaryocytopoiesis was compared. The effect of APP on 5 human megakaryocytopoiesis was determined using a modification of the liquid suspension megakaryocytopoiesis assay described in **Example IV**. In this assay, human peripheral stem cells (PSC) are treated with APP before and after *mpl*-IgG affinity chromatography. GP II_bIII_a stimulation of megakaryocytopoiesis is quantitated with an ¹²⁵I anti-II_bIII_a antibody (**Fig. 5**). Shown in **Fig. 5** 10% APP caused 10 approximately a 3-fold stimulation while APP depleted of *mpl* ligand had no effect. Significantly, the *mpl* ligand depleted APP did not induce proliferation of the Ba/F3-*mpl* cells.

In another experiment, soluble human *mpl*-IgG added at days 0, 2 and 4 to 15 cultures containing 10% APP neutralized the stimulatory effects of APP on human megakaryocytopoiesis (**Fig. 6**). These results indicate that the *mpl* ligand plays a role in regulating human megakaryocytopoiesis and therefore may be useful for the treatment of thrombocytopenia.

2. Molecular cloning of the *mpl* ligand

20 Based on the amino-terminal amino acid sequence obtained from the 30 kDa, 28 kDa and 18 kDa proteins (see above), two degenerate oligonucleotide primer pools were designed and used to amplify porcine genomic DNA by PCR. It was reasoned that if the amino-terminal amino acid sequence was encoded by a single 25 exon then the correct PCR product was expected to be 69 bp long. A DNA fragment of this size was found and subcloned into pGEMT. The sequences of the oligonucleotide PCR primers and the three clones obtained are shown in **Example V**. The amino acid sequence (PRLLNKLLR [SEQ ID NO: 12]) of the peptide encoded between the PCR primers was identical to that obtained by amino-terminal protein sequencing of the porcine ligand (see residues 9-17 for the 28 and 30 kDa porcine protein sequences 30 above).

A synthetic oligonucleotide based on the sequence of the PCR fragment was used to screen a human genomic DNA library. A 45-mer oligonucleotide was designed and synthesized based on the sequence of the PCR fragment. This oligonucleotide had the following sequence:

5' GCC-GTG-AAG-GAC-GTG-GTC-GTC-ACG-AAG-CAG-TTT-ATT-TAG-GAG-TCG 3'

A (SEQ ID NO: 13)

This deoxyoligonucleotide was used to screen a human genomic DNA library in 5 λ gem12 under low stringency hybridization and wash conditions according to Example VI. Positive clones were picked, plaque purified and analyzed by restriction mapping and southern blotting. A 390 bp EcoRI-XbaI fragment that hybridized to the 45-mer was subcloned into pBluescript SK-. DNA sequencing of this 10 clone confirmed that DNA encoding the human homolog of the porcine *mpl* ligand had been isolated. The human DNA sequence and deduced amino acid sequence are shown in Fig. 7. The predicted positions of introns in the genomic sequence are also indicated by arrows, and define a putative exon ("exon 3").

Based on the human "exon 3" sequence (Example VI) oligonucleotides corresponding to the 3' and 5' ends of the exon sequence were synthesized. These 2 15 primers were used in PCR reactions employing as a template cDNA prepared from various human tissues. The expected size of the correct PCR product was 140 bp. After analysis of the PCR products on a 12% polyacrylamide gel, a DNA fragment of the expected size was detected in cDNA libraries prepared from human adult kidney, 293 fetal kidney cells and cDNA prepared from human fetal liver.

20 A fetal liver cDNA library (7×10^6 clones) in lambda DR2 was next screened with the same 45-mer oligonucleotide used to screen the human genomic library and the fetal liver cDNA library under low stringency hybridization conditions. Positive clones were picked, plaque purified and the insert size was determined by PCR. One clone with a 1.8 kb insert was selected for further analysis. Using the procedures described 25 in Example VII the nucleotide and deduced amino acid sequence of the human *mpl* ligand were obtained. These sequences are presented in Fig. 8.

3. Structure of the Human *mpl* ligand

The human *mpl* ligand cDNA sequence (Fig. 8) comprises 1774 nucleotides 30 followed by a poly(A) tail. It contains 215 nucleotides of 5' untranslated sequence and a 3' untranslated region of 498 nucleotides. The presumed initiation codon at nucleotide position (216-218) is within a consensus sequence favorable for eukaryotic translation initiation. The open reading frame is 1059 nucleotides long and encodes a 353 amino acid residue polypeptide, beginning at nucleotide position 220. The N- 35 terminus of the predicted amino acid sequence is highly hydrophobic and probably corresponds to a signal peptide. Computer analysis of the predicted amino acid

sequence (von Heijne *et al.*, *Eur. J. Biochem.*, **133**:17-21 [1983]) indicates a potential cleavage site for signal peptidase between residues 21 and 22. Cleavage at that position would generate a mature polypeptide of 332 amino acid residues beginning with the amino-terminal sequence obtained from *mpl* ligand purified from porcine plasma. The predicted non-glycosylated molecular weight of the 332 amino acid residue ligand is about 38 kDa. There are 6 potential N-glycosylation sites and 4 cysteine residues.

Comparison of the *mpl* ligand sequence with the Genbank sequence database revealed 23% identity between the amino terminal 153 residues of the ML and erythropoietin (Fig. 9). When conservative substitutions are taken into account, this region of ML shows 50% similarity to erythropoietin. Both erythropoietin and the ML contain four cysteines. Three of the 4 cysteines are conserved in ML, including the first and last cysteines, but none of the glycosylation sites. Site-directed mutagenesis experiments have shown that the first and last cysteines of erythropoietin form a disulfide bond that is required for function (Wang, F.F. *et al.*, *Endocrinology* **116**:2286-2292 (1983)). By analogy, the first and last cysteines of ML may also form a critical disulfide bond. All potential *mpl* ligand N-glycosylation sites are located in the carboxy-terminal half of the *mpl* ligand polypeptide.

Similar to erythropoietin, the ML mRNA does not contain the consensus polyadenylation sequence AAUAAA, nor the regulatory element AUUUA that is present in 3' untranslated regions of many cytokines and is thought to influence mRNA stability (Shaw *et al.*, *Cell*, **46**:659-667 [1986]). Northern blot analysis reveals low levels of a single 1.8 kb ML RNA transcript in both fetal and adult liver. After longer exposure, a weaker band of the same size could be detected in adult kidney. By comparison, erythropoietin is expressed in fetal liver and, in response to hypoxia, the adult kidney and liver (Jacobs *et al.*, *Nature*, **313**:804-809 [1985] and Bondurant *et al.*, *Molec. Cell. Biol.*, **6**:2731-2733 [1986]).

The importance of the C-terminal region of the ML remains to be elucidated. Based on the presence of the six potential sites for N-linked glycosylation and the ability of the ligand to bind lectin-affinity columns, this region of the ML is likely glycosylated. In some gel elution experiments, we observed activity resolving with a Mr around 60,000 which may represent the full length, glycosylated molecule. The C-terminal region may therefore act to stabilize and increase the half-life of circulating ML. In the case of erythropoietin, the non-glycosylated form has full *in vitro* biological activity, but has a significantly reduced plasma half-life relative to glycosylated erythropoietin (Takeuchi *et al.*, *J. Biol. Chem.*, **265**:12127-12130 [1990]; Narhi *et al.*, *J.*

Biol. Chem., **266**:23022-23026 [1991] and Spivack *et al.*, *Blood*, **7**:90-99 [1989]). The C-terminal domain of ML contains two di-basic amino acid sequences [Arg-Arg motifs at positions 153-154 and 245-246] that could serve as potential processing sites. Cleavage at these sites may be responsible for generating the 30, 28 and 18 kDa forms of the ML isolated from APP. Significantly, the Arg₁₅₃-Arg₁₅₄ sequence occurs immediately following the erythropoietin-like domain of the ML.

These observations indicate that full length ML may represent a precursor protein that undergoes limited proteolysis to generate the mature ligand. Comparison of human and porcine ML sequences shows 83% identity between the erythropoietin-like domains, but only 67% between the C-terminal domains. The dibasic site present at position 153-154 in the human ML is conserved in porcine ML, consistent with the possibility that the erythropoietin-like domain of the ML represents the mature ligand.

4. The murine *mpl* ligand

A DNA fragment corresponding to the coding region of the human *mpl* ligand was obtained by PCR, gel purified and labeled in the presence of ³²P-dATP and ³²P-dCTP. This probe was used to screen 10⁶ clones of a mouse liver cDNA library in Igt10. The isolated murine ML (mML) cDNA clone (Fig. 10) comprises 1443 nucleotides. The presumed initiation codon at nucleotide position 138-141 is within a consensus sequence favorable for eukaryotic translation initiation (Kozak, M. *J. Cell Biol.* **108**:229-241 (1989)). It defines an open reading frame of 1056 nucleotides, which predicts a primary translation product of 352 amino acids. Flanking this open reading frame are 137 nucleotides of 5' and 247 nucleotides of 3' untranslated sequence. There is no poly(A) tail following the 3' untranslated region indicating that the clone is probably not complete. The N-terminus of the predicted amino acid sequence is highly hydrophobic and probably represents a signal peptide. Computer analysis (von Heijne, G. *Eur. J. Biochem.* **133**:17-21 (1983)) indicates a potential cleavage site for signal peptidase between residues 21 and 22. Cleavage at that position would generate a mature polypeptide of 331 amino acids (35 kDa). The sequence contains 4 cysteines, all conserved in the human sequence and seven potential N-glycosylation sites, 5 of which are conserved in the human sequence. Again, as with hML, all seven potential N-glycosylation sites are located in the C-terminal half of the protein.

The overall amino acid sequence identity between human and mouse ML (Fig. 11) is 72% but this homology is not evenly distributed. The region defined as the EPO-like domain (amino acids 1-153 for the human sequence and 1-149 for the

mouse) is better conserved (86% homology) than the carboxy-terminal region of the protein (62% homology). This may further indicate that only the erythropoietin-like domain is important for the biological activity of the protein. Interestingly, only the di-basic amino acid motif immediately following the EPO-like domain at position 153-154 in the human sequence is present in the murine sequence. This is consistent with the possibility that the full length ML may represent a precursor protein that undergoes limited proteolysis to generate the mature ligand.

The EPO-like domain of hML contains four residues, 111-114, not found at the corresponding location in mML. A similar four residue "deletion" form has been observed in one porcine ML clone. These deletions occur in regions believed to correspond to inter-helical loops ^{separating} ~~separating~~ amphapathic α -helical bundles. By analogy to EPO, where deletion of portions of the inter-helical loops does not significantly attenuate biological activity, it is believed similar deletions to the ML sequence will produce biologically active ML. Thus it is believed, for example, des-111-114 hML and other inter-helical loop deletion variants will have equivalent (qualitative) biological activity.

5. Expression of Recombinant Human *mpl* ligand

To confirm that the cloned human cDNA encoded a ligand for *mpl*, it was expressed in mammalian cells under the control of the cytomegalovirus immediate early promoter using the expression vector pRK5-hML. Supernatants from transiently transfected human embryonic kidney 293 cells were found to stimulate 3 H-thymidine incorporation in Ba/F3-*mpl* cells, but not in parental Ba/F3 cells (Fig 12A). Media from the 293 cells transfected with the pRK vector alone did not contain this activity. Addition of *mpl*-IgG to the media abolished the stimulation (data not shown). These results show that the cloned cDNA encodes a functional human ML (hML).

To determine if the erythropoietin-like domain alone could bind and activate *mpl*, a truncated form of hML consisting of residues 1-153 (rhML₁₅₃) was expressed in 293 cells. Supernatants from transfected cells were found to have activity similar to that present in supernatants from cells expressing the full length hML (Fig 12A), indicating that the C-terminal domain of ML is not required for binding and activation of c-*mpl*.

6. *mpl* ligand stimulates megakaryocytopoiesis and thrombopoiesis

Both the full length (rhML) and the truncated (rhML₁₅₃) forms of recombinant hML stimulated human megakaryocytopoiesis *in vitro* (Fig. 12B). This effect was

observed in the absence of other exogenously added hematopoietic growth factors. With the exception of IL-3, the ML is the only hematopoietic growth factor that exhibited this activity. IL-11, IL-6, IL-1, erythropoietin, G-CSF, IL-9, LIF, kit ligand, M-CSF, OSM and GM-CSF had no effect on megakaryocytopoiesis when tested separately in our 5 assay (data not shown). This result demonstrates that the ML has megakaryocyte-stimulating activity, and indicates a role for ML in regulating megakaryocytopoiesis.

Thrombopoietic activities present in plasma of thrombocytopenic animals have been shown to stimulate platelet production in a mouse rebound thrombocytosis assay (McDonald, *Proc. Soc. Exp. Biol. Med.*, **14**:1006-1001 [1973] and McDonald *et al.*, 10 *Scand. J. Haematol.*, **16**:326-334 [1976]). In this model mice are made acutely thrombocytopenic using specific antiplatelet serum, resulting in a predictable rebound thrombocytosis. Such immunothrombocytemic mice are more responsive to exogenous thrombopoietin-like activities than are normal mice (McDonald, *Proc. Soc. Exp. Biol. Med.*, **14**:1006-1001 [1973]), just as exhypoxic mice are more sensitive to 15 erythropoietin than normal are mice (McDonald, *et al.*, *J. Lab. Clin. Med.*, **77**:134-143 [1971]). To determine whether the rML stimulates platelet production *in vivo*, mice in rebound thrombocytosis were injected with partially purified rhML. Platelet counts and incorporation of ^{35}S into platelets were then quantitated. Injection of mice with 64,000 or 32,000 units of rML significantly increased platelet production, as evidenced by a 20 ~20% increase in platelet counts ($p=0.0005$ and 0.0001, respectively) and a ~40% increase in ^{35}S incorporation into platelets ($p=0.003$) in the treated mice versus control mice injected with excipient alone (**Fig. 12C**). This level of stimulation is comparable to that which we have observed with IL-6 in this model (data not shown). Treatment with 16,000 units of rML did not significantly stimulate platelet production. 25 These results indicate that ML stimulates platelet production in a dose-dependent manner and therefore possesses thrombopoietin-like activity.

7. Megakaryocytopoiesis and the *mpl*-ligand

It has been proposed that megakaryocytopoiesis is regulated at multiple cellular 30 levels (Williams *et al.*, *J. Cell Physiol.*, **110**:101-104 [1982] and Williams *et al.*, *Blood Cells*, **15**:123-133 [1989]). This is based largely on the observation that certain hematopoietic growth factors stimulate proliferation of megakaryocyte progenitors while others appear to primarily affect maturation. The results presented here suggest 35 that the ML acts both as an proliferative and maturation factor. That ML stimulates proliferation of megakaryocyte progenitors is supported by several lines of evidence. First, APP stimulates both proliferation and maturation of human megakaryocytes *in*

vitro, and this stimulation is completely inhibited by *mpl*-IgG (Fig. 5 and 6). Furthermore, the inhibition of megakaryocyte colony formation by c-*mpl* antisense oligonucleotides (Methia *et al.*, *Blood*, 82:1395-1401 [1993]) and the finding that c-*mpl* can transduce a proliferative signal in cells into which it is transfected (Skoda *et al.*, 5 *EMBO*, 12:2645-2653 [1993] and Vigon *et al.*, *Oncogene*, 8:2607-2615 [1993]) also indicate that ML stimulates proliferation. The apparent expression of c-*mpl* during all stages of megakaryocyte differentiation (Methia *et al.*, *Blood*, 82:1395-1401 [1993]) and the ability of recombinant ML to rapidly stimulate platelet production *in vivo* indicate that ML also affects maturation. The availability of recombinant ML makes 10 possible a careful evaluation of its role in regulating megakaryocytopoiesis and thrombopoiesis as well as its potential to influence other hematopoietic lineages.

8. Methods for Measurement of Thrombopoietic activity

Thrombopoietic activity may be measured in various assays including an *in vivo* mouse platelet rebound synthesis assay, induction of platelet cell surface antigen assay as measured by an anti-platelet immunoassay (anti-GPII_bIII_a) for a human leukemia megakaryoblastic cell line (CMK) (see Sato *et al.*, *Brit. J. Haematol.*, 72:184-190 [1989]), and induction of polyploidization in a megakaryoblastic cell line (DAMI) (see Ogura *et al.*, *Blood*, 72(1):49-60 [1988]). Maturation of megakaryocytes from 15 immature, largely non-DNA synthesizing cells, to morphologically identifiable megakaryocytes involves a process that includes appearance of cytoplasmic organelles, acquisition of membrane antigens (GPII_bIII_a), endoreplication and release of platelets as described in the background. A lineage specific promoter (*i.e.*, the *mpl* ligand) of megakaryocyte maturation would be expected to induce at least some of 20 these changes in immature megakaryocytes leading to platelet release and alleviation of thrombocytopenia. Thus, assays were designed to measure the emergence of these parameters in immature megakaryocyte cell lines, *i.e.*, CMK and DAMI cells. The CMK assay (**Example VIII**) measures the appearance of a specific platelet marker, GPII_bIII_a, and platelet shedding. The DAMI assay (**Example IX**) measures 25 endoreplication since increases in ploidy are hallmarks of mature megakaryocytes. Recognizable megakaryocytes have ploidy values of 2N, 4N, 8N, 16N, 32N, *etc.* Finally, the *in vivo* assay (**Example X**) is useful in demonstrating that administration 30 of the test compound (here the *mpl* ligand) results in elevation of platelet numbers.

9. General Recombinant Preparation of *mpl* Ligand and variants

Preferably *mpl* ligand is prepared by standard recombinant procedures which involve production of the *mpl* ligand polypeptide by culturing cells transfected to express *mpl* ligand nucleic acid (typically by transforming the cells with an expression vector) and recovering the polypeptide from the cells. However, it is optionally envisioned that the *mpl* ligand may be produced by homologous recombination, or with recombinant production methods utilizing control elements introduced into cells already containing DNA encoding the *mpl* ligand. For example, a powerful promoter/enhancer element, a suppressor, or an exogenous transcription modulatory element may be inserted in the genome of the intended host cell in proximity and orientation sufficient to influence the transcription of DNA encoding the desired *mpl* ligand polypeptide. The control element does not encode the *mpl* ligand, rather the DNA is indigenous to the host cell genome. One next screens for cells making the receptor polypeptide of this invention, or for increased or decreased levels of expression, as desired.

Thus, the invention contemplates a method for producing *mpl* ligand comprising inserting into the genome of a cell containing the *mpl* ligand nucleic acid molecule a transcription modulatory element in sufficient proximity and orientation to the nucleic acid molecule to influence transcription thereof, with an optional further step comprising culturing the cell containing the transcription modulatory element and the nucleic acid molecule. The invention also contemplates a host cell containing the indigenous *mpl* ligand nucleic acid molecule operably linked to exogenous control sequences recognized by the host cell.

A. Isolation of DNA Encoding *mpl* ligand Polypeptide

The DNA encoding *mpl* ligand polypeptide may be obtained from any cDNA library prepared from tissue believed to possess the *mpl* ligand mRNA and to express it at a detectable level. The *mpl* ligand gene may also be obtained from a genomic DNA library or by *in vitro* oligonucleotide synthesis from the complete nucleotide or amino acid sequence.

Libraries are screened with probes designed to identify the gene of interest or the protein encoded by it. For cDNA expression libraries, suitable probes include monoclonal or polyclonal antibodies that recognize and specifically bind to the *mpl* ligand. For cDNA libraries suitable probes include oligonucleotides of about 20-80 bases in length that encode known or suspected portions of the *mpl* ligand cDNA from the same or different species; and/or complementary or homologous cDNAs or fragments thereof that encode the same or a similar gene. Appropriate probes for

screening genomic DNA libraries include, but are not limited to, oligonucleotides, cDNAs, or fragments thereof that encode the same or a similar gene, and/or homologous genomic DNAs or fragments thereof. Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures as 5 described in Chapters 10-12 of Sambrook *et al.*, *supra*.

An alternative means to isolate the gene encoding *mpl* ligand is to use PCR methodology as described in section 14 of Sambrook *et al.*, *supra*. This method requires the use of oligonucleotide probes that will hybridize to DNA encoding the *mpl* ligand. Strategies for selection of oligonucleotides are described below.

10 A preferred method of practicing this invention is to use carefully selected oligonucleotide sequences to screen cDNA libraries from various tissues, preferably human or porcine kidney (adult or fetal) or liver cell lines. For example, human fetal liver cell line cDNA libraries are screened with the oligonucleotide probes. Alternatively, human genomic libraries may be screened with the oligonucleotide 15 probes.

The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized. The actual nucleotide sequence(s) is usually designed based on regions of the *mpl* ligand which have the least codon redundancy. The oligonucleotides may be degenerate at one or 20 more positions. The use of degenerate oligonucleotides is of particular importance where a library is screened from a species in which preferential codon usage is not known.

25 The oligonucleotide must be labeled such that it can be detected upon hybridization to DNA in the library being screened. The preferred method of labeling is to use ATP (e.g., $\gamma^{32}\text{P}$) and polynucleotide kinase to radiolabel the 5' end of the oligonucleotide. However, other methods may be used to label the oligonucleotide, including, but not limited to, biotinylation or enzyme labeling.

30 Of particular interest is the *mpl* ligand nucleic acid that encodes a full-length *mpl* ligand polypeptide. In some preferred embodiments, the nucleic acid sequence includes the native *mpl* ligand signal sequence. Nucleic acid having all the protein coding sequence is obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence.

*B. Amino Acid Sequence Variants of Native *mpl* ligand*

35 Amino acid sequence variants of *mpl* ligand are prepared by introducing appropriate nucleotide changes into the *mpl* ligand DNA, or by *in vitro* synthesis of the desired *mpl* ligand polypeptide. Such variants include, for example, deletions from, or

insertions or substitutions of, residues within the amino acid sequence for the porcine *mpl* ligand. For example, carboxy terminus portions of the mature full length *mpl* ligand may be removed by proteolytic cleavage, either *in vivo* or *in vitro*, or by cloning and expressing a fragment or the DNA encoding full length *mpl* ligand to produce a 5 biologically active variant. Any combination of deletion, insertion, and substitution is made to arrive at the final construct, provided that the final construct possesses the desired biological activity. The amino acid changes also may alter post-translational processes of the *mpl* ligand, such as changing the number or position of glycosylation sites. For the design of amino acid sequence variants of the *mpl* ligand, the location of 10 the mutation site and the nature of the mutation will depend on the *mpl* ligand characteristic(s) to be modified. The sites for mutation can be modified individually or in series, *e.g.*, by (1) substituting first with conservative amino acid choices and then with more radical selections depending upon the results achieved, (2) deleting the target residue, or (3) inserting residues of the same or a different class adjacent to the 15 located site, or combinations of options 1-3.

A useful method for identification of certain residues or regions of the *mpl* ligand polypeptide that are preferred locations for mutagenesis is called "alanine scanning mutagenesis," as described by Cunningham and Wells, *Science*, **244**:1081-1085 [1989]. Here, a residue or group of target residues are identified (*e.g.*, charged 20 residues such as arg, asp, his, lys, and glu) and replaced by any, but preferably a neutral or negatively charged, amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with the surrounding aqueous environment in or outside the cell. Those domains demonstrating functional sensitivity to the substitutions then are refined by introducing further or other variants at or for the sites 25 of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation *per se* need not be predetermined. For example, to optimize the performance of a mutation at a given site, ala scanning or random mutagenesis is conducted at the target codon or region and the expressed *mpl* ligand variants are screened for the optimal combination of desired activity.

30 There are two principal variables in the construction of amino acid sequence variants: the location of the mutation site and the nature of the mutation. For example, variants of the *mpl* ligand polypeptide include variants from the *mpl* ligand sequence, and may represent naturally occurring alleles (which will not require manipulation of the *mpl* ligand DNA) or predetermined mutant forms made by mutating the DNA, either 35 to arrive at an allele or a variant not found in nature. In general, the location and

nature of the mutation chosen will depend upon the *mpl* ligand characteristic to be modified.

Amino acid sequence deletions generally range from about 1 to 30 residues, more preferably about 1 to 10 residues, and typically are contiguous. Amino acid sequence deletions for the *mpl* ligand may include the entire carboxy-terminus 5 glyccoprotein domain. Contiguous deletions ordinarily are made in even numbers of residues, but single or odd numbers of deletions are within the scope hereof. Deletions may be introduced into regions of low homology among the *mpl* ligands that share the most sequence identity to modify the activity of the *mpl* ligand. Or deletions 10 may be introduced into regions of low homology among human *mpl* ligand and other mammalian *mpl* ligand polypeptides that share the most sequence identity to the human *mpl* ligand. Deletions from a mammalian *mpl* ligand polypeptide in areas of substantial homology with other mammalian *mpl* ligands will be more likely to modify 15 the biological activity of the *mpl* ligand more significantly. The number of consecutive deletions will be selected so as to preserve the tertiary structure of *mpl* ligands in the affected domain, e.g., beta-pleated sheet or alpha helix.

Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid 20 residues. Intrasequence insertions (i.e., insertions within the mature *mpl* ligand sequence) may range generally from about 1 to 10 residues, more preferably 1 to 5, most preferably 1 to 3. An exemplary preferred fusion is that of *mpl* ligand or fragment thereof and another cytokine or fragment thereof. Examples of terminal insertions include mature *mpl* ligand with an N-terminal methionyl residue, an artifact of the direct 25 expression of mature *mpl* ligand in recombinant cell culture, and fusion of a heterologous N-terminal signal sequence to the N-terminus of the mature *mpl* ligand molecule to facilitate the secretion of mature *mpl* ligand from recombinant hosts. Such signal sequences generally will be obtained from, and thus homologous to, the intended host cell species. Suitable sequences include STII or Ipp for *E. coli*, alpha 30 factor for yeast, and viral signals such as herpes gD for mammalian cells.

Other insertional variants of the *mpl* ligand molecule include the fusion to the N- or C-terminus of *mpl* ligand of immunogenic polypeptides (i.e., not endogenous to the host to which the fusion is administered), e.g., bacterial polypeptides such as beta-lactamase or an enzyme encoded by the *E. coli trp* locus, or yeast protein, and C-terminal fusions with proteins having a long half-life such as immunoglobulin constant 35

regions (or other immunoglobulin regions), albumin, or ferritin, as described in WO 89/02922 published 6 April 1989.

A third group of variants are amino acid substitution variants. These variants have at least one amino acid residue in the *mpl* ligand molecule removed and a different residue inserted in its place. The sites of greatest interest for substitutional mutagenesis include sites identified as the active site(s) of *mpl* ligand and sites where the amino acids found in other analogues are substantially different in terms of side-chain bulk, charge, or hydrophobicity, but where there is also a high degree of sequence identity at the selected site among various *mpl* ligand species and/or within the various animal analogues of one *mpl* ligand member.

Other sites of interest are those in which particular residues of the *mpl* ligand obtained from various family members and/or animal species within one member are identical. These sites, especially those falling within a sequence of at least three other identically conserved sites, are substituted in a relatively conservative manner. Such conservative substitutions are shown in **Table 2** under the heading of preferred substitutions. If such substitutions result in a change in biological activity, then more substantial changes, denominated exemplary substitutions in **Table 2**, or as further described below in reference to amino acid classes, are introduced and the products screened.

Table 2

	<u>Original Residue</u>	<u>Exemplary Substitutions</u>	<u>Preferred Substitutions</u>
5			
	Ala (A)	val; leu; ile	val
	Arg (R)	lys; gln; asn	lys
	Asn (N)	gln; his; lys; arg	gln
	Asp (D)	glu	glu
10	Cys (C)	ser	ser
	Gln (Q)	asn	asn
	Glu (E)	asp	asp
	Gly (G)	pro	pro
	His (H)	asn; gln; lys; arg	arg
15	Ile (I)	leu; val; met; ala; phe; norleucine	leu
	Leu (L)	norleucine; ile; val; met; ala; phe	ile
	Lys (K)	arg; gln; asn	arg
20	Met (M)	leu; phe; ile	leu
	Phe (F)	leu; val; ile; ala	leu
	Pro (P)	gly	gly
	Ser (S)	thr	thr
	Thr (T)	ser	ser
25	Trp (W)	tyr	tyr
	Tyr (Y)	trp; phe; thr; ser	phe
	Val (V)	ile; leu; met; phe; ala; norleucine	leu

30 Substantial modifications in function or immunological identity of the *mpl* ligand are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.

35 Naturally occurring residues are divided into groups based on common side-chain properties:

- (1) hydrophobic: norleucine, met, ala, val, leu, ile;
- (2) neutral hydrophilic: cys, ser, thr;
- (3) acidic: asp, glu;
- (4) basic: asn, gln, his, lys, arg;
- 5 (5) residues that influence chain orientation: gly, pro; and
- (6) aromatic: trp, tyr, phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another. Such substituted residues also may be introduced into the conservative substitution sites or, more preferably, into the remaining (non-conserved) sites.

In one embodiment of the invention, it is desirable to inactivate one or more protease cleavage sites that are present in the molecule. These sites are identified by inspection of the encoded amino acid sequence, in the case of trypsin, e.g., for an arginyl or lysinyl residue. When protease cleavage sites are identified, they are rendered inactive to proteolytic cleavage by substituting the targeted residue with another residue, preferably a basic residue such as glutamine or a hydrophobic residue such as serine; by deleting the residue; or by inserting a prolyl residue immediately after the residue.

In another embodiment, any methionyl residues other than the starting methionyl residue of the signal sequence, or any residue located within about three residues N- or C-terminal to each such methionyl residue, is substituted by another residue (preferably in accordance with **Table 2**) or deleted. Alternatively, about 1-3 residues are inserted adjacent to such sites.

Any cysteine residues not involved in maintaining the proper conformation of the *mpl* ligand also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking.

Nucleic acid molecules encoding amino acid sequence variants of *mpl* ligand are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of *mpl* ligand polypeptide.

Oligonucleotide-mediated mutagenesis is a preferred method for preparing substitution, deletion, and insertion variants of *mpl* ligand DNA. This technique is well known in the art as described by Adelman *et al.*, *DNA*, 2:183 [1983]. Briefly, *mpl* ligand DNA is altered by hybridizing an oligonucleotide encoding the desired mutation

to a DNA template, where the template is the single-stranded form of a plasmid or bacteriophage containing the unaltered or native DNA sequence of *mpl* ligand. After hybridization, a DNA polymerase is used to synthesize an entire second complementary strand of the template that will thus incorporate the oligonucleotide 5 primer, and will code for the selected alteration in the *mpl* ligand DNA.

Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on either side of the nucleotide(s) coding for the mutation. This ensures that the oligonucleotide will hybridize properly to the 10 single-stranded DNA template molecule. The oligonucleotides are readily synthesized using techniques known in the art such as that described by Crea *et al.*, *Proc. Natl. Acad. Sci. USA*, 75:5765 [1978].

The DNA template can be generated by those vectors that are either derived 15 from bacteriophage M13 vectors (the commercially available M13mp18 and M13mp19 vectors are suitable), or those vectors that contain a single-stranded phage origin of replication as described by Viera *et al.*, *Meth. Enzymol.*, 153:3 [1987]. Thus, the DNA that is to be mutated may be inserted into one of these vectors to generate single-stranded template. Production of the single-stranded template is described in 20 Sections 4.21-4.41 of Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Laboratory Press, NY 1989).

Alternatively, single-stranded DNA template may be generated by denaturing double-stranded plasmid (or other) DNA using standard techniques.

For alteration of the native DNA sequence (to generate amino acid sequence variants, for example), the oligonucleotide is hybridized to the single-stranded 25 template under suitable hybridization conditions. A DNA polymerizing enzyme, usually the Klenow fragment of DNA polymerase I, is then added to synthesize the complementary strand of the template using the oligonucleotide as a primer for synthesis. A heteroduplex molecule is thus formed such that one strand of DNA encodes the mutated form of the *mpl* ligand, and the other strand (the original 30 template) encodes the native, unaltered sequence of the *mpl* ligand. This heteroduplex molecule is then transformed into a suitable host cell, usually a prokaryote such as *E. coli* JM101. After the cells are grown, they are plated onto agarose plates and screened using the oligonucleotide primer radiolabeled with 32-phosphate to identify the bacterial colonies that contain the mutated DNA. The 35 mutated region is then removed and placed in an appropriate vector for protein

production, generally an expression vector of the type typically employed for transformation of an appropriate host.

The method described immediately above may be modified such that a homoduplex molecule is created wherein both strands of the plasmid contain the mutation(s). The modifications are as follows: The single-stranded oligonucleotide is annealed to the single-stranded template as described above. A mixture of three deoxyribonucleotides, deoxyriboadenosine (dATP), deoxyriboguanosine (dGTP), and deoxyribothymidine (dTTP), is combined with a modified thio-deoxyribocytosine called dCTP-(aS) (which can be obtained from the Amersham Corporation). This mixture is added to the template-oligonucleotide complex. Upon addition of DNA polymerase to this mixture, a strand of DNA identical to the template, except for the mutated bases is generated. In addition, this new strand of DNA will contain dCTP-(aS) instead of dCTP, which serves to protect it from restriction endonuclease digestion.

After the template strand of the double-stranded heteroduplex is nicked with an appropriate restriction enzyme, the template strand can be digested with *ExoIII* nuclease or another appropriate nuclease past the region that contains the site(s) to be mutagenized. The reaction is then stopped to leave a molecule that is only partially single-stranded. A complete double-stranded DNA homoduplex is then formed using DNA polymerase in the presence of all four deoxyribonucleotide triphosphates, ATP, and DNA ligase. This homoduplex molecule can then be transformed into a suitable host cell such as *E. coli* JM101, as described above.

DNA encoding *mpl* ligand mutants with more than one amino acid to be substituted may be generated in one of several ways. If the amino acids are located close together in the polypeptide chain, they may be mutated simultaneously using one oligonucleotide that codes for all of the desired amino acid substitutions. If, however, the amino acids are located some distance from each other (separated by more than about ten amino acids), it is more difficult to generate a single oligonucleotide that encodes all of the desired changes. Instead, one of two alternative methods may be employed.

In the first method, a separate oligonucleotide is generated for each amino acid to be substituted. The oligonucleotides are then annealed to the single-stranded template DNA simultaneously, and the second strand of DNA that is synthesized from the template will encode all of the desired amino acid substitutions.

The alternative method involves two or more rounds of mutagenesis to produce the desired mutant. The first round is as described for the single mutants: wild-type DNA is used for the template, an oligonucleotide encoding the first desired amino acid

substitution(s) is annealed to this template, and the heteroduplex DNA molecule is then generated. The second round of mutagenesis utilizes the mutated DNA produced in the first round of mutagenesis as the template. Thus, this template already contains one or more mutations. The oligonucleotide encoding the additional 5 desired amino acid substitution(s) is then annealed to this template, and the resulting strand of DNA now encodes mutations from both the first and second rounds of mutagenesis. This resultant DNA can be used as a template in a third round of mutagenesis, and so on. PCR mutagenesis is also suitable for making amino acid variants of *mpl* ligand polypeptide. While the following discussion refers to DNA, it is 10 understood that the technique also finds application with RNA. The PCR technique generally refers to the following procedure (see Erlich, *supra*, the chapter by R. Higuchi, p. 61-70): When small amounts of template DNA are used as starting material in a PCR, primers that differ slightly in sequence from the corresponding region in a template DNA can be used to generate relatively large quantities of a 15 specific DNA fragment that differs from the template sequence only at the positions where the primers differ from the template. For introduction of a mutation into a plasmid DNA, one of the primers is designed to overlap the position of the mutation and to contain the mutation; the sequence of the other primer must be identical to a stretch of sequence of the opposite strand of the plasmid, but this sequence can be 20 located anywhere along the plasmid DNA. It is preferred, however, that the sequence of the second primer is located within 200 nucleotides from that of the first, such that in the end the entire amplified region of DNA bounded by the primers can be easily sequenced. PCR amplification using a primer pair like the one just described results 25 in a population of DNA fragments that differ at the position of the mutation specified by the primer, and possibly at other positions, as template copying is somewhat error-prone.

If the ratio of template to product material is extremely low, the vast majority of product DNA fragments incorporate the desired mutation(s). This product material is used to replace the corresponding region in the plasmid that served as PCR template 30 using standard DNA technology. Mutations at separate positions can be introduced simultaneously by either using a mutant second primer, or performing a second PCR with different mutant primers and ligating the two resulting PCR fragments simultaneously to the vector fragment in a three (or more)-part ligation.

In a specific example of PCR mutagenesis, template plasmid DNA (1 μ g) is 35 linearized by digestion with a restriction endonuclease that has a unique recognition site in the plasmid DNA outside of the region to be amplified. Of this material, 100 ng

is added to a PCR mixture containing PCR buffer, which contains the four deoxynucleotide triphosphates and is included in the GeneAmp® kits (obtained from Perkin-Elmer Cetus, Norwalk, CT and Emeryville, CA), and 25 pmole of each oligonucleotide primer, to a final volume of 50 μ l. The reaction mixture is overlayed
5 with 35 μ l mineral oil. The reaction mixture is denatured for five minutes at 100°C, placed briefly on ice, and then 1 μ l *Thermus aquaticus* (*Taq*) DNA polymerase (5 units/ μ l, purchased from Perkin-Elmer Cetus) is added below the mineral oil layer. The reaction mixture is then inserted into a DNA Thermal Cycler (purchased from Perkin-Elmer Cetus) programmed as follows:

10 2 min. 55°C
30 sec. 72°C, then 19 cycles of the following:
30 sec. 94°C
30 sec. 55°C, and
30 sec. 72°C.

15 At the end of the program, the reaction vial is removed from the thermal cycler and the aqueous phase transferred to a new vial, extracted with phenol/chloroform (50:50 vol), and ethanol precipitated, and the DNA is recovered by standard procedures. This material is subsequently subjected to the appropriate treatments for insertion into a vector.

20 Another method for preparing variants, cassette mutagenesis, is based on the technique described by Wells *et al.*, *Gene*, 34:315 [1985]. The starting material is the plasmid (or other vector) comprising the *mpl* ligand DNA to be mutated. The codon(s) in the *mpl* ligand DNA to be mutated are identified. There must be a unique restriction endonuclease site on each side of the identified mutation site(s). If no such restriction
25 sites exist, they may be generated using the above-described oligonucleotide-mediated mutagenesis method to introduce them at appropriate locations in the *mpl* ligand DNA. After the restriction sites have been introduced into the plasmid, the plasmid is cut at these sites to linearize it. A double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but
30 containing the desired mutation(s) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oligonucleotide is referred to as the cassette. This cassette is designed to have 3' and 5' ends that are compatible with the ends of the linearized plasmid, such that it can be directly ligated to the plasmid. This plasmid
35 now contains the mutated *mpl* ligand DNA sequence.

C. Insertion of Nucleic Acid into a Replicable Vector

The nucleic acid (e.g., cDNA or genomic DNA) encoding native or variant *mpl* ligand polypeptide is inserted into a replicable vector for further cloning (amplification of the DNA) or for expression. Many vectors are available, and selection of the 5 appropriate vector will depend on (1) whether it is to be used for DNA amplification or for DNA expression, (2) the size of the nucleic acid to be inserted into the vector, and (3) the host cell to be transformed with the vector. Each vector contains various components depending on its function (amplification of DNA or expression of DNA) and the host cell with which it is compatible. The vector components generally include, 10 but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.

(i) Signal Sequence Component

The *mpl* ligand of this invention may be expressed not only directly, but also as 15 a fusion with a heterologous polypeptide, preferably a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the *mpl* ligand DNA that is inserted into the vector. The heterologous 20 signal sequence selected should be one that is recognized and processed (i.e., cleaved by a signal peptidase) by the host cell. For prokaryotic host cells that do not recognize and process the native *mpl* ligand signal sequence, the signal sequence is substituted by a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, Ipp, or heat-stable enterotoxin II leaders. For 25 yeast secretion the native signal sequence may be substituted by, e.g., the yeast invertase, alpha factor, or acid phosphatase leaders, the *C. albicans* glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90/13646 published 15 November 1990. In mammalian cell expression the native signal 30 sequence (i.e., the *mpl* ligand presequence that normally directs secretion of *mpl* ligand from its native mammalian cells *in vivo*) is satisfactory, although other mammalian signal sequences may be suitable, such as signal sequences from other *mpl* ligand polypeptides or from the same *mpl* ligand from a different animal species, signal sequences from a *mpl* ligand, and signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders, for example, the herpes simplex gD signal.

(ii) *Origin of Replication Component*

Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Generally, in cloning vectors this sequence is one that enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 μ plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells. Generally, the origin of replication component is not needed for mammalian expression vectors (the SV40 origin may typically be used only because it contains the early promoter).

Most expression vectors are "shuttle" vectors, i.e., they are capable of replication in at least one class of organisms but can be transfected into another organism for expression. For example, a vector is cloned in *E. coli* and then the same vector is transfected into yeast or mammalian cells for expression even though it is not capable of replicating independently of the host cell chromosome.

DNA may also be amplified by insertion into the host genome. This is readily accomplished using *Bacillus* species as hosts, for example, by including in the vector a DNA sequence that is complementary to a sequence found in *Bacillus* genomic DNA. Transfection of *Bacillus* with this vector results in homologous recombination with the genome and insertion of *mpl* ligand DNA. However, the recovery of genomic DNA encoding *mpl* ligand is more complex than that of an exogenously replicated vector because restriction enzyme digestion is required to excise the *mpl* ligand DNA.

(iii) *Selection Gene Component*

Expression and cloning vectors should contain a selection gene, also termed a selectable marker. This gene encodes a protein necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for *Bacilli*.

One example of a selection scheme utilizes a drug to arrest growth of a host cell. Those cells that are successfully transformed with a heterologous gene express a protein conferring drug resistance and thus survive the selection regimen. Examples

of such dominant selection use the drugs neomycin (Southern *et al.*, *J. Molec. Appl. Genet.*, 1:327 [1982]) mycophenolic acid (Mulligan *et al.*, *Science*, 209:1422 [1980]) or hygromycin Sugden *et al.*, *Mol. Cell. Biol.*, 5:410-413 [1985]). The three examples given above employ bacterial genes under eukaryotic control to convey resistance to 5 the appropriate drug G418 or neomycin (geneticin), xgpt (mycophenolic acid), or hygromycin, respectively.

Examples of other suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the *mpl* ligand nucleic acid, such as dihydrofolate reductase (DHFR) or thymidine kinase. The mammalian cell 10 transformants are placed under selection pressure that only the transformants are uniquely adapted to survive by virtue of having taken up the marker. Selection pressure is imposed by culturing the transformants under conditions in which the concentration of selection agent in the medium is successively changed, thereby 15 leading to amplification of both the selection gene and the DNA that encodes *mpl* ligand polypeptide. Amplification is the process by which genes in greater demand for the production of a protein critical for growth are reiterated in tandem within the chromosomes of successive generations of recombinant cells. Increased quantities of *mpl* ligand are synthesized from the amplified DNA.

For example, cells transformed with the DHFR selection gene are first identified 20 by culturing all of the transformants in a culture medium that contains methotrexate (Mtx), a competitive antagonist of DHFR. An appropriate host cell when wild-type DHFR is employed is the Chinese hamster ovary (CHO) cell line deficient in DHFR activity, prepared and propagated as described by Urlaub and Chasin, *Proc. Natl. Acad. Sci. USA*, 77:4216 [1980]. The transformed cells are then exposed to increased 25 levels of Mtx. This leads to the synthesis of multiple copies of the DHFR gene, and, concomitantly, multiple copies of other DNA comprising the expression vectors, such as the DNA encoding *mpl* ligand. This amplification technique can be used with any otherwise suitable host, *e.g.*, ATCC No. CCL61 CHO-K1, notwithstanding the presence of endogenous DHFR if, for example, a mutant DHFR gene that is highly 30 resistant to Mtx is employed (EP 117,060). Alternatively, host cells [particularly wild-type hosts that contain endogenous DHFR] transformed or co-transformed with DNA sequences encoding *mpl* ligand, wild-type DHFR protein, and another selectable marker such as aminoglycoside 3' phosphotransferase (APH) can be selected by cell growth in medium containing a selection agent for the selectable marker such as an 35 aminoglycosidic antibiotic, *e.g.*, kanamycin, neomycin, or G418. See U.S. Patent No. 4,965,199.

A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid YRp7 (Stinchcomb *et al.*, *Nature*, **282**:39 [1979]; Kingsman *et al.*, *Gene*, **7**:141 [1979]; or Tschemper *et al.*, *Gene*, **10**:157 [1980]). The *trp1* gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 (Jones, *Genetics*, **85**:12 [1977]). The presence of the *trp1* lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan. Similarly, *Leu2*-deficient yeast strains (ATCC No. 20,622 or 38,626) are complemented by known plasmids bearing the *Leu2* gene.

10 (iv) *Promoter Component*

Expression and cloning vectors usually contain a promoter that is recognized by the host organism and is operably linked to the *mpl* ligand nucleic acid. Promoters are untranslated sequences located upstream (5') to the start codon of a structural gene (generally within about 100 to 1000 bp) that control the transcription and translation of particular nucleic acid sequence, such as the *mpl* ligand nucleic acid sequence, to which they are operably linked. Such promoters typically fall into two classes, inducible and constitutive. Inducible promoters are promoters that initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, *e.g.*, the presence or absence of a nutrient or a change in temperature. At this time a large number of promoters recognized by a variety of potential host cells are well known. These promoters are operably linked to *mpl* ligand encoding DNA by removing the promoter from the source DNA by restriction enzyme digestion and inserting the isolated promoter sequence into the vector. Both the native *mpl* ligand promoter sequence and many heterologous promoters may be used to direct amplification and/or expression of the *mpl* ligand DNA. However, heterologous promoters are preferred, as they generally permit greater transcription and higher yields of expressed *mpl* ligand as compared to the native *mpl* ligand promoter.

Promoters suitable for use with prokaryotic hosts include the β -lactamase and lactose promoter systems (Chang *et al.*, *Nature*, **275**:615 [1978]; and Goeddel *et al.*, *Nature*, **281**:544 [1979]), alkaline phosphatase, a tryptophan (*trp*) promoter system (Goeddel, *Nucleic Acids Res.*, **8**:4057 [1980] and EP 36,776) and hybrid promoters such as the tac promoter (deBoer *et al.*, *Proc. Natl. Acad. Sci. USA*, **80**:21-25 [1983]). However, other known bacterial promoters are suitable. Their nucleotide sequences have been published, thereby enabling a skilled worker operably to ligate them to DNA encoding *mpl* ligand (Siebenlist *et al.*, *Cell*, **20**:269 [1980]) using linkers or adaptors to supply any required restriction sites. Promoters for use in bacterial

systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding *mpl* ligand polypeptide.

Promoter sequences are known for eukaryotes. Virtually all eukaryotic genes have an AT-rich region located approximately 25 to 30 bases upstream from the site where transcription is initiated. Another sequence found 70 to 80 bases upstream from the start of transcription of many genes is a CXCAAT region where X may be any nucleotide. At the 3' end of most eukaryotic genes is an AATAAA sequence that may be the signal for addition of the poly A tail to the 3' end of the coding sequence. All of these sequences are suitably inserted into eukaryotic expression vectors.

Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase (Hitzeman *et al.*, *J. Biol. Chem.*, **255**:2073 [1980]) or other glycolytic enzymes (Hess *et al.*, *J. Adv. Enzyme Reg.*, **7**:149 [1968]; and Holland, *Biochemistry*, **17**:4900 [1978]), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in Hitzeman *et al.*, EP 73,657A. Yeast enhancers also are advantageously used with yeast promoters.

Mpl ligand transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and most preferably Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, from heat-shock promoters, and from the promoter normally associated with the *mpl* ligand sequence, provided such promoters are compatible with the host cell systems.

The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment that also contains the SV40 viral origin of replication. Fiers *et al.*, *Nature*, **273**:113 [1978]; Mulligan and Berg, *Science*, **209**:1422-1427 [1980]; Pavlakis *et al.*, *Proc. Natl. Acad. Sci. USA*, **78**:7398-7402 [1981]. The immediate early

promoter of the human cytomegalovirus is conveniently obtained as a *Hind*III E restriction fragment. Greenaway *et al.*, *Gene*, **18**:355-360 [1982]. A system for expressing DNA in mammalian hosts using the bovine papilloma virus as a vector is disclosed in U.S. Patent No. 4,419,446. A modification of this system is described in 5 U.S. Patent No. 4,601,978. See also Gray *et al.*, *Nature*, **295**:503-508 [1982] on expressing cDNA encoding immune interferon in monkey cells; Reyes *et al.*, *Nature*, **297**:598-601 [1982] on expression of human β -interferon cDNA in mouse cells under the control of a thymidine kinase promoter from herpes simplex virus; Canaani and Berg, *Proc. Natl. Acad. Sci. USA*, **79**:5166-5170 [1982] on expression of the human 10 interferon β 1 gene in cultured mouse and rabbit cells; and Gorman *et al.*, *Proc. Natl. Acad. Sci. USA*, **79**:6777-6781 [1982] on expression of bacterial CAT sequences in CV-1 monkey kidney cells, chicken embryo fibroblasts, Chinese hamster ovary cells, HeLa cells, and mouse NIH-3T3 cells using the Rous sarcoma virus long terminal repeat as a promoter.

15 (v) *Enhancer Element Component*

Transcription of a DNA encoding the *mpl* ligand of this invention by higher eukaryotes is often increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act 20 on a promoter to increase its transcription. Enhancers are relatively orientation and position independent, having been found 5' (Laimins *et al.*, *Proc. Natl. Acad. Sci. USA*, **78**:993 [1981]) and 3' (Lusky *et al.*, *Mol. Cell Bio.*, **3**:1108 [1983]) to the transcription unit, within an intron (Banerji *et al.*, *Cell*, **33**:729 [1983]), as well as within the coding 25 sequence itself (Osborne *et al.*, *Mol. Cell Bio.*, **4**:1293 [1984]). Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, a-fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the 30 replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. See also Yaniv, *Nature*, **297**:17-18 [1982] on enhancing elements for activation of eukaryotic promoters. The enhancer may be spliced into the vector at a position 5' or 3' to the *mpl* ligand encoding sequence, but is preferably located at a site 5' from the promoter.

(vi) *Transcription Termination Component*

35 Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA.

Such sequences are commonly available from the 5' and, occasionally 3' untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding *mpl* ligand.

5 (vii) *Construction and Analysis of Vectors*

Construction of suitable vectors containing one or more of the above listed components employs standard ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to generate the plasmids required.

10 For analysis to confirm correct sequences in plasmids constructed, the ligation mixtures are used to transform *E. coli* K12 strain 294 (ATCC No. 31,446) and successful transformants selected by ampicillin or tetracycline resistance where appropriate. Plasmids from the transformants are prepared, analyzed by restriction endonuclease digestion, and/or sequenced by the method of Messing *et al.*, *Nucleic Acids Res.*, 9:309 [1981] or by the method of Maxam *et al.*, *Methods in Enzymology*, 15 65:499 [1980].

15 (viii) *Transient Expression Vectors*

Particularly useful in the practice of this invention are expression vectors that provide for the transient expression in mammalian cells of DNA encoding the *mpl* ligand polypeptide. In general, transient expression involves the use of an expression vector that is able to replicate efficiently in a host cell, such that the host cell accumulates many copies of the expression vector and, in turn, synthesizes high levels of a desired polypeptide encoded by the expression vector. Sambrook *et al.*, *supra*, pp. 16.17 - 16.22. Transient expression systems, comprising a suitable expression vector and a host cell, allow for the convenient positive identification of polypeptides encoded by cloned DNAs, as well as for the rapid screening of such polypeptides for desired biological or physiological properties. Thus, transient expression systems are particularly useful in the invention for purposes of identifying analogues and variants of *mpl* ligand polypeptide that have *mpl* ligand polypeptide biological activity.

30 (ix) *Suitable Exemplary Vertebrate Cell Vectors*

Other methods, vectors, and host cells suitable for adaptation to the synthesis of *mpl* ligand in recombinant vertebrate cell culture are described in Gething *et al.*, *Nature*, 293:620-625 [1981]; Mantei *et al.*, *Nature*, 281:40-46 [1979]; Levinson *et al.*; 35 EP 117,060; and EP 117,058. A particularly useful plasmid for mammalian cell culture

expression of *mpl* ligand is pRK5 (EP 307,247 U. S. patent no. 5,258,287) or pSVI6B (PCT Publication No. WO 91/08291).

D. Selection and Transformation of Host Cells

Suitable host cells for cloning or expressing the vectors herein are the 5 prokaryote, yeast, or higher eukaryotic cells described above. Suitable prokaryotes include eubacteria, such as Gram-negative or Gram-positive organisms, for example, *E. coli*, *Bacilli* such as *B. subtilis*, *Pseudomonas* species such as *P. aeruginosa*, *Salmonella typhimurium*, or *Serratia marcescans*. One preferred *E. coli* cloning host is 10 *E. coli* 294 (ATCC No. 31,446), although other strains such as *E. coli* B, *E. coli* X1776 (ATCC No. 31,537), and *E. coli* W3110 (ATCC No. 27,325) are suitable. These examples are illustrative rather than limiting. Preferably the host cell should secrete 15 minimal amounts of proteolytic enzymes. Alternatively, *in vitro* methods of cloning, e.g., PCR or other nucleic acid polymerase reactions, are suitable.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or 15 yeast are suitable hosts for *mpl* ligand encoding vectors. *Saccharomyces cerevisiae*, or common baker's yeast, is the most commonly used among lower eukaryotic host microorganisms. However, a number of other genera, species, and strains are 20 commonly available and useful herein, such as *Schizosaccharomyces pombe* (Beach and Nurse, *Nature*, **290**:140 [1981]; EP 139,383 published 2 May 1985), *Kluyveromyces* hosts (U.S. Patent No. 4,943,529) such as, e.g., *K. lactis* (Louvencourt 25 *et al.*, *J. Bacteriol.*, **737** [1983]), *K. fragilis*, *K. bulgaricus*, *K. thermotolerans*, and *K. marxianus*, *yarrowia* [EP 402,226], *Pichia pastoris* (EP 183,070; Sreekrishna *et al.*, *J. Basic Microbiol.*, **28**:265-278 [1988]), *Candida*, *Trichoderma reesia* (EP 244,234), *Neurospora crassa* (Case *et al.*, *Proc. Natl. Acad. Sci. USA*, **76**:5259-5263 [1979]), 30 and filamentous fungi such as, e.g, *Neurospora*, *Penicillium*, *Tolypocladium* (WO 91/00357 published 10 January 1991), and *Aspergillus* hosts such as *A. nidulans* (Ballance *et al.*, *Biochem. Biophys. Res. Commun.*, **112**:284-289 [1983]; Tilburn *et al.*, *Gene*, **26**:205-221 [1983]; Yelton *et al.*, *Proc. Natl. Acad. Sci. USA*, **81**:1470-1474 35 [1984]) and *A. niger* (Kelly and Hynes, *EMBO J.*, **4**:475-479 [1985]).

Suitable host cells for the expression of glycosylated *mpl* ligand are derived 30 from multicellular organisms. Such host cells are capable of complex processing and glycosylation activities. In principle, any higher eukaryotic cell culture is workable, whether from vertebrate or invertebrate culture. Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains and variants and corresponding 35 permissive insect host cells from hosts such as *Spodoptera frugiperda* (caterpillar), *Aedes aegypti* (mosquito), *Aedes albopictus* (mosquito), *Drosophila melanogaster*

(fruitfly), and *Bombyx mori* have been identified. See, e.g., Luckow *et al.*, *Bio/Technology*, 6:47-55 [1988]; Miller *et al.*, *Genetic Engineering*, Setlow *et al.*, eds., Vol. 8 (Plenum Publishing, 1986), pp. 277-279; and Maeda *et al.*, *Nature*, 315:592-594 [1985]. A variety of viral strains for transfection are publicly available, e.g., the L-1 5 variant of *Autographa californica* NPV and the Bm-5 strain of *Bombyx mori* NPV, and such viruses may be used as the virus herein according to the present invention, particularly for transfection of *Spodoptera frugiperda* cells.

Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco can be utilized as hosts. Typically, plant cells are transfected by incubation with 10 certain strains of the bacterium *Agrobacterium tumefaciens*, which has been previously manipulated to contain the *mpl* ligand DNA. During incubation of the plant cell culture with *A. tumefaciens*, the DNA encoding the *mpl* ligand is transferred to the plant cell host such that it is transfected, and will, under appropriate conditions, express the *mpl* ligand DNA. In addition, regulatory and signal sequences compatible 15 with plant cells are available, such as the nopaline synthase promoter and polyadenylation signal sequences. Depicker *et al.*, *J. Mol. Appl. Gen.*, 1:561 [1982]. In addition, DNA segments isolated from the upstream region of the T-DNA 780 gene are capable of activating or increasing transcription levels of plant-expressible genes in recombinant DNA-containing plant tissue. EP 321,196 published 21 June 1989.

20 However, interest has been greatest in vertebrate cells, and propagation of vertebrate cells in culture (tissue culture) has become a routine procedure in recent years (Tissue Culture, Academic Press, Kruse and Patterson, editors [1973]). Examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 25 or 293 cells subcloned for growth in suspension culture, Graham *et al.*, *J. Gen. Virol.*, 36:59 [1977]); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, *Proc. Natl. Acad. Sci. USA*, 77:4216 [1980]); mouse sertoli cells (TM4, Mather, *Biol. Reprod.*, 23:243-251 [1980]); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, 30 ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather *et al.*, *Annals N.Y. Acad. Sci.*, 383:44-68 [1982]); MRC 5 cells; FS4 cells; and a human hepatoma line 35 (Hep G2).

Host cells are transfected and preferably transformed with the above-described expression or cloning vectors of this invention and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.

5 Transfection refers to the taking up of an expression vector by a host cell whether or not any coding sequences are in fact expressed. Numerous methods of transfection are known to the ordinarily skilled artisan, for example, CaPO₄ and electroporation. Successful transfection is generally recognized when any indication of the operation of this vector occurs within the host cell.

10 Transformation means introducing DNA into an organism so that the DNA is replicable, either as an extrachromosomal element or by chromosomal integrant. Depending on the host cell used, transformation is done using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in section 1.82 of Sambrook *et al.*, *supra*, is generally used for prokaryotes
15 or other cells that contain substantial cell-wall barriers. Infection with *Agrobacterium tumefaciens* is used for transformation of certain plant cells, as described by Shaw *et al.*, *Gene*, 23:315 [1983] and WO 89/05859 published 29 June 1989. In addition, plants may be transfected using ultrasound treatment as described in WO 91/00358 published 10 January 1991. For mammalian cells without such cell walls, the calcium
20 phosphate precipitation method of Graham and van der Eb, *Virology*, 52:456-457 [1978] is preferred. General aspects of mammalian cell host system transformations have been described by Axel in U.S. Patent No. 4,399,216 issued 16 August 1983. Transformations into yeast are typically carried out according to the method of Van
25 Solingen *et al.*, *J. Bact.*, 130:946 [1977] and Hsiao *et al.*, *Proc. Natl. Acad. Sci. (USA)*, 76:3829 [1979]. However, other methods for introducing DNA into cells such as by nuclear injection, electroporation, or protoplast fusion may also be used.

E. Culturing the Host Cells

Prokaryotic cells used to produce the *mp* ligand polypeptide of this invention are cultured in suitable media as described generally in Sambrook *et al.*, *supra*.

30 The mammalian host cells used to produce the *mp* ligand of this invention may be cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ([MEM], Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ([DMEM], Sigma) are suitable for culturing the host cells. In addition, any of the media described in Ham and Wallace, *Meth. Enz.*,
35 58:44 [1979], Barnes and Sato, *Anal. Biochem.*, 102:255 [1980], U.S. Patent No. 4,767,704; 4,657,866; 4,927,762; or 4,560,655; WO 90/03430; WO 87/00195; U.S.

Patent Re. 30,985; or copending U.S.S.N. 07/592,107 or 07/592,141, both filed on 3 October 1990, the disclosures of all of which are incorporated herein by reference, may be used as culture media for the host cells. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as 5 insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleosides (such as adenosine and thymidine), antibiotics (such as Gentamycin™ drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary 10 supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

The host cells referred to in this disclosure encompass cells in *in vitro* culture as 15 well as cells that are within a host animal.

F. Detecting Gene Amplification/Expression

Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, northern blotting to quantitate the transcription of mRNA (Thomas, *Proc. Natl. Acad. Sci. USA*, **77**:5201-5205 [1980]), dot 20 blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Various labels may be employed, most commonly radioisotopes, particularly ³²P. However, other techniques may also be employed, such as using biotin-modified nucleotides for introduction into a polynucleotide. The biotin then serves as the site for binding to avidin or antibodies, 25 which may be labeled with a wide variety of labels, such as radionuclides, fluorescers, enzymes, or the like. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the 30 formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.

Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. With 35 immunohistochemical staining techniques, a cell sample is prepared, typically by dehydration and fixation, followed by reaction with labeled antibodies specific for the

gene product coupled, where the labels are usually visually detectable, such as enzymatic labels, fluorescent labels, luminescent labels, and the like. A particularly sensitive staining technique suitable for use in the present invention is described by Hsu *et al.*, *Am. J. Clin. Path.*, **75**:734-738 [1980].

5 Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native *mpl* ligand polypeptide or against a synthetic peptide based on the DNA sequences provided herein as described further below.

10 G. *Purification of mpl ligand Polypeptide*

Mpl ligand preferably is recovered from the culture medium as a secreted polypeptide, although it also may be recovered from host cell lysates when directly expressed without a secretory signal.

When *mpl* ligand is expressed in a recombinant cell other than one of human origin, the *mpl* ligand is completely free of proteins or polypeptides of human origin. However, it is still usually necessary to purify *mpl* ligand from other recombinant cell proteins or polypeptides to obtain preparations that are substantially homogeneous as to the *mpl* ligand *per se*. As a first step, the culture medium or lysate is centrifuged to remove particulate cell debris. The membrane and soluble protein fractions are then separated. Alternatively, a commercially available protein concentration filter (e.g., Amicon or Millipore Pellicon ultrafiltration units) may be used. The *mpl* ligand may then be purified from the soluble protein fraction and from the membrane fraction of the culture lysate, depending on whether the *mpl* ligand is membrane bound. *Mpl* ligand thereafter is purified from contaminant soluble proteins and polypeptides by salting out and exchange or chromatographic procedures employing various gel matrices. These matrices include; acrylamide, agarose, dextran, cellulose and others common to protein purification. Exemplary chromatography procedures suitable for protein purification include; immunoaffinity (e.g., anti-*hmp* ligand Mab), receptoraffinity (e.g., *mp*-IgG or protein A Sepharose), hydrophobic interaction chromatography (HIC) (e.g., ether, butyl, or phenyl Toyopearl), lectin chromatography (e.g., Con A-Sepharose, lentil-lectin-Sepharose), size exclusion (e.g., Sephadex G-75), cation- and anion-exchange columns (e.g., DEAE or carboxymethyl- and sulfopropyl-cellulose), and reverse-phase high performance liquid chromatography (RP-HPLC) (see e.g., Urdal *et al.*, *J. Chromatog.*, **296**:171 [1984] where two sequential RP-HPLC steps are used to purify recombinant human IL-2). Other purification steps optionally include; ethanol

precipitation; ammonium sulfate precipitation; chromatofocusing; preparative SDS-PAGE, and the like.

Mpl ligand variants in which residues have been deleted, inserted, or substituted are recovered in the same fashion as native *mpl* ligand, taking account of any substantial changes in properties occasioned by the variation. For example, preparation of a *mpl* ligand fusion with another protein or polypeptide, e.g., a bacterial or viral antigen, facilitates purification; an immunoaffinity column containing antibody to the antigen can be used to adsorb the fusion polypeptide. Immunoaffinity columns such as a rabbit polyclonal anti-*mpl* ligand column can be employed to absorb the *mpl* ligand variant by binding it to at least one remaining immune epitope. Alternatively, the *mpl* ligand may be purified by affinity chromatography using a purified *mpl*-IgG coupled to a (preferably) immobilized resin such as Affi-Gel 10 (Bio-Rad, Richmond, CA) or the like, by means well known in the art. A protease inhibitor such as phenyl methyl sulfonyl fluoride (PMSF) also may be useful to inhibit proteolytic degradation during purification, and antibiotics may be included to prevent the growth of adventitious contaminants. One skilled in the art will appreciate that purification methods suitable for native *mpl* ligand may require modification to account for changes in the character of *mpl* ligand or its variants upon expression in recombinant cell culture.

20 *H. Covalent Modifications of mpl ligand Polypeptide*

Covalent modifications of *mpl* ligand polypeptides are included within the scope of this invention. Both native *mpl* ligand and amino acid sequence variants of the *mpl* ligand may be covalently modified. One type of covalent modification included within the scope of this invention is a *mpl* ligand fragment. Variant *mpl* ligand fragments having up to about 40 amino acid residues may be conveniently prepared by chemical synthesis or by enzymatic or chemical cleavage of the full-length or variant *mpl* ligand polypeptide. Other types of covalent modifications of the *mpl* ligand or fragments thereof are introduced into the molecule by reacting targeted amino acid residues of the *mpl* ligand or fragments thereof with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues.

Cysteinyl residues most commonly are reacted with α -haloacetates (and corresponding amines), such as chloroacetic acid or chloroacetamide, to give carboxymethyl or carboxyamidomethyl derivatives. Cysteinyl residues also are derivatized by reaction with bromotrifluoroacetone, α -bromo- β -(5-imidazolyl)propionic acid, chloroacetyl phosphate, N-alkylmaleimides, 3-nitro-2-pyridyl disulfide, methyl 2-

pyridyl disulfide, p-chloromercuribenzoate, 2-chloromercuri-4-nitrophenol, or chloro-7-nitrobenzo-2-oxa-1,3-diazole.

Histidyl residues are derivatized by reaction with diethylpyrocarbonate at pH 5.5-7.0 because this agent is relatively specific for the histidyl side chain. Para-bromophenacyl bromide also is useful; the reaction is preferably performed in 0.1M sodium cacodylate at pH 6.0.

Lysinyl and amino terminal residues are reacted with succinic or other carboxylic acid anhydrides. Derivatization with these agents has the effect of reversing the charge of the lysinyl residues. Other suitable reagents for derivatizing -amino-containing residues include imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2,4-pentanedione; and transaminase-catalyzed reaction with glyoxylate.

Arginyl residues are modified by reaction with one or several conventional reagents, among them phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin. Derivatization of arginine residues requires that the reaction be performed in alkaline conditions because of the high pK_a of the guanidine functional group. Furthermore, these reagents may react with the groups of lysine as well as the arginine epsilon-amino group.

The specific modification of tyrosyl residues may be made, with particular interest in introducing spectral labels into tyrosyl residues by reaction with aromatic diazonium compounds or tetranitromethane. Most commonly, N-acetylimidazole and tetranitromethane are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively. Tyrosyl residues are iodinated using ^{125}I or ^{131}I to prepare labeled proteins for use in radioimmunoassay, the chloramine T method described above being suitable.

Carboxyl side groups (aspartyl or glutamyl) are selectively modified by reaction with carbodiimides ($R-N=C=N-R'$), where R and R' are different alkyl groups, such as 1-cyclohexyl-3-(2-morpholinyl-4-ethyl)carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl)carbodiimide. Furthermore, aspartyl and glutamyl residues are converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.

Derivatization with bifunctional agents is useful for crosslinking *mpl* ligand to a water-insoluble support matrix or surface for use in the method for purifying anti-*mpl* ligand antibodies, and *vice versa*. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including

disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), and bifunctional maleimides such as bis-N-maleimido-1,8-octane. Derivatizing agents such as methyl-3-[(p-azidophenyl)dithio]propioimidate yield photoactivatable intermediates that are capable of forming crosslinks in the presence of light. Alternatively, reactive water-insoluble matrices such as cyanogen bromide-activated carbohydrates and the reactive substrates described in U.S. Patent Nos. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; and 4,330,440 are employed for protein immobilization.

Glutamyl and asparaginyl residues are frequently deamidated to the corresponding glutamyl and aspartyl residues, respectively. These residues are deamidated under neutral or basic conditions. The deamidated form of these residues falls within the scope of this invention.

Other modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the α -amino groups of lysine, arginine, and histidine side chains (T.E. Creighton, *Proteins: Structure and Molecular Properties*, W.H. Freeman & Co., San Francisco, pp. 79-86 [1983]), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the *mpl* ligand polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. By altering is meant deleting one or more carbohydrate moieties found in native *mpl* ligand, and/or adding one or more glycosylation sites that are not present in the native *mpl* ligand.

Glycosylation of polypeptides is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-acetylglactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.

Addition of glycosylation sites to the *mpl* ligand polypeptide is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the native *mpl* ligand sequence (for O-linked glycosylation

sites). For ease, the *mpl* ligand amino acid sequence is preferably altered through changes at the DNA level, particularly by mutating the DNA encoding the *mpl* ligand polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids. The DNA mutation(s) may be made using methods 5 described above under the heading of "Amino Acid Sequence Variants of *mpl* Ligand."

Another means of increasing the number of carbohydrate moieties on the *mpl* ligand is by chemical or enzymatic coupling of glycosides to the polypeptide. These 10 procedures are advantageous in that they do not require production of the polypeptide in a host cell that has glycosylation capabilities for N- or O-linked glycosylation. Depending on the coupling mode used, the sugar(s) may be attached to (a) arginine 15 and histidine, (b) free carboxyl groups, (c) free sulfhydryl groups such as those of cysteine, (d) free hydroxyl groups such as those of serine, threonine, or hydroxyproline, (e) aromatic residues such as those of phenylalanine, tyrosine, or tryptophan, or (f) the amide group of glutamine. These methods are described in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, *CRC Crit. Rev. Biochem.*, pp. 259-306 [1981].

Removal of carbohydrate moieties present on the *mpl* ligand polypeptide may 20 be accomplished chemically or enzymatically. Chemical deglycosylation requires exposure of the polypeptide to the compound trifluoromethanesulfonic acid, or an equivalent compound. This treatment results in the cleavage of most or all sugars except the linking sugar (N-acetylglucosamine or N-acetylgalactosamine), while leaving the polypeptide intact. Chemical deglycosylation is described by Hakimuddin, 25 *et al.*, *Arch. Biochem. Biophys.*, **259**:52 [1987] and by Edge *et al.*, *Anal. Biochem.*, **118**:131 [1981]. Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura *et al.*, *Meth. Enzymol.*, **138**:350 [1987].

Glycosylation at potential glycosylation sites may be prevented by the use of the compound tunicamycin as described by Duskin *et al.*, *J. Biol. Chem.*, **257**:3105 [1982]. Tunicamycin blocks the formation of protein-N-glycoside linkages.

Another type of covalent modification of *mpl* ligand comprises linking the *mpl* 30 ligand polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

It will be appreciated that some screening of the recovered *mpl* ligand variant 35 will be needed to select the optimal variant for binding to a *mpl* and having the

immunological and/or biological activity defined above. One can screen for stability in recombinant cell culture or in plasma (e.g., against proteolytic cleavage), high affinity to a *mpl* member, oxidative stability, ability to be secreted in elevated yields, and the like. For example, a change in the immunological character of the *mpl* ligand 5 polypeptide, such as affinity for a given antibody, is measured by a competitive-type immunoassay. Other potential modifications of protein or polypeptide properties such as redox or thermal stability, hydrophobicity, or susceptibility to proteolytic degradation are assayed by methods well known in the art.

10 **10. General Methods for Preparation of Antibodies to the *mpl***

85

Ligand

Antibody Preparation

(i) Polyclonal antibodies

15 Polyclonal antibodies to *mpl* ligand polypeptides or fragments are generally raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the *mpl* ligand and an adjuvant. It may be useful to conjugate the *mpl* ligand or a fragment containing the target amino acid sequence to a protein that is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine 20 thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glytaraldehyde, succinic anhydride, SOCl_2 , or $\text{R}^1\text{N}=\text{C}=\text{NR}$, where R and R¹ are different alkyl groups.

25 Animals are immunized against the *mpl* ligand polypeptide or fragment, immunogenic conjugates or derivatives by combining 1 mg of 1 μg of the peptide or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with 1/5 to 1/10 the original amount of peptide or conjugate in 30 Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later the animals are bled and the serum is assayed for *mpl* ligand antibody titer. Animals are boosted until the titer plateaus. Preferably, the animal boosted with the conjugate of the same *mpl* ligand, but conjugated to a different protein and/or through 35 a different cross-linking reagent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are used to enhance the immune response.

(ii) Monoclonal antibodies

Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies, *i.e.*, the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Thus, the modifier "monoclonal" indicates the character of the antibody as not being a mixture of discrete antibodies.

For example, the *mpl* ligand monoclonal antibodies of the invention may be made using the hybridoma method first described by Kohler & Milstein, *Nature*, 10 256:495 [1975], or may be made by recombinant DNA methods (U.S. Patent No. 4,816,567 (Cabilly *et al.*)).

In the hybridoma method, a mouse or other appropriate host animal, such as hamster is immunized as hereinabove described to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for 15 immunization. Alternatively, lymphocytes may be immunized *in vitro*. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, *Monoclonal Antibodies: Principles and Practice*, pp.59-103 (Academic Press, 1986)).

The hybridoma cells thus prepared are seeded and grown in a suitable culture 20 medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of 25 HGPRT-deficient cells.

Preferred myeloma cells are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. Among these, preferred myeloma cell lines are murine 30 myeloma lines, such as those derived from MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, California USA, and SP-2 cells available from the American Type Culture Collection, Rockville, Maryland USA. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, *J. Immunol.*, 133:3001 [1984]; Brodeur *et al.*, *Monoclonal Antibody Production Techniques and Applications*, pp.51-63, Marcel Dekker, Inc., New York, 1987).

Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against *mpl* ligand. Preferably, the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).

5 The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson & Pollard, *Anal. Biochem.*, **107**:220 [1980].

10 After hybridoma cells are identified that produce antibodies of the desired specificity, affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, *supra*). Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium or RPMI-1640 medium. In addition, the hybridoma cells may be grown *in vivo* as ascites tumors in an animal.

15 The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

20 DNA encoding the monoclonal antibodies of the invention is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin 25 protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences, (Cabilly *et al.*, *supra*; Morrison, *et al.*, *Proc. Nat. Acad. Sci.*, **81**:6851 [1984]), or by covalently joining to the immunoglobulin coding sequence all or part of 30 the coding sequence for a non-immunoglobulin polypeptide.

35 Typically such non-immunoglobulin polypeptides are substituted for the constant domains of an antibody of the invention, or they are substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for a *mpl* ligand and another antigen-combining site having specificity for a different antigen.

Chimeric or hybrid antibodies also may be prepared *in vitro* using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include 5 iminothiolate and methyl-4-mercaptoputyrimidate.

For diagnostic applications, the antibodies of the invention typically will be labeled with a detectable moiety. The detectable moiety can be any one which is capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as ^3H , ^{14}C , ^{32}P , ^{35}S , or ^{125}I , a 10 fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin; radioactive isotopic labels, such as, e.g., ^{125}I , ^{32}P , ^{14}C , or ^3H , or an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase.

Any method known in the art for separately conjugating the antibody to the 15 detectable moiety may be employed, including those methods described by Hunter, *et al.*, *Nature*, **144**:945 [1962]; David, *et al.*, *Biochemistry*, **13**:1014 [1974]; Pain, *et al.*, *J. Immunol. Meth.*, **40**:219 [1981]; and Nygren, *J. Histochem. and Cytochem.*, **30**:407 [1982].

The antibodies of the present invention may be employed in any known assay 20 method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays. Zola, *Monoclonal Antibodies: A Manual of Techniques*, pp.147-158 (CRC Press, Inc., 1987).

Competitive binding assays rely on the ability of a labeled standard (which may 25 be a *mpl* ligand or an immunologically reactive portion thereof) to compete with the test sample analyte (*mpl* ligand) for binding with a limited amount of antibody. The amount of *mpl* ligand in the test sample is inversely proportional to the amount of standard that becomes bound to the antibodies. To facilitate determining the amount 30 of standard that becomes bound, the antibodies generally are insolubilized before or after the competition, so that the standard and analyte that are bound to the antibodies may conveniently be separated from the standard and analyte which remain unbound.

Sandwich assays involve the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope, of the protein (*mpl* ligand) to be detected. In a sandwich assay, the test sample analyte is bound by a first antibody which is 35 immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three part complex. David & Greene, U.S. Patent No. 4,376,110. The second antibody may itself be labeled with a detectable moiety (direct

sandwich assays) or may be measured using an anti-immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assay). For example, one type of sandwich assay is an ELISA assay, in which case the detectable moiety is an enzyme (e.g., horseradish peroxidase).

5 (iii) Humanized and human antibodies

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones *et al.*, *Nature*, **321**:522-525 [1986]; Riechmann *et al.*, *Nature*, **332**:323-327 [1988]; Verhoeyen *et al.*, *Science*, **239**:1534-1536 [1988]), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (Cabilly *et al.*, *supra*), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

20 The choice of human variable domains, both light and heavy, to be used in
making the humanized antibodies is very important in order to reduce antigenicity.
According to the so called "best-fit" method, the sequence of the variable domain of a
rodent antibody is screened against the entire library of known human variable
domain sequences. The human sequence which is closest to that of the rodent is then
25 accepted as the human framework (FR) for the humanized antibody (Sims *et al.*, *J.
Immunol.*, **151**:2296 [1993]; Chothia and Lesk, *J. Mol. Biol.*, **196**:901 [1987]). Another
method uses a particular framework derived from the consensus sequence of all
human antibodies of a particular subgroup of light or heavy chains. The same
framework may be used for several different humanized antibodies (Carter *et al.*, *Proc.
30 Natl. Acad. Sci. USA*, **89**:4285 [1992]; Presta *et al.*, *J. Immunol.*, **151**:2623 [1993]).

It is further important that antibodies be humanized with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three dimensional models of the parental and humanized sequences. Three dimensional immunoglobulin models are commonly available and are familiar to those

skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, *i.e.*,
5 the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the consensus and import sequence so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. In general, the CDR residues are directly and most substantially involved in influencing antigen binding. For further
10 details see U.S. application Serial No. 07/934,373 filed 21 August 1992, which is a continuation-in-part of application Serial No. 07/715,272 filed 14 June 1991.

Alternatively, it is now possible to produce transgenic animals (*e.g.*, mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, it has been
15 described that the homozygous deletion of the antibody heavy chain joining region (J_H) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge. See, *e.g.*, Jakobovits *et al.*, *Proc. Natl. Acad. Sci.*
20 *USA*, **90**:2551-255 [1993]; Jakobovits *et al.*, *Nature*, **362**:255-258 [1993]; Bruggermann *et al.*, *Year in Immuno.*, **7**:33 [1993]. Human antibodies can also be produced in phage display libraries (Hoogenboom and Winter, *J. Mol. Biol.* **227**, 381 [1991]; Marks *et al.*, *J. Mol. Biol.* **222**, 581 [1991]).

(iv) *Bispecific antibodies*

25 Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. Methods for making bispecific antibodies are known in the art.

Traditionally, the recombinant production of bispecific antibodies is based on the coexpression of two immunoglobulin heavy chain-light chain pairs, where the two
30 heavy chains have different specificities (Millstein and Cuello, *Nature*, **305**:537-539 [1983]). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule, which is usually done by affinity chromatography steps, is rather
35 cumbersome, and the product yields are low. Similar procedures are disclosed in

PCT publication No. WO 93/08829 (published 13 May 1993), and in Traunecker *et al.*, *EMBO*, **10**:3655-3659 [1991].

According to a different and more preferred approach, antibody variable domains with the desired binding specificities (antibody-antigen combining sites) are fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy chain constant domain, comprising at least part of the hinge, CH₂ and CH₃ regions. It is preferred to have the first heavy chain constant region (CH₁) containing the site necessary for light chain binding, present in at least one of the fusions. DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are cotransfected into a suitable host organism. This provides for great flexibility in adjusting the mutual proportions of the three polypeptide fragments in embodiments when unequal ratios of the three polypeptide chains used in the construction provide the optimum yields. It is, however, possible to insert the coding sequences for two or all three polypeptide chains in one expression vector when the expression of at least two polypeptide chains in equal ratios results in high yields or when the ratios are of no particular significance. In a preferred embodiment of this approach, the bispecific antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. It was found that this asymmetric structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way of separation. This approach is disclosed in copending application Serial No. 07/931,811 filed 17 August 1992.

For further details of generating bispecific antibodies see, for example, Suresh *et al.*, *Methods in Enzymology*, **121**:210 [1986].

(v) *Heteroconjugate antibodies*

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (PCT publication Nos. WO 91/00360 and WO 92/00373; EP 03089). Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Patent No. 4,676,980, along with a number of cross-linking techniques.

IV. Therapeutic Use of the Megakaryocytopoietic Protein *mpl* Ligand

The biologically active *mpl* ligand having hematopoietic effector function and referred to here as a megakaryocytopoietic or thrombocytopoietic protein (TPO) may be used in a sterile pharmaceutical preparation or formulation to stimulate megakaryocytopoietic or thrombopoietic activity in patients suffering from thrombocytopenia due to impaired production, sequestration, or increased destruction of platelets. Thrombocytopenia-associated bone marrow hypoplasia (e.g., aplastic anemia following chemotherapy or bone marrow transplant) may be effectively treated with the compounds of this invention as well as disorders such as disseminated intravascular coagulation (DIC), immune thrombocytopenia (including HIV-induced ITP and non HIV-induced ITP), idiopathic thrombocytopenia, and thrombotic thrombocytopenia. Additionally, these megakaryocytopoietic proteins may be useful in treating myeloproliferative thrombocytotic diseases as well as thrombocytosis from inflammatory conditions and in iron deficiency.

Still other disorders usefully treated with the megakaryocytopoietic proteins of this invention include defects or damage to platelets resulting from drugs, poisoning or activation on artificial surfaces. In these cases, the instant compounds may be employed to stimulate "shedding" of new "undamaged" platelets. For a more complete list of useful applications, see the "Background" *supra*, especially section (a)-(f) and references cited therein.

The megakaryocytopoietic proteins of the instant invention may be employed alone or in combination with other cytokines, hematopoietins, interleukins, growth factors, or antibodies in the treatment of the above-identified disorders and conditions. Thus, the instant compounds may be employed in combination with other protein or peptide having thrombopoietic activity including; G-CSF, GM-CSF, LIF, M-CSF, IL-1, IL-3, erythropoietin (EPO), kit ligand, IL-6, and IL-11.

The megakaryocytopoietic proteins of the instant invention are prepared in a mixture with a pharmaceutically acceptable carrier. This therapeutic composition can be administered intravenously or through the nose or lung. The composition may also be administered parenterally or subcutaneously as desired. When administered systematically, the therapeutic composition should be pyrogen-free and in a parenterally acceptable solution having due regard for pH, isotonicity, and stability. These conditions are known to those skilled in the art. Briefly, dosage formulations of the compounds of the present invention are prepared for storage or administration by mixing the compound having the desired degree of purity with physiologically acceptable carriers, excipients, or stabilizers. Such materials are non-toxic to the

recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, acetate and other organic acid salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) peptides such as polyarginine, proteins, such as serum albumin, gelatin, or immunoglobulins;

5 hydrophilic polymers such as polyvinylpyrrolidinone; amino acids such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium and/or nonionic surfactants such as Tween, Pluronics or

10 polyethyleneglycol.

About 0.5 to 500 mg of a compound or mixture of the megakaryocytopoietic protein as the free acid or base form or as a pharmaceutically acceptable salt, is compounded with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, flavor, etc., as called for by accepted pharmaceutical practice.

15 The amount of active ingredient in these compositions is such that a suitable dosage in the range indicated is obtained.

Sterile compositions for injection can be formulated according to conventional pharmaceutical practice. For example, dissolution or suspension of the active compound in a vehicle such as water or naturally occurring vegetable oil like sesame, peanut, or cottonseed oil or a synthetic fatty vehicle like ethyl oleate or the like may be desired. Buffers, preservatives, antioxidants and the like can be incorporated according to accepted pharmaceutical practice.

Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the polypeptide, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels [e.g., poly(2-hydroxyethyl-methacrylate) as described by Langer *et al.*, *J. Biomed. Mater. Res.*, **15**:167-277 [1981] and Langer, *Chem. Tech.*, **12**:98-105 [1982] or poly(vinylalcohol)], polylactides (U.S. Patent No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman *et al.*, *Biopolymers*, **22**:547-556 [1983]), non-degradable ethylene-vinyl acetate (Langer *et al.*, *supra*), degradable lactic acid-glycolic acid copolymers such as the Lupron Depot™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid (EP 133,988).

35 While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for

shorter time periods. When encapsulated proteins remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for protein stabilization depending on the mechanism 5 involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulphydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

10 Sustained-release megakaryocytopoietic protein compositions also include liposomally entrapped megakaryocytopoietic protein. Liposomes containing megakaryocytopoietic protein are prepared by methods known *per se*: DE 3,218,121; Epstein *et al.*, *Proc. Natl. Acad. Sci. USA*, **82**:3688-3692 [1985]; Hwang *et al.*, *Proc. Natl. Acad. Sci. USA*, **77**:4030-4034 [1980]; EP 52,322; EP 36,676; EP 88,046; EP 15 143,949; EP 142,641; Japanese patent application 83-118008; U.S. Patent Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. % cholesterol, the selected proportion being adjusted for the optimal megakaryocytopoietic protein therapy.

20 The dosage will be determined by the attending physician taking into consideration various factors known to modify the action of drugs including severity and type of disease, body weight, sex, diet, time and route of administration, other medications and other relevant clinical factors. Typically, the daily regimen will range from 1-3000 µg/kg body weight. Preferably the dosage will range from 1-1000 µg/kg 25 body weight. Most preferably, the dosage will range from 1 to 150 µg/kg/day. Optionally, the dosage range will be the same as that of other interleukins, especially EPO. Therapeutically effective dosages may be determined by either *in vitro* or *in vivo* methods.

30

EXAMPLES

Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and illustrative examples, make and utilize the present invention to the fullest extent. The following working examples therefore specifically 35 point out preferred embodiments of the present invention, and are not to be construed as limiting in any way of the remainder of the disclosure.

EXAMPLE I***Partial Purification of the Porcine mpl Ligand***

Platelet-poor plasma was collected from normal or aplastic anemic pigs. Pigs
5 were rendered aplastic by irradiation with 900 cGy of total body irradiation using a
4mEV linear accelerator. The irradiated pigs were supported for 6-8 days with
intramuscular injections of cefazolin. Subsequently, their total blood volume was
removed under general anesthesia, heparinized, and centrifuged at 1800 x g for
30min. to make platelet-poor plasma. The megakaryocyte stimulating activity was
10 found to peak 6 days after irradiation.

Aplastic porcine plasma obtained from irradiated pigs is made 4M with NaCl
and stirred for 30 min. at room temperature. The resultant precipitate is removed by
centrifugation at 3800 rpm in a Sorvall RC3B and the supernatant is loaded onto a
Phenyl-Toyopearl column (220 ml) equilibrated in 10 mM NaPO₄ containing 4M NaCl.
15 The column is washed with this buffer until A₂₈₀ is <0.05 and eluted with dH₂O. The
eluted protein peak is diluted with dH₂O to a conductivity of 15mS and loaded onto a
Blue-Sepharose column equilibrated (240 ml) in PBS. Subsequently, the column is
washed with 5 column volumes each of PBS and 10mM NaPO₄ (pH 7.4) containing
2M urea. Proteins are eluted from the column with 10mM NaPO₄ (pH 7.4) containing
20 2M urea and 1M NaCl. The eluted protein peak is made 0.01% octyl glucoside(n-octyl
b-D-glucopyranoside) and 1 mM each with EDTA and Pefabloc (Boehinger
Mannheim) and loaded directly onto tandemly linked CD4-IgG (Capon, D.J. *et al.*
Nature 337:525-531 [1989]) and *mpl*-IgG Ultralink (Pierce) columns (see below). The
CD4-IgG (2 ml) column is removed after the sample is loaded and the *mpl*-IgG (4 ml)
25 column is washed with 10 column volumes each of PBS and PBS containing 2 M
NaCl and eluted with 0.1M glycine-HCl pH 2.25. Fractions are collected into 1/10th
volume 1M Tris-HCl (pH 8.0).

Analysis of eluted fractions from the *mpl*-affinity column by SDS-PAGE (4-20%,
Novex gel) run under reducing conditions, revealed the presence of several proteins
30 (Fig. 3). Proteins that silver stain with the strongest intensity resolve with apparent Mr
of 66,000, 55,000, 30,000, 28,000 and 14,000. To determine which of these proteins
stimulate proliferation of Ba/F3-*mpl* cell cultures these proteins were eluted from the
gel as described in **Example II** below.

Ultralink Affinity Columns

10-20 mg of *mpl*-IgG or CD4-IgG in PBS are coupled to 0.5 grams of Ultralink resin (Pierce) as described by the manufacturer's instructions.

5 ***Construction and Expression of mpl-IgG***

A chimeric molecule comprising the entire extracellular domain of human *mpl* (amino acids 1-491) and the Fc region of a human IgG1 molecule was expressed in 293 cells. A cDNA fragment encoding amino acids 1-491 of human *mpl* was obtained by PCR from a human platelet cDNA library and sequenced. A Clal site was inserted 10 at the 5' end and a BstEII site at the 3' end. This fragment was cloned upstream of the IgG1 Fc coding region in a Bluescript vector between the Clal and the BstEII sites after partial digestion of the PCR product with BstEII because of 2 other BstEII sites present in the DNA encoding the extracellular domain of *mpl*. The BstEII site introduced at the 15 3' end of the *mpl* PCR product was designed to have the Fc region in frame with the *mpl* extracellular domain. The construct was subcloned into pRK5-tkneo vector between the Clal and XbaI sites and transfected into 293 human embryonic kidney cells by the calcium phosphate method. The cells were selected in 0.4 mg/ml G418 and individual clones were isolated. *Mpl*-IgG expression from isolated clones was determined using a human Fc specific ELISA. The best expression clone had an 20 expression level of 1-2 mg/ml of *mpl*-IgG.

Ba/F3 mpl P Expressing Cells and mpl ligand Assay

A cDNA corresponding to the entire coding region of human *mpl* P was cloned 25 into pRK5-tkneo which was subsequently linearized with NotI and transfected into the IL-3 dependent cell line Ba/F3 by electroporation (1×10^7 cells, 9605F, 250Volts). Three days later selection was started in the presence of 2 mg/ml of G418. The cells selected as pools or individual clones were obtained by limiting dilution in 96 well plates. Selected cells were maintained in RPMI containing 15% FBS, 1mg /ml G418, 30 20mM Glutamine, 10mM HEPES and 100 μ g/ml of Pen-Strep. Expression of *mpl* P in selected clones was determined by FACS analysis using a anti-*mpl* P rabbit polyclonal antibody.

To determine the presence of *mpl* ligand from various sources, the *mpl* P Ba/F3 35 cells were starved of IL-3 overnight at a cell density of 5×10^5 cells/ml in a humidified incubator at 37°C in 5% CO₂ and air. Following IL-3 starvation the cells were plated out in 96 well culture dishes at a density of 50,000 cells in 200 μ l of media with or without diluted samples and cultured for 24 hrs in a cell culture incubator. 20 μ l of

serum free RPMI media containing 1 μ Ci of 3 H-thymidine was added to each well for the last 6-8 hrs. . The cells were then harvested on 96 well GF/C filter plates and washed 5 times with water. The filters were counted in the presence of 40 μ l of scintillation fluid (microscint 20) in a Packard Top Count counter.

5

EXAMPLE II

Highly Purified Porcine mpl Ligand Gel Elution Protocol

10 Equal amounts of affinity purified *mpl* ligand (fraction 6 eluted from the *mpl*-IgG column) and 2X Laemmli sample buffer were mixed at room temperature without reducing agent and loaded onto a Novex 4-20% polyacrylamide gel as quickly as possible. The sample was not heated. As a control, sample buffer without ligand was run in an adjacent lane. The gel was run at 4-6°C at 135 volts for approximately 2 1/4 hours. The running buffer was initially at room temperature. The gel was then 15 removed from the gel box and the plate on one side of the gel removed.

20 A replica of the gel was made on nitrocellulose as follows: A piece of nitrocellulose was wet with distilled water and carefully laid on top of the exposed gel face so air bubbles were excluded. Fiducial marks were placed on the nitrocellulose and the gel plate so the replica could be accurately repositioned after staining. After 25 approximately 2 minutes, the nitrocellulose was carefully removed, and the gel was wrapped in plastic wrap and placed in the refrigerator. The nitrocellulose was stained with Biorad's gold total protein stain by first agitating it in 3 x 10 ml 0.1% Tween 20 + 0.5 M NaCl + 0.1 M Tris-HCl pH 7.5 over approximately 45 minutes followed by 3 x 10 ml purified water over 5 minutes. The gold stain was then added and allowed to 30 develop until the bands in the standards were visible. The replica was then rinsed with water, placed over the plastic wrap on the gel and carefully aligned with the fiducial marks. The positions of the Novex standards were marked on the gel plate and lines were drawn to indicate the cutting positions. The nitrocellulose and plastic wrap were then removed and the gel cut along the indicated lines with a sharp razor blade. The cuts were extended beyond the sample lanes so they could be used to determine the positions of the slices when the gel was stained. After the slices were removed, the remaining gel was silver stained and the positions of the standards and the cut marks were measured. The molecular weights corresponding to the cut positions were determined from the Novex standards.

35 The 12 gel slices were placed into the cells in two Biorad model 422 electro-eluters. 12-14K molecular weight cutoff membrane caps were used in the cells. 50

mM ammonium bicarbonate + 0.05% SDS (approximately pH 7.8) was the elution buffer. One liter of buffer was chilled approximately 1 hour in a 4-6°C coldroom before use. Gel slices were eluted at 10 ma/cell (40 v initially) in a 4-6°C coldroom. Elution took approximately 4 hours. The cells were then carefully removed and the liquid above the frit removed with a pipet. The elution chamber was removed and any liquid above the membrane cap removed with a pipet. The liquid in the membrane cap was removed with a Pipetman and saved. 50 μ l aliquots of purified water were then placed in the cap, agitated and removed until all the SDS crystals dissolved. These washes were combined with the saved liquid above. Total elution sample volume was 300-500 μ l per gel slice. Samples were placed in 10 mm Spectrapor 4 12-14K cutoff dialysis tubing which had been soaked several hours in purified water. They were dialyzed overnight at 4-6°C against 600 ml of phosphate buffered saline (PBS is approximately 4 mM in potassium) per 6 samples. The buffer was replaced the next morning and dialysis continued for 2.5 hours. Samples were then removed from the dialysis bags and placed in microfuge tubes. The tubes were placed on ice for 1 hour, microfuged at 14K rpm for 3 min. and the supernatants carefully removed from the precipitated SDS. The supernatants were then placed on ice for approximately 1 hour more and microfuged again for 4 min. The supernatants were diluted in phosphate buffered saline and submitted for the activity assay. Remaining samples were frozen at -70°C.

EXAMPLE III

Porcine mpl Ligand Microsequencing

Fraction 6 (2.6 ml) from the *mpl*-IgG affinity column was concentrated on a 25 Microcon-10 (Amicon). In order to prevent the *mpl* ligand from absorbing to the Microcon, the membrane was rinsed with 1% SDS and 5 μ l of 10 % SDS was added to fraction 6 . Sample buffer (20 μ l) of 2X was added to the fraction #6 after Microcon concentration (20 μ l) and the total volume (40 μ l) was loaded on a single lane of a 4-20 % gradient acrylamide gel (Novex). The gel was run following Novex protocol. The 30 gel was then equilibrated for 5 min. prior to electroblotting in 10 mM 3-(cyclohexylamino)-1-propanesulfonic acid (CAPS) buffer, pH 11.0, containing 10% methanol. Electroblotting onto Immobilon-PSQ membranes (Millipore) was carried out for 45 min. at 250 mA constant current in a BioRad Trans-Blot transfer cell (32). The PVDF membrane was stained with 0.1% Coomassie Blue R-250 in 40% methanol, 35 0.1% acetic acid for 1 min. and destained for 2-3 min. with 10% acetic acid in 50%

methanol. The only proteins that were visible in the Mr 18,000-35,000 region of the blot had Mr of 30,000, 28,000 and 22,000.

Bands at 30, 28 and 22 kDa were subjected to protein sequencing. Automated protein sequencing was performed on a model 470A Applied Biosystem sequencer equipped with an on-line PTH analyzer. The sequencer was modified to inject 80-90% of the sample (Rodriguez, *J. Chromatogr.*, **350**:217-225 [1985]). Acetone (~ 12 μ l/l) was added to solvent A to balance the UV absorbance. Electroblotted proteins were sequenced in the Blott cartridge. Peaks were integrated with Justice Innovation software using Nelson Analytical 970 interfaces. Sequence interpretation was performed on a VAX 5900 (Henzel *et al.*, *J. Chromatogr.*, **404**:41-52 [1987]). N-terminal sequences (using one letter code with uncertain residues in parenthesis) of indicated gel bands were:

1) **30 kDa** (1.8 pmol)

15 1 5 10 15 20 25 (1)
A (S) P A P P A(C)D P R L L N K L L R D D (H/S) V L H (G) R L (SEQ ID NO: 9);

2) **28 kDa** (0.5 pmol)

1 5 10 15 20 25 (2)
A (S) P A P P A X D P R L L N K L L R D D (H) V L (H) G R (SEQ ID NO: 10); and

20 3) **22 kDa** (0.5 pmol)

1 5 10 (3)
A X P A P P A X D P R L X (N) (K) (SEQ ID NO: 11).

EXAMPLE IV

25 *Liquid Suspension Megakaryocytopoiesis Assay*

Human peripheral stem cells (PSC) (obtained from consenting patients) were diluted 5 fold with IMDM media (Gibco) and centrifuged for 15 min. at room temp. at 800 x g. The cell pellets were resuspended in IMDM and layered onto 60% Percoll (density 1.077 gm/ml) (Pharmacia) and centrifuged at 800 x g for 30 min. The light density mononuclear cells were aspirated at the interface and washed 2x with IMDM and plated out at $1-2 \times 10^6$ cells/ml in IMDM containing 30% FBS (1 ml final volume) in 24 well tissue culture clusters (Costar). APP or *mpl* ligand depleted APP was added to 10% and cultures were grown for 12-14 days in a humidified incubator at 37°C in 5% CO₂ and air. The cultures were also grown in the presence of 10% APP with 0.5 μ g of *mpl*-IgG added at days 0, 2 and 4. APP was depleted of *mpl* ligand by passing APP through a *mpl*-IgG affinity column.

To quantitate megakaryocytopoiesis in these liquid suspension cultures, a modification of Solberg *et al.* was used and employs a radiolabeled murine IgG monoclonal antibody (HP1-1D) to GPIIbIIIa (provided by Dr. Nichols, Mayo Clinic). 100 µg of HP1-1D (see Grant, B. *et al. Blood* 69:1334-1339 [1987]). was radiolabeled 5 with 1mCi of Na¹²⁵I using enzymobeads (Biorad, Richmond, CA) as described by the manufacturer's instructions. Radiolabeled HP1-1D was stored at -70°C in PBS containing 0.01% octyl-glucoside. Typical specific activities were 1-2 x 10⁶ cpm/µg (>95% precipitated by 12.5% trichloroacetic acid).

Liquid suspension cultures were set up in triplicate for each experimental point. 10 After 12-14 days in culture the 1ml cultures were transferred to 1.5ml eppendorf tubes and centrifuged at 800 x g for 10 min. at room temp. and the resultant cell pellets were resuspended in 100 µl of PBS containing 0.02% EDTA and 20% bovine calf serum. 10ng of ¹²⁵I-HP1-1D in 50 µl of assay buffer was added to the resuspended cultures and incubated for 60 min. at room temperature (RT) with occasional shaking. 15 Subsequently, cells were collected by centrifugation at 800 x g for 10 min. at RT and washed 2x with assay buffer. The pellets were counted for 1 min. in a gamma counter (Packard). Non-specific binding was determined by adding 1 µg of unlabeled HP1-1D for 60 min. before the addition of labeled HP1-1D. Specific binding was determined as the total ¹²⁵I-HP1-1D bound minus that bound in the presence of excess unlabeled 20 HP1-1D.

EXAMPLE V

Oligonucleotide PCR Primers

Based on the amino-terminal amino acid sequence obtained from the 30 kDa, 25 28 kDa and 22 kDa proteins, degenerate oligonucleotides were designed for use as polymerase chain reaction (PCR) primers. Two primer pools were synthesized, a positive sense 20 mer pool encoding amino acid residues 2-8 (*mpl* 1) and an anti-sense 21-mer pool complimentary to sequences encoding amino acids 18-24 (*mpl* 2).

30 *mpl* 1 5' CCN GCN CCN CCN GCN TGY GA 3' (2,048-fold degenerate) (SEQ ID
A NO: 14)

mpl 2 5' NCC RTG NAR NAC RTG RTC RTC 3' (2,048-fold degenerate) (SEQ ID NO:
A 15)

35

Porcine genomic DNA, isolated from porcine peripheral blood lymphocytes, was used as a template for PCR. The 50 μ l reaction contained: 0.8 μ g of porcine genomic DNA in 10mM Tris-HCl (pH 8.3), 50mM KCl, 3mM MgCl₂, 100 μ g/ml BSA, 400 μ M dNTPs, 1 μ M of each primer pool and 2.5 units of Taq polymerase. Initial template denaturation 5 was at 94°C for 8 min. followed by 35 cycles of 45 seconds at 94°C, 1 min. at 55°C and 1 min. at 72°C. The final cycle was allowed to extend for 10 min. at 72°C. PCR products were separated by electrophoresis on a 12% polyacrylamide gel and visualized by staining with ethidium bromide. If the amino-terminal amino acid sequence is encoded by a single exon then the correct PCR product is expected to be 10 69 bp. A DNA fragment of this size was eluted from the gel and subcloned into pGEMT (Promega). Sequences of three clones are shown below:

(1) gemT3

15 5' CCAGCGCCGC CAGCCTGTGA CCCCCGACTC CTAAATAAAC TGCTCGTGA
3' GGTCGCGGCG GTCGGACACT GGGGGCTGAG GATTATTG ACGGAGCACT

A TGACCACGTT CAGCACGGC 69 (SEQ ID NO: 16) *b*
AC ACTGGTGCAA GTCGTGCCG (SEQ ID NO: 17)

20 (2) gemT7

5' CCAGCACCTC CGGCATGTGA CCCCCGACTC CTAAATAAAC TGCTCGTGA
3' GGTCGTGGAG GCCGTACACT GGGGGCTGAG GATTATTG ACGAAGCACT

AC CGACCACGTC CATCACGGC 69 (SEQ ID NO: 18) *a*
AC GCTGGTGCAAG GTAGTGCCG (SEQ ID NO: 19)

(3) gemT9

P R L L N K L L R (SEQ ID

A *14* NO: 12)
30 5' CCAGCACCGCCGGCATGTGACCCCCGACTCCTAAATAACTGCTCGTGACG
3' GGTCGTGGCGGCCGTACACTGGGGCTGAGGATTATTGACGAAGCACTGC

AC ATCATGTCTATCACGGT 3' (SEQ ID NO: 20) *20*
AC TAGTACAGATAGTGCCA 5' (SEQ ID NO: 21) *25*
35

The position of the PCR primers is indicated by the underlined bases. These results verify the N-terminal sequence obtained for amino acids 9-17 for the 30 kDa, 28 kDa and 18 kDa proteins and indicated that this sequence is encoded by a single exon of porcine DNA.

5

EXAMPLE VI

Human mpl Ligand Gene

Based on the results from **Example V**, a 45-mer deoxyoligonucleotide was designed and synthesized to screen a genomic library. The 45-mer had the following 10 sequence:

5' GCC-GTG-AAG-GAC-GTG-GTC-GTC-ACG-AAG-CAG-TTT-ATT-TAG-GAG-TCG 3'
(SEQ ID NO: 13)

15 This oligonucleotide was ^{32}P -labeled with ($\gamma^{32}\text{P}$)-ATP and T4 kinase and used to screen a human genomic DNA library in λ gem12 under low stringency hybridization and wash conditions. Positive clones were picked, plaque purified and analyzed by restriction mapping and southern blotting. Clone #4 was selected for additional analysis.

20 A 2.8 kb BamHI-XbaI fragment that hybridized to the 45-mer was subcloned into pBluescript SK-. Partial DNA sequencing of this clone was ^{performed} using as primers oligonucleotides specific to the porcine *mpl* ligand DNA sequence. The sequence obtained confirmed that DNA encoding the human homolog of the porcine *mpl* ligand had been isolated. An EcoRI restriction site was detected in the sequence 25 allowing us to isolate a 390 bp EcoRI-XbaI fragment from the 2.8 kb BamHI-XbaI and to subclone it in pBluescript SK-.

Both strands of this fragment were sequenced. The human DNA sequence and deduced amino acid sequence are shown in **Fig. 7**. The predicted positions of 30 introns in the genomic sequence are also indicated by arrows, and define a putative exon ("exon 3").

Examination of the predicted amino acid sequence confirms that a serine residue is the first amino acid of the mature *mpl* ligand, as determined from direct amino acid sequence analysis. Immediately upstream from this codon the predicted amino acid sequence is highly suggestive of a signal sequence involved in secretion 35 of the mature *mpl* ligand. This signal sequence coding region is probably interrupted at nucleotide position 68 by an intron.

In the 3' direction the exon appears to terminate at nucleotide 196. This exon therefore encodes a sequence of 42 amino acids, 16 of which are likely to be part of a signal sequence and 26 of which are part of the mature human *mpl* ligand.

5

EXAMPLE VII

mpl Ligand cDNA

1. Full Length Human *mpl* Ligand cDNA

Based on the human "exon 3" sequence (Example VI) 2 non-degenerate 10 oligonucleotides corresponding to the 3' and 5' ends of the exon sequence were synthesized.

Forward primer: 5' GCT AGC TCT AGA AAT TGC TCC TCG TGG

TCA TGC TTC T 3'

(SEQ ID NO: 22)

21
24

AC
15

Reverse primer: 5' CAG TCT GCC GTG AAG GAC ATG G 3'

(SEQ ID NO: 23)

25
22

AC

These 2 primers were used in PCR reactions employing as a template DNA from various human cDNA libraries or 1 ng of Quick Clone cDNA (Clonetech) from 20 various tissues using the conditions described in the Example VI. The expected size of the correct PCR product was 140 bp. After analysis of the PCR products on a 12% polyacrylamide gel, a DNA fragment of the expected size was detected in cDNA libraries prepared from adult kidney, 293 fetal kidney cells and cDNA prepared from human fetal liver (Clonetech cat. #7171-1).

25 A fetal liver cDNA library in lambda DR2 (Clonetech cat. # HL1151x) was screened with the same 45 mer oligonucleotide used to screen the human genomic library. The oligonucleotide was labelled with (γ ³²P)-ATP using T4 polynucleotide kinase. The library was screened under low stringency hybridization conditions. The filters were prehybridized for 2h then hybridized with the probe overnight at 42°C in 30 20% formamide, 5xSSC, 10xDenhardt's, 0.05M sodium phosphate (pH 6.5), 0.1% sodium pyrophosphate, 50 μ g/ml of sonicated salmon sperm DNA for 16h. Filters were then rinsed in 2xSSC and then washed once in 0.5xSSC, 0.1% SDS at 42°C. Filters were exposed overnight to Kodak X-Ray film. Positive clones were picked, 35 plaque purified and the insert size was determined by PCR using oligonucleotides flanking the BamHI-XbaI cloning in lambda DR2 (Clonetech cat. #6475-1). 5 μ l of phage stock was used as a template source. Initial denaturation was for 7 min. at

94°C followed by 30 cycles of amplification (1 min. at 94°C, 1 min. at 52°C and 1.5 min. at 72°C). Final extention was for 15 min. at 72°C. Clone # FL2b had a 1.8kb insert and was selected for further analysis.

The plasmid pDR2 (Clonetech, Lambda DR2 & pDR2 cloning and Expression System Library Protocol Handbook, p 42) contained within the lambda DR2 phage arms, was rescued as described per manufacturer's instructions (Clonetech, Lambda DR2 & pDR2 cloning and Expression System Library Protocol Handbook, p 29-30). Restriction analysis of the plasmid pDR2-FL2b with BamHI and XbaI indicated the presence of an internal BamHI restriction site in the insert approximately at position 650. Digestion of the plasmid with BamHI-XbaI cut the insert in two fragments, one of 0.65 kb and one of 1.15 kb. DNA sequence was determined with three different classes of template derived from the plasmid pDR2-FL2b. DNA sequencing of double-stranded plasmid DNA was carried out with the ABI373 (Applied Biosystems, Foster City, California) automated fluorescent DNA sequencer using standard protocols for 15 dye-labeled dideoxy nucleoside triphosphate terminators (dye-terminators) and custom synthesized walking primers (Sanger *et al.*, *Proc. Natl. Acad. Sci. USA*, **74**:5463-5467 [1977]; Smith *et al.*, *Nature*, **321**:674-679 [1986]). Direct sequencing of polymerase chain reaction amplified fragments from the plasmid was done with the ABI373 sequencer using custom primers and dye-terminator reactions. Single 20 stranded template was generated with the M13 Janus vector (DNASTAR, Inc., Madison, Wisconsin) (Burland *et al.*, *Nucl. Acids Res.*, **21**:3385-3390 [1993]). BamHI-XbaI (1.15 kb) and BamHI (0.65 kb) fragments were isolated from the plasmid pDR2-FL2b, the ends filled in with T4 DNA polymerase in the presence of deoxynucleotides, and then subcloned into the SmaI site of M13 Janus. Sequencing was carried out with 25 standard protocols for dye-labeled M13 Universal and Reverse primers, or walking primers and dye-terminators. Manual sequencing reactions were carried out on single strand M13 DNA using walking primers and standard dideoxy-terminator chemistry (Sanger *et al.*, *Proc. Natl. Acad. Sci. USA*, **74**:5463-5467 [1977]), ³³P-labeled alpha-dATP and Sequenase (United States Biochemical Corp., Cleveland, Ohio). 30 DNA sequence assembly was carried out with Sequencher V2.1b12 (Gene Codes Corporation, Ann Arbor, Michigan). The nucleotide and deduced sequences of hML are provided in **Fig. 8**.

2. *Murine mpl Ligand cDNA*

35 A DNA fragment corresponding to the coding region of the human *mpl* ligand was obtained by PCR, gel purified and labeled by random priming in the presence of

32P-dATP and 32P-dCTP. This probe was used to screen 10⁶ clones of a mouse liver cDNA library in Ig10 (Clontech cat# ML3001a). Duplicate filters were hybridized in 35% formamide, 5xSSC, 10xDenhardt's, 0.05M sodium phosphate (pH 6.5), 0.1% sodium pyrophosphate, 50 µg/ml of sonicated salmon sperm DNA overnight in the presence of the probe. Filters were rinsed in 2xSSC and then washed once in 0.5xSSC, 0.1% SDS at 42°C. Hybridizing phage were plaque-purified and the cDNA inserts were subcloned into the Bluescript plasmid. Clone LD with a 1.5 kb insert was chosen for further analysis and both strands were sequenced as described above for the human ML cDNA. The nucleotide and deduced amino acid sequences of mML are provided in **Fig. 10**. Comparison of hML and mML amino acid sequences are presented in **Fig. 11**. Considerable identity for both nucleotide and deduced amino acid sequences are observed in the EPO-like domains of these ML's and thus cDNA clones from libraries of other species may be obtained by the above described procedures.

15

Transient Expression of mpl Ligand

In order to subclone the full-length insert contained in pDR2-FL2b, the plasmid was digested with XbaI to completion, then partially digested with BamHI. A DNA fragment corresponding to the 1.8 kb insert was gel purified and subcloned in pRK5 (pRK5-hmp^l I) (see U.S. Patent No. 5,258,287 for construction of pRK5) under the control of the cytomegalovirus immediate early promoter. DNA from the construct pRK5-hmp^l I was prepared by the PEG method and transfected in Human embryonic kidney 293 cells maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with F-12 nutrient mixture, 20 mM Hepes (pH 7.4) and 10% fetal bovine serum. Cells were transfected by the calcium phosphate method as described (Gorman, C. [1985] in *DNA Cloning: A Practical Approach* (Glover, D. M., ed) Vol. II, pp. 143-190, IRL Press, Washington, D. C.). 36 h after transfection, the supernatant of the transfected cells was assayed for activity in the proliferation assay (see **Example I**). Supernatant of 293 cells transfected with pRK vector only gave no stimulation of the Ba/F3 or Ba/F3-*mpl* cells (**Fig. 12A**). Supernatant of cells transfected with pRK5-hmp^l I had no effect on the Ba/F3 cells but dramatically stimulates the proliferation of Ba/F3-*mpl* cells (**Fig. 12A**), indicating that this cDNA encodes a functionally active human *mpl* ligand.

35

35 and quantitated as follows:
 the changes in DNA content are measured by flow cytometry. Polyploidy is measured
 and 0.05% Tween-20 is added to each well. Following a one hour incubation at 37°C
 for five minutes and 150 μ l of 1mg/ml RNase containing 0.1mg/ml propidium iodide
 by aspiration. After incubation at 4°C for 15 minutes, the plates are spun at 2000 rpm
 Cells are fixed by the addition of 200 μ l ice-cold 70% Ethanol-PBS and resuspended
 30 supernatants are discarded and 200 μ l of PBS-0.1% BSA wash step is repeated.
 Plates are spun in a Sorvall 6000B centrifuge at 1000 rpm for five minutes at 4°C.
 are then incubated for 48 hours at 37°C in a 5% CO₂ incubator. After incubation,
 the TPO standard or experimental samples is added to DAMI cell suspension. Cells
 25 preparation for the assay, the cells are harvested, washed, and resuspended at
 1x10⁶ cells/ml in IMDM + 1% horse serum. In a 96-well round-bottom plate, 100 μ l of
 DAMI cells are maintained in IMDM + 10% horse serum (Gibco) supplemented
 with 10mM glutamine, 100ng/ml Penicillin G, and 50 μ g/ml streptomycin. In
 20 **DAMI Assay for Thrombopoietin (TPO) by Measuring Endomototic Activity**

EXAMPLE IX

20 **DAMI Assay for Thrombopoietin (TPO) by Measuring Endomototic Activity**

15 CMK cells are maintained in RPMI 1640 medium (Sigma) supplemented with
 10% fetal bovine serum and 10mM glutamine. In preparation for the assay, the cells
 are harvested, washed and resuspended at 5x10⁵ cells/ml in serum-free G/F medium
 supplemented with 5mg/l bovine insulin, 10mg/l apo-transferrin, 1 X trace elements. In
 each well at appropriate dilutions in 100 μ l volumes. 100 μ l of the CMK cell
 a 96-well flat-bottom plate, the TPO standard or experimental samples are added to
 5 **GP11b/IIa Expression**

5 CMK cells are maintained in RPMI 1640 medium (Sigma) supplemented with
 10% fetal bovine serum and 10mM glutamine. In preparation for the assay, the cells
 are harvested, washed and resuspended at 5x10⁵ cells/ml in serum-free G/F medium
 supplemented with 5mg/l bovine insulin, 10mg/l apo-transferrin, 1 X trace elements. In
 each well at appropriate dilutions in 100 μ l volumes. 100 μ l of the CMK cell
 a 96-well flat-bottom plate, the TPO standard or experimental samples are added to
 10 **GP11b/IIa Expression**

10 CMK cells are maintained in RPMI 1640 medium (Sigma) supplemented with
 10% fetal bovine serum and 10mM glutamine. In preparation for the assay, the cells
 are harvested, washed and resuspended at 5x10⁵ cells/ml in serum-free G/F medium
 supplemented with 5mg/l bovine insulin, 10mg/l apo-transferrin, 1 X trace elements. In
 each well at appropriate dilutions in 100 μ l volumes. 100 μ l of the CMK cell
 a 96-well flat-bottom plate, the TPO standard or experimental samples are added to
 15 **GP11b/IIa Expression**

15 CMK cells are maintained in RPMI 1640 medium (Sigma) supplemented with
 10% fetal bovine serum and 10mM glutamine. In preparation for the assay, the cells
 are harvested, washed and resuspended at 5x10⁵ cells/ml in serum-free G/F medium
 supplemented with 5mg/l bovine insulin, 10mg/l apo-transferrin, 1 X trace elements. In
 each well at appropriate dilutions in 100 μ l volumes. 100 μ l of the CMK cell
 a 96-well flat-bottom plate, the TPO standard or experimental samples are added to
 20 **GP11b/IIa Expression**

20 CMK cells are maintained in RPMI 1640 medium (Sigma) supplemented with
 10% fetal bovine serum and 10mM glutamine. In preparation for the assay, the cells
 are harvested, washed and resuspended at 5x10⁵ cells/ml in serum-free G/F medium
 supplemented with 5mg/l bovine insulin, 10mg/l apo-transferrin, 1 X trace elements. In
 each well at appropriate dilutions in 100 μ l volumes. 100 μ l of the CMK cell
 a 96-well flat-bottom plate, the TPO standard or experimental samples are added to
 25 **GP11b/IIa Expression**

25 CMK cells are maintained in RPMI 1640 medium (Sigma) supplemented with
 10% fetal bovine serum and 10mM glutamine. In preparation for the assay, the cells
 are harvested, washed and resuspended at 5x10⁵ cells/ml in serum-free G/F medium
 supplemented with 5mg/l bovine insulin, 10mg/l apo-transferrin, 1 X trace elements. In
 each well at appropriate dilutions in 100 μ l volumes. 100 μ l of the CMK cell
 a 96-well flat-bottom plate, the TPO standard or experimental samples are added to
 30 **GP11b/IIa Expression**

30 CMK cells are maintained in RPMI 1640 medium (Sigma) supplemented with
 10% fetal bovine serum and 10mM glutamine. In preparation for the assay, the cells
 are harvested, washed and resuspended at 5x10⁵ cells/ml in serum-free G/F medium
 supplemented with 5mg/l bovine insulin, 10mg/l apo-transferrin, 1 X trace elements. In
 each well at appropriate dilutions in 100 μ l volumes. 100 μ l of the CMK cell
 a 96-well flat-bottom plate, the TPO standard or experimental samples are added to
 35 **GP11b/IIa Expression**

Normalized Polyploid Ratio (NPR) =

$$\frac{(\% \text{Cells in } >\text{G2+M}/\% \text{Cells in } <\text{G2+M}) \text{ with TPO}}{(\% \text{Cells in } >\text{G2+M}/\% \text{Cells in } <\text{G2+M}) \text{ in control}}$$

EXAMPLE X

Thrombopoietin (TPO) in vivo Assay (Mouse Platelet Rebound Assay)

10 *In vivo Assay for ³⁵S Determination of Platelet Production*

C57BL6 mice (obtained from Charles River) are injected intraperitoneally (IP) with 1 ml goat anti-mouse platelet serum (6 amps) on day 1 to produce thrombocytopenia. On days 5 and 6, mice are given two IP injections of the factor or PBS as the control. On day 7, thirty μ Ci of $\text{Na}_2^{35}\text{SO}_4$ in 0.1 ml saline are injected 15 intravenously and the percent ³⁵S incorporation of the injected dose into circulating platelets is measured in blood samples obtained from treated and control mice. Platelet counts and leukocyte counts are made at the same time from blood obtained from the retro-orbital sinus.

20 EXAMPLE XI

*Synthetic *mpl*-ligand*


Although Human *mpl*-ligand (h-ML) is usually made using recombinant methods, it can also be synthesized via enzymatic ligation of synthetic peptide fragments using methods described below. Synthetic production of h-ML allows the 25 incorporation of unnatural amino acids or synthetic functionalities such as polyethylene glycol. Previously, a mutant of the serine protease subtilisin BPN, subtiligase (S221C/P225A) was engineered to efficiently ligate peptide esters in aqueous solution (Abrahmsen *et al.*, *Biochem.*, **30**:4151-4159 [1991]). It has now been shown that synthetic peptides can be enzymatically ligated in a sequential 30 manor to produce enzymatically active long peptides and proteins such as ribonuclease A (Jackson *et al.*, *Science*, [1994]). This technology, described in more detail below, has enabled us to chemically synthesize long proteins that previously could be made only with recombinant DNA technology.

A general strategy for h-ML[I-153] synthesis using subtiligase is shown 35 (**Scheme 1**). Beginning with a fully deprotected peptide corresponding to the C-terminal fragment of the protein, an N-terminal protected, C-terminal activated ester

peptide is added along with subtiligase. When the reaction is complete, the product is isolated by reverse phase HPLC and the protecting group is removed from the N-terminus. The next peptide fragment is ligated, deprotected and the process is repeated using successive peptides until full length protein is obtained. The process
 5 is similar to solid phase methodology in that an N-terminal protected C-terminal
 B activated peptide is ligated to the N-terminus of the preceding peptide and protein is synthesized in a C->N direction. However because each coupling results in addition of up to 50 residues and the products are isolated after each ligation, much longer highly pure proteins can be synthesized in reasonable yields.

10

Scheme 1. Strategy for Synthesis of h-ML Using Subtiligase



15 Based on our knowledge of the sequence specificity of the subtiligase as well as the amino acid sequence of h-ML, we divided h-ML[1-153] into seven fragments 18-25 residues in length (**Table 3**). Previous experiments indicated that these fragments should be efficiently ligated by the subtiligase. A suitable protecting group for the N-terminus of each donor ester peptide was needed to prevent self ligation. We chose

an isonicotinyl (iNOC) protecting group (Veber *et al.*, *J. Org. Chem.*, **42**:3286-3289 [1977]) because it is water soluble, it can be incorporated at the last step of solid phase peptide synthesis and it is stable to anhydrous HF used to deprotect and cleave peptides from the solid phase resin. In addition, it can be removed from the peptide after each ligation under mild reducing conditions (Zn/CH₃CO₂H) to afford a free N-terminus for subsequent ligations. A glycolate-lysyl-amide (glc-K-NH₂) ester was used for C-terminal activation based on previous experiments which showed this to be efficiently acylated by subtiligase (Abrahmsen *et al.*, *Biochem.*, **30**:4151-4159 [1991]). The iNOC-protected, glc-K-amide activated peptides can be synthesized using standard solid phase methods as outlined (**Scheme 2**). The peptides are then sequentially ligated until the full protein is produced and the final product refolded *in vitro*. Based on homology with EPO, disulfide pairs probably are formed between cysteine residues 7 and 151 and between 28 and 85. Oxidation of the disulfides could be accomplished by stirring the reduced material under an oxygen atmosphere for several hours. The refolded material can then be purified by HPLC and fractions containing active protein pooled and lyophilized. As an alternative, disulfides can be differentially protected to control sequential oxidation between specific disulfide pairs. Protection of cysteines 7 and 151 with acetamidomethyl (acm) groups would ensure oxidation of 28 and 85. The acm groups could then be removed and residues 7 and 151 oxidized. Conversely, residues 28 and 85 could be acm protected and oxidized in case sequential oxidation is required for correct folding. ^{Optionally}, ^{Cysteines} Cysteines 28 and 85 may be substituted with another natural or unnatural residue other than Cys to insure proper oxidation of ^{cysteines} cysteines 7 and 151.

25 **Table 3.**
Peptide Fragments Used For Total Synthesis of h-ML Using Ligase


<u>Fragment</u>	<u>Sequence</u>
Ac 1 (SEQ ID NO: 24) 30 (1-23)	iNOC-HN-SPAPPACDLRVLSKLLRDSHVVLH-glc-K-NH ₂ ²³ ²⁴
Ac 2 (SEQ ID NO: 25) (24-46)	iNOC-HN-SRLSQCPEVHPLPTPVLLPAVDF-glc-K-NH ₂ ²⁴ ²⁵
Ac 3 (SEQ ID NO: 26) (47-69)	iNOC-HN-SLGEWKTQMEETKAQDILGAVTL-glc-K-NH ₂ ²⁶ ²⁷
Ac 4 (SEQ ID NO: 27) 35 Ac 5 (SEQ ID NO: 28)	iNOC-HN-LLEGVMAARGQLGPTCLSSL-glc-K-NH ₂ (70-89) iNOC-HN-LGQLSGQVRLLGALQLS-glc-K-NH ₂ (90-107) ²⁷ ²⁸

AC 6 (SEQ ID NO: 29) iNOC-HN-LGTQLPPQGRRTAHKDPNAIF-glc-K-NH2 (108-128)
AC 7 (SEQ ID NO: 30) H2N-LSFQHLLRGKVRFLMLVGGSTLCVR-CO2 (129-153)

5 Peptide ligations are carried out at 25°C in 100mM tricine, pH 8 (freshly prepared and degassed by vacuum filtration through a 5 μ M filter). Typically the C-terminal fragment is dissolved in buffer (2-5 mM peptide) and a 10x stock solution of subtiligase (1 mg/mL in 100mM tricine, pH 8) is added to bring the final enzyme concentration to ~ 5 μ M. A 3-5 molar excess of the glc-K-NH₂ activated donor peptide
10 is then added as a solid, dissolved, and the mixture allowed to stand at 25°C. The ligations are monitored by analytical reverse phase C18 HPLC (CH₃CN/H₂O gradient with 0.1% TFA). The ligation products are purified by preparative HPLC and lyophilized. Isonicotinyl (iNOC) deprotection was performed by stirring HCl activated zinc dust with the protected peptide in acetic acid. The zinc dust is removed by
15 filtration and the acetic acid evaporated under vacuum. The resulting peptide can be used directly in the next ligation and the process is repeated. Synthetic h-ML[1-153] can be ligated by procedures analogous to those described above to synthetic or recombinant h-MP [154-332] to produce synthetic or semisynthetic full length h-ML.

Synthetic h-ML has many advantages over recombinant. Unnatural side chains
20 can be introduced in order to improve potency or specificity. Polymer functionalities such as polyethylene glycol can be incorporated to improve duration of action. For example, polyethylene glycol can be attached to lysine residues of the individual fragments (**Table 3**) before or after one or more ligation steps have been performed. Protease sensitive peptide bonds can be removed or altered to improve stability *in vivo*. In addition, heavy atom derivatives can be synthesized to aid in structure
25 determination.

Scheme 2. Solid Phase Synthesis of Peptide Fragments for Segment Ligation.



5 a) Lysyl-paramethylbenzhydrylamine (MBHA) resin **1** (0.63 meq./gm., Advanced ChemTech) is stirred with
bromoacetic acid (5 eq.) and diisopropyl carbodiimide (5 eq.) for 1 h. at 25°C in dimethylacetamide (DMA)
to afford the bromoacetyl derivative **2**. b) The resin is washed extensively with DMA and individual Boc-
protected amino acids (3 eq., Bachem) are esterified by stirring with sodium bicarbonate (6 eq.) in
10 dimethylformamide (DMF) for 24 h. at 50°C to afford the corresponding glycolate-phenylalanyl-amide-resin
3. The amino acetylated resin **3** is washed with DMF (3x) and dichloromethane (CH₂Cl₂) (3x) and can be
stored at room temperature for several months. The resin **3** can then be loaded into an automated
peptide synthesizer (Applied Biosystems 430A) and the peptides elongated using standard solid phase
procedures (5). c) The N- α -Boc group is removed with a solution of 45% trifluoroacetic acid in CH₂Cl₂. d)
15 Subsequent Boc-protected amino acids (5 eq.) are preactivated using benzotriazol-1-yl-oxy-tris-
(dimethylamino) phosphonium hexafluorophosphate (BOP, 4 eq.) and N-methylmorpholine (NMM, 10
eq.) in DMA and coupled for 1-2 h. e) The final N- α -Boc group is removed (TFA/CH₂Cl₂) to afford **4** and
the isonicotinyl (iNOC) protecting group is introduced as described previously (4) via stirring with of 4-

5 isonicotinyl-2-4-dinitrophenyl carbonate (3 eq.) and NMM (6 eq.) in DMA at 25°C for 24 h. f) Cleavage and deprotection of the peptide via treatment with anhydrous HF (5% anisole/ 5% ethylmethyl sulfide) at 0°C for 1 h. affords the iNOC-protected, glycolate-lys-amide activated peptide 5 which is purified by reverse phase C18 HPLC (CH₃CN/H₂O gradient, 0.1% TFA). The identity of all substrates is confirmed by mass spectrometry.

SUPPLEMENTAL ENABLEMENT

10 The invention as claimed is enabled in accordance with the above specification and readily available references and starting materials. Nevertheless, Applicants have deposited with the American Type Culture Collection, Rockville, Md., USA (ATCC) the cell line listed below:

15 Escherichia coli, DH10B-pBSK - hmp/l 1.8, ATCC accession no. CRL 69575, deposited February 24, 1994.

20 This deposit was made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and the regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture for 30 years from date of deposit. The organisms will be made available by ATCC under the terms of the Budapest Treat, and subject to an agreement between Applicants and ATCC which assures unrestricted availability upon issuance of the pertinent U.S. patent. Availability of the deposited strain is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

25

30 While the invention has necessarily been described in conjunction with preferred embodiments and specific working examples, one of ordinary skill, after reading the foregoing specification, will be able to effect various changes, substitutions of equivalents, and alterations to the subject matter set forth herein, without departing from the spirit and scope thereof. Hence, the invention can be practiced in ways other than those specifically described herein. It is therefore intended that the protection granted by letters patent hereon be limited only by the appended claims and equivalents thereof.

35 All references cited herein are hereby expressly incorporated by reference.